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I. Abstract 
Human Cytomegalovirus (CMV) is a highly prevalent -herpesvirus that establishes life-long 
latency after primary infection. Congenital CMV infection is the most common viral compli-
cation in newborns, causing a number of late sequelae that range from impaired hearing 
to mental retardation. At the same time, managing CMV reactivation during immunosup-
pression remains a major hurdle in post-transplant care. 
Since CMV-specific T cells are critical for controlling viral reactivation, monitoring of T cell 
responses is a promising strategy to identify patients at risk for symptomatic CMV disease. 
T cell responses are mostly quantified after antigen-specific restimulation, which requires 
presentation of pathogen-derived peptides by antigen-presenting cells (APCs). Here, it was 
tested if protein carbamoylation, a posttranslational modification of amino groups occur-
ring in vivo during renal dysfunction or inflammation, impacts the uptake of recombinant 
proteins into APCs and, as a result, also T cell restimulation. The CMV proteins immediate-
early 1 (IE-1) and pp65, which are the main targets of T cell-mediated immunity during CMV 
infection, as well as the Epstein-Barr virus (EBV) protein BZLF1 were chosen as model pro-
teins and recombinantly produced for addressing this question. As a result of protein car-
bamoylation, antigen-specific restimulation of T cells was increased for pp65 (mean increase 
39%, ranging from 6-112% for different blood donors) and BZLF1 (mean increase 80%, 
ranging from 5-161%), but decreased for IE-1. Mass spectrometry analysis revealed that 
lysine residues were almost completely modified (>90%), while arginine carbamoylation 
was negligible under the chosen conditions (0.3%). The removal of positive charges from 
amino groups as a result of carbamoylation was found to be important for the enhanced 
restimulation of pp65-specific T cells, since this effect could be reverted by addition of the 
polyanionic competitor fucoidan. In addition, protein maleylation, another posttranslational 
modification removing positive charges from amino groups, mediated a similar increase in 
the restimulation of pp65-specific T cells. T cell responses to carbamoylated pp65 were 
increased compared to the unmodified protein, irrespective of whether monocytes, macro-
phages or dendritic cells acted as APCs. Improved restimulation of pp65-specific T cells was 
shown to be the result of enhanced protein uptake into APCs, which increased both MHC-I 
and MHC-II presentation.  
In summary, protein charges appear to have a major influence on uptake into antigen-
presenting cells, which could be harnessed for improving current methods for T cell im-
munomonitoring and the design of novel vaccines. 
In the second part of this thesis, new viral vectors delivering the T cell immunogens IE-1 and 
pp65 were evaluated with regard to suitability as future CMV vaccine candidates. The vec-
tors were based on Adenovirus 19a/64 (Ad19a/64) or Sendai virus (SeV) and compared side-
by-side to the well-established vector platforms Ad5 and Modified Vaccinia Ankara (MVA). 
All vectors were characterized virologically and immunologically in a series of ex vivo assays 
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with a focus on dendritic cells (DCs), which are the main population priming T cell responses 
in vivo.  
It was found that unlike Ad5, Ad19a/64 vectors readily transduce a broad panel of immune 
cells, including monocytes, T cells, NK cells and monocyte-derived dendritic cells (moDCs). 
Both Ad19a/64- and MVA-transduced moDCs efficiently restimulated IE-1 or pp65-specific 
T cells, but MVA induced a higher amount of cytotoxicity in this cell type. Ad5 and Ad19 
induced upregulation of the maturation markers CD86 and HLA-DR in moDCs whereas ex-
pression of CD80 and CD83 was largely unaltered. By contrast, MVA transduction led to 
downregulation of all markers. 
To enhance the safety of SeV vectors, a replication-deficient strain (rdSeV) that infects target 
cells in a non-productive manner while retaining viral gene expression was used in this the-
sis. rdSeV was compared to the parental, replication-competent Sendai virus strain (rcSeV) 
as well as MVA. rcSeV was capable of replicating to high titers in DCs while rdSeV infected 
cells abortively. Due to the higher degree of attenuation, IE-1 and pp65 protein levels me-
diated by rdSeV after infection of DCs were markedly reduced compared to the parental 
rcSeV strains, but antigen-specific restimulation of T cell clones was not negatively affected 
by this. Importantly, rdSeV showed reduced cytotoxic effects compared to rcSeV and MVA 
and was capable of mediating DC maturation as well as secretion of Interferon α and Inter-
leukin 6.  
Taken together, these data demonstrate that both rdSeV and Ad19a/64 have great poten-
tial as novel vector systems for the delivery of CMV immunogens. 
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II. Zusammenfassung 
Das humane Zytomegalievirus (CMV) weist weltweit hohe Seroprävalenz auf und etabliert 
nach der Primärinfektion lebenslange Latenz. Infektionen mit CMV sind die häufigste virale 
Komplikation bei Neugeborenen und verursachen eine Reihe von Spätfolgen wie Schwer-
hörigkeit oder geistige Behinderungen. Zusätzlich stellen CMV Reaktivierungen die bedeu-
tendste pathogen-assoziierte Komplikation bei Transplantatempfängern dar. 
Da T Zellen eine entscheidende Rolle bei der Kontrolle viraler Reaktivierungen einnehmen, 
stellt die Überwachung CMV-spezifischer T Zell Antworten eine vielversprechende Strategie 
zur frühzeitigen Identifikation von Patienten mit erhöhtem Risiko für symptomatische CMV 
Erkrankung dar. Derzeit werden pathogen-spezifische T Zellen hauptsächlich infolge von 
Restimulation mit entsprechenden Antigenen nachgewiesen und quantifiziert, was deren 
Prozessierung und Präsentation durch Antigen-Präsentierenden Zellen (APCs) voraussetzt. 
In dieser Arbeit wurde untersucht, ob Carbamoylierung (eine posttranslationale Modifika-
tion die auch in vivo im Zuge von Niereninsuffizienz oder Entzündungen vorkommt) die 
Aufnahme rekombinanter Proteine in APCs und damit die Restimulation von T Zellen beein-
flusst. Hierfür wurden die CMV Proteine Immediate-early 1 (IE-1) und pp65, welche wäh-
rend CMV Infektionen die stärksten T Zell Antworten hervorrufen, sowie das Epstein-Barr 
virus (EBV) Protein BZLF1 rekombinant hergestellt. Carbamoylierung verbesserte die Resti-
mulation pp65-spezifischer T Zellen im Durchschnitt um 39%, (6-112%, je nach individuel-
lem Blutspender) und BZLF1-spezifischer T Zellen um 80% (5-161%), wohingegen die IE-1 
Antworten stark verringert waren. Massenspektrometrische Analysen zeigten, dass unter 
den gewählten Reaktionsbedingungen Lysine quantitativ modifiziert wurden (>90%), wo-
hingegen Arginin-Carbamoylierung kaum nachzuweisen war (0.3%). Es zeigte sich außer-
dem, dass das Entfernen positiver Ladungen infolge der Carbamoylierung notwendig für 
die verbesserte T Zell Restimulation ist, da sich der Effekt durch Zugabe des polyanionischen 
Kompetitors Fucoidan aufheben ließ. Zudem hatte Maleylierung, eine weitere posttransla-
tionale Modifikation, welche das Entfernen positiver Ladungen von Aminogruppen zur 
Folge hat, einen ähnlichen Einfluss auf die Restimulierung pp65-spezifischer T Zellen. Die 
Verbesserung der T Zell Stimulation durch carbamoyliertes pp65 war unabhängig davon ob 
Monozyten, Makrophagen oder dendritische Zellen als APCs fungierten. Der Grund hierfür 
scheint eine generell erhöhte Aufnahme in Antigen-präsentierende Zellen zu sein, wobei 
sowohl MHC-I, als auch MHC-II Präsentation verbessert waren.  
Zusammenfassend lässt sich festhalten, dass die Ladung von Proteinen die Aufnahme in 
APCs stark beeinflusst, was beispielsweise in die Verbesserung aktueller T Zell Diagnostika 
oder die Herstellung neuartiger Impfstoffe einfließen könnte. 
Im zweiten Teil dieser Arbeit wurden neuartige virale Vektoren für die Verabreichung der 
T Zell Immunogene IE-1 und pp65 hinsichtlich ihrer Eignung als CMV Impfstoffkandidaten 
evaluiert. Die Vektoren basieren auf dem Adenovirus Subtyp 19a/64 (Ad19a/64), sowie 
Sendai Virus (SeV) und wurden direkt mit den etablierten Vektoren Adenovirus Subtyp 5 
  Zusammenfassung 
10 
 
(Ad5) und Modified Vaccinia Ankara (MVA) verglichen. Alle Vektoren wurden in einer Reihe 
von ex vivo Studien hinsichtlich verschiedener virologischer und immunologischer Parame-
ter charakterisiert. Hierbei lag ein besonderer Fokus auf dendritischen Zellen (DCs), da diese 
in vivo hauptsächlich für das Priming naiver T Zellen verantwortlich sind. 
Hierbei zeigte sich, dass Ad19a/64 Vektoren im Gegensatz zu Ad5 in der Lage sind, ein 
breites Panel an Immunzellen, bestehend aus Monozyten, T Zellen, NK Zellen und mono-
cyte-derived dendritic cells (moDCs), zu transduzieren. Sowohl Ad19a/64, als auch MVA 
waren in der Lage, moDCs effizient zu transduzieren und die Restimulation IE-1- und pp65-
spezifischer T Zell Klone zu vermitteln. Allerdings induzierte MVA in einem deutlich stärkeren 
Ausmaß als Ad19a/64 Zytotoxizität in DCs. Infolge der Transduktion mit Ad5 und Ad19a/64 
wurden die Maturationsmarker CD86 und HLA-DR hochreguliert, wobei das Expressionsni-
veau der Marker CD80 und CD83 unverändert blieb. Im Gegensatz dazu wurde die Expres-
sion aller Maturationsmarker infolge der Transduktion mit MVA herabreguliert. 
Um die Sicherheit SeV-basierter Vektoren zu erhöhen, wurde in dieser Arbeit ein replikati-
onsdefizienter Virusstamm (rdSeV) eingesetzt, der die Expression viraler Gene in Zielzellen 
induziert, wobei die Bildung neuer Viruspartikel unterbleibt. rdSeV wurde sowohl mit dem 
parentalen, replikationskompetenten SeV Stamm (rcSeV), als auch mit MVA verglichen. Es 
zeigte sich, dass rcSeV effizient in humanen DCs repliziert, wohingegen Infektion mit rdSeV 
abortiv abläuft. Mit dem erhöhten Grad an Attenuierung von rdSeV ging, verglichen mit 
rcSeV, zugleich ein vermindertes Expressionsniveau von IE-1 und pp65 einher, jedoch war 
die Restimulation antigenspezifischer T Zellen hiervon nicht negativ beeinflusst. Es ist zudem 
hervorzuheben, dass rdSeV auch geringere Zytotoxizität im Vergleich mit rcSeV und MVA 
aufwies und die Maturation von DCs, sowie die Sezernierung von Interferon α und Interleu-
kin 6 induzierte.  
Insgesamt zeigen diese Daten, dass sowohl rdSeV, als auch Ad19a/64 vielversprechende 
neue Vektorsysteme für die Verabreichung von CMV Immunogenen darstellen. 
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III. Introduction 
III.1. Human Cytomegalovirus 
The family Herpesviridae comprises more than 100 known individual virus species that are 
capable of infecting a wide variety of mammals, birds and reptiles1. They share a common 
virion architecture that is characterized by the presence of an icosahedral nucleocapsid con-
taining a linear, double-stranded DNA genome. The capsid is surrounded by an amorphous 
layer termed the tegument and further enveloped by a host cell-derived lipid bilayer with 
viral glycoproteins (Figure 1)2. Nine herpesviruses, which are classified into three subfamilies, 
have humans as their primary host: α-herpesviruses (herpes-simplex virus type 1 and 2, var-
icella-zoster virus) -herpesviruses (human cytomegalovirus, human herpesvirus types 6A 
and 6B) -herpesviruses (Epstein-Barr virus, human herpesvirus type 7, Kaposi's sar-
coma-associated herpesvirus).  
 
Figure 1  Structural features of 
herpesvirus particles 
Herpesviruses exhibit a characteris-
tic virion architecture that includes 
an icosahedral capsid containing a 
double-stranded DNA (dsDNA) ge-
nome. The nucleocapsid is sur-
rounded by a lipid envelope, which 
holds different types of glycopro-
tein spikes that are involved in ad-
hesion and membrane fusion. Cap-
sid and envelope are separated by 
an unstructured layer referred to as 
the tegument, which contains viral 
and host cell-derived proteins. Fig-
ure adapted from Gardner and 
Tortorella3. 
 
Human cytomegalovirus (CMV, HHV-5), which owes its name to the characteristic enlarge-
y the prototype of 
-herpesviruses4. CMV is distributed globally and infects the majority of the human popula-
tion. Seroprevalence rates range, depending on the geographic region, from 30% to 100%, 
but generally increase with age5 7. Like all herpesviruses, CMV establishes life-long latency 
with periodic reactivations after primary infection8. Horizontal transmission can occur 
through close contact with persons who excrete the virus in their body fluids, for example 
by kissing, sexual contact or breastfeeding. Blood transfusion, solid-organ transplantation 
(SOT) or hematopoietic stem cell transplantation (HSCT) constitute additional routes of CMV 
transmission9. At the same time, vertical transmission from mother to child can occur pre- 
or perinatally as a result of primary infection or viral reactivation during pregnancy10. Given 
that persistently infected individuals are not protected from reinfection despite virus-specific 
cellular and humoral immunity, superinfection with an additional CMV strain can also in-
crease the risk of mother-to-child transmission11,12.  
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III.2. Virion composition and replication 
CMV, which is among the most complex human-pathogenic viruses known, displays a virion 
architecture that is characteristic of all herpesviruses (Figure 1). With approximately 235 
kilobase pairs (kb), CMV has the largest genome of all herpesviruses known to cause disease 
in humans13. The exact number of genes encoded by CMV is still a matter of debate and 
varies, depending on the annotation criteria, strongly from about 150 to more than 23014
16. Next to an undefined number of protein-coding genes, CMV also encodes several long 
noncoding- and micro-RNAs1,17. The genome is flanked by terminal repeat (TR) sequences 
and divided by internal repeats (IR) into two individual genomic regions that are referred to 
as unique long (UL, upstream of IRs) and unique short (US, downstream of IRs; Figure 2). 
Accordingly, CMV genes are named by a prefix indicating the unique region in which they 
are found and numbered sequentially18,19. The genome is enclosed by an icosahedral protein 
capsid made up of 162 capsomers. It is formed by 4 capsid proteins termed major capsid 
protein (MCP, UL86), triplex 1 (TRI1, UL46), triplex 2 (TRI2, UL85) and smallest capsid pro-
tein (SCP, UL48A)20. 
 
Figure 2  Schematic representation of the Cytomegalovirus genome  
The genome of CMV is flanked by repeat sequences referred to as terminal repeat long (TRL) and terminal 
repeat short (TRS). Additional repeat sequences, termed internal repeat long (IRL) and internal repeat short 
(IRS), divide the genome into two individual sections which contain protein-coding genes: unique long (UL) 
and unique short (US). 
The capsid is surrounded by the viral tegument, an unstructured layer that contains a high 
number of viral proteins. In fact, more than half of the 71 viral proteins that are found 
within CMV particles are located in the tegument, along with numerous host cell-derived 
proteins21. During viral replication, tegument proteins are involved in a number of key steps 
such as capsid delivery to the nucleus (UL47 and UL4821), gene regulation (UL8222) and 
assembly of newly generated virions (UL9923), yet the function of many tegument compo-
nents remains elusive. Evasion of innate and adaptive immune responses, which is critical 
for viral replication, is also carried out in part by tegument proteins. For instance, the phos-
phoprotein pp65 (UL83), which is the most abundant protein both in the tegument as well 
as in the entire virion15, protects infected cells from innate immunity by inhibiting natural 
killer (NK) cell cytotoxicity through interaction with the NKp30 activating receptor24. In ad-
dition, pp65 also counteracts adaptive immune responses by mediating the accumulation 
of HLA class II molecules in lysosomes and inducing the degradation of the HLA-DR α-chain 
in this compartment25. 
Capsid and tegument are encased by a host-derived lipid envelope containing various gly-
coprotein complexes (GCs) that are necessary for entry into different cell types (Figure 3). 
These complexes comprise oligomers of gB (GC I; encoded by UL55), the gM/gN dimer (GC 
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II; UL100/ UL73), the gH/gL/gO trimer (GCIII; UL75/UL115/UL74) and the pentameric com-
plex (PC) consisting of gH/gL and UL128/UL130/UL131a. The core fusion machinery consists 
of the proteins gB, gH and gL, which are conserved throughout the herpesvirus family26. 
Entry into fibroblasts takes place by macropinocytosis, followed by the fusion of viral and 
cellular membranes. This process is mediated by GC I and GC III and requires no changes in 
pH27,28. By contrast, entry into epithelial, endothelial, dendritic cells and monocytes requires 
virion uptake via endocytosis or macropinocytosis and a fusion event that relies on vesicle 
acidification. This entry pathway is mediated by GC I, GC III and PC29 33. The function of GC 
II in these processes is still not fully understood, but it is presumed to induce initial tethering 
of virus particles to target cells through interaction with heparan sulfate proteoglycans34. 
 
Figure 3  Quaternary structure and 
topology of glycoprotein complexes 
Glycoproteins (gp) on CMV virions are 
present in several glycoprotein complexes 
(GCs). These complexes include GC I (gB, 
which consists of gp58 and gp116), GC II 
(gM and gN), GC III (gH, gO, gL) and the 
pentameric complex (PC, gH/gL and 
UL128/130/131a). Orange lines indicate 
subunits that are held together by disul-
fide bonds. Figure adapted from Gardner 
and Tortorella3. 
Upon entry, the capsid is released into the host cell cytoplasm and transported along mi-
crotubules to the nuclear membrane, where viral DNA is inserted through nuclear pores35. 
Expression of CMV genes occurs in three sequential phases termed immediate-early (IE), 
early (E) and late (L). Immediate-early genes are the first to be transcribed and their proteins 
mediate the transcription of early gene products which are, among others, responsible for 
the replication of viral DNA36,37. In turn, the presence of early-phase proteins is a prerequisite 
for transition into the late phase, where structural components for the assembly of progeny 
virions are mainly synthesized38. 
Expression of IE genes occurs immediately upon nuclear entry of CMV DNA and does not 
require de novo synthesis of viral proteins. IE genes in the UL region comprise the IE-A 
(major immediate early) and IE-B locus as well as UL115-119. Additional IE genes located in 
the US region include US3 and the TRS1/IRS1 genes36. From the major immediate-early lo-
cus, multiple proteins are being produced by alternative splicing, with the 72 kDa IE-1 
(UL123) and the 86 kDa IE-2 (UL122) being the most abundant and important ones39. IE-2 
is the principal activator of early genes and its presence is indispensable for viral replica-
tion40. IE-1 is also capable of mediating early gene expression, but under certain in vitro 
conditions like infection at high multiplicities of infection (MOIs), viral replication can also 
be completed in the absence of this protein41. In addition to viral genes, IE proteins also 
modulate a number of host genes36. IE-1 and IE-2 further contribute to viral immune evasion 
by various mechanisms, for instance by blocking apoptosis42 or dampening cytokine release 
from infected cells by interfering with JAK- -signalling43 45. Moreover, IE-1 
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also antagonizes host immunity by promoting the disassembly of PML nuclear bodies, which 
are key mediators of innate immune responses within the cell nucleus46 48. 
Early genes mostly function in one of two ways: One subset of gene products is directly 
involved in viral DNA synthesis, cleavage and packing of the viral genome. The other subset 
creates a cellular environment that is ideal for viral replication, for example by modulating 
factors that are involved in control of cellular DNA synthesis or by contributing to the eva-
sion of immune responses37. Viral DNA synthesis occurs in the host cell nucleus from a ge-
nomic region termed oriLyt and requires, next to some cellular factors, a variety of viral 
proteins including the helicase-primase complex (UL105, UL70 and UL10249), the viral DNA 
polymerase (UL54)50 as well as its accessory protein (UL44)51 and the single-stranded DNA 
binding protein (UL57)52. Replication of the viral genome is an essential activation event for 
the expression of late genes which are required for virus assembly and egress38. Capsid 
assembly and DNA packaging occur in the nucleus, followed by translocation of DNA-con-
taining capsids into the cytoplasm, which is mediated by the virally encoded nuclear egress 
complex (NEC, UL50 and UL53)53,54. During nuclear egress, capsids obtain a primary enve-
lope derived from the inner nuclear membrane, which is subsequently lost by fusion with 
the outer nuclear membrane55,56. Further maturation steps, during which capsids obtain 
their final tegument layer, then take place in the cytoplasm57. CMV virions obtain their sec-
ondary envelope, including viral glycoproteins, by budding into vesicles of the trans-Golgi 
network. Finally, mature virions are released by fusion of the vesicle membrane with the 
plasma membrane of the host cell58. 
In some cell types, transcription of IE genes is suppressed, a scenario in which CMV is ca-
pable of switching from lytic replication to a latent phase59. During latency, no progeny 
virus is produced and only a small set of latency-associated genes is transcribed60. Cells from 
the myeloid lineage like CD34+ progenitor cells, monocyte precursors and monocytes have 
been proposed as a site of latency for CMV61 64. Reactivation of lytic replication presumably 
occurs as a result of terminal monocyte differentiation, for example to dendritic cells65,66. 
 
III.3. Immune responses to CMV 
Upon infection, CMV triggers a multitude of innate and adaptive host immune responses. 
Although the virus cannot be eliminated entirely as soon as latent reservoirs are established, 
CMV reactivation events are efficiently confined in immunocompetent individuals, thereby 
inhibiting systemic virus spread and symptomatic CMV disease. This life-long interaction 
with the immune system leaves a profound imprint on various effector cell populations, 
particularly on T cells, B cells and NK cells. 
As a first line of defense, CMV is subject to innate sensing by Toll-like receptors (TLRs) and 
other pattern-recognition receptors13. This is exemplified by the activation of TLR3 and TLR9 
during infection with murine cytomegalovirus (MCMV)67,68, or the interaction of gB/gH from 
  Introduction 
15 
 
human cytomegalovirus with TLR269,70. Toll-like receptor engagement leads to the produc-
tion of inflammatory cytokines, ultimately resulting in the activation of effector cell subsets, 
such as NK cells. 
An important role for NK cells in controlling CMV infection has been firmly established from 
studies demonstrating their involvement in the clearance of experimental MCMV infec-
tion71,72. Moreover, the adoptive transfer of NK cells can provide protection from MCMV 
infection in mice73, and in humans, CMV infection can occasionally be controlled by NK 
cells, even in the absence of additional T cell responses74. Natural killer cells are a highly 
diverse group of lymphocytes that are capable of eliminating pathogen-infected or cancer-
ous cells through the secretion of cytolytic effector molecules38. They are divided into vari-
ous subsets, based on the expression of characteristic combinations of activating and inhib-
itory cell surface receptors. NK cell activation is regulated by a fine-tuned integration of 
signals from those invariant, germline-encoded receptors75. It was recently demonstrated 
that infection with Cytomegalovirus induces the clonal expansion of NK cells expressing the 
activating receptor NKG2C76. While NKG2C+ cells normally make up only a minority of NK 
cells in peripheral blood, their frequency was found to be markedly increased upon acute 
CMV infection77. Such expansion of NKG2C+ cells has also been described for other viral 
infections such as HIV and HBV, but was only observed in CMV seropositive individuals78. 
s required for secondary expansion of this NK 
subset in response to other viral infections. Nevertheless, the initial activation of NKG2C+ 
NK cells is likely not a result of direct recognition of CMV, but rather by differences in the 
expression of MHC-I molecules on infected cells, especially upregulation of HLA-E79. Along 
with selective expansion, NKG2C+ cells from CMV seropositive donors were also found to 
produce more IFN- upon stimulation, compared to the identical NK subset from CMV ser-
onegative donors80. These findings, which imply immune memory-like properties, are fur-
ther underlined by profound epigenetic alterations in NKG2C+ NK cells as a result of CMV 
infection81. Such results challenge the traditional view of innate immune cells as being short-
lived and incapable of retaining any form of memory and blur the lines between innate and 
adaptive immunity82. 
Next to NK cell mediated immunity, CMV infection also triggers antibody responses against 
the various glycoprotein complexes that are located on the virion surface (Figure 3)83. The 
contribution of antibody responses to protection from Cytomegalovirus infection is contro-
versial, in part due to the fact that seropositive individuals can get superinfected with an-
other CMV strain even despite detectable antibody responses. However, there is substantial 
evidence supporting a role for humoral immunity in restricting viral dissemination and lim-
iting the severity of CMV disease13,84,85. During natural CMV infection, detectable antibody 
responses are mostly directed against gB, gH/gL and Pentameric complex (PC)86,87. Of those, 
PC-specific antibody responses appear to have the highest neutralizing capacity and vac-
cines that are based on this complex elicit strong and broadly neutralizing responses in 
different animal models88 91. PC-specific antibodies are also 100- to 1000-fold more potent 
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in inhibiting epithelial and endothelial cell infection compared with those targeting gB or 
gH/gL/gO92. Consequently, such antibody responses may be superior in preventing the in-
fection of placental cytotrophoblasts, which adopt an endothelial phenotype during gesta-
tion (Figure 4)83. Although many molecular determinants of intrauterine CMV infection are 
still unclear, infection of this cell type is thought to be a critical event during CMV transmis-
sion to fetuses93,94. This is supported by studies that found a reduced risk of fetal transmis-
sion when primary CMV infection during pregnancy was concomitant with early develop-
ment of PC-specific antibodies95,96. As a result, the PC is a central component of many cur-
rent vaccine concepts that aim at the induction of antibody responses for the prevention of 
mother-to-child transmission97. 
Despite an undisputable contribution of NK- and B cells, T cell-mediated immunity is still 
considered the predominant mechanism by which latent CMV infection is controlled in 
vivo13. CMV infection induces profound changes in the T cell memory compartment and an 
extraordinarily large proportion of T cells is often dedicated solely to this pathogen. Domi-
nant responses to single epitopes regularly reach 5-10% of total CD8+ T cells in peripheral 
blood and up to 30% of the overall cytotoxic T cell (CTL) responses are sometimes CMV-
specific in healthy adults98,99. However, there is considerable variation in magnitude and 
breadth of T cell responses between individuals, a phenomenon that is still not fully under-
stood100. Typically, T cell responses to CMV tend to increase with age, display an effector 
memory (TEM) phenotype and lack markers of T cell exhaustion99,101,102. The gradual expan-
sion and long-term maintenance of CMV-specific T cell populations after initial infection is 
ally defined 
and was originally introduced in the context of MCMV infection103. It is remarkable that 
large numbers of CMV-specific T cells are sustained over many years without diminished 
effector functions, given that in other chronic viral infections such as HIV, HBV or HCV, 
virus-specific T cells typically decrease in number and show signs of exhaustion over 
time104,105. It has been hypothesized that this is due to differences in the antigenic burden, 
since the aforementioned viruses typically replicate continuously and to high titers in vivo. 
This results in constant stimulation of virus-specific T cells, a condition that favors functional 
exhaustion over time. By contrast, CMV reactivation from latency seems to occur sporadi-
cally and on a smaller scale, therefore avoiding permanent restimulation of T cells106,107. 
However, it is still unclear if the extraordinarily high number of CMV-specific T cells in some 
individuals is a requirement for protection or simply the result of gradual, life-long expan-
sion of an initial pool of effector cells that is driven by periodic reactivation events108. Due 
to its profound and long-lasting impact on the immune system, CMV is also suspected of 
accelerating immune senescence, but it is currently not clear if this has clinical implica-
tions109,110. 
Although many questions about the nature of the CMV-specific T cell pool are still un-
addressed, their potency in controlling CMV infection is well established. For instance, an-
tibody-mediated depletion of CD8+ T cells in rhesus monkeys leads to reactivation of 
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rhCMV111. Depletion of lymphocytes in mice also results in reactivation of MCMV replica-
tion, which can be suppressed by adoptive transfer of T cells112,113. Similarly, CMV-specific T 
cell responses and subsequent control of viral replication, could be restored in immunocom-
promised patients through adoptive T cell transfer114 116. T cell responses are directed 
against a high number of CMV proteins: Using overlapping 15-mer peptides comprising 213 
CMV genes for the stimulation of T cells from 33 seropositive adults, Sylwester et al. found 
that a total of 151 open-reading frames (70%) were immunogenic98. Most individuals rec-
ognize 5-10 proteins in each T cell subset, with IE-1, IE-2 and pp65 generally inducing the 
strongest CTL responses and gB, pp65, UL16 and TRL14 dominating the CD4+ T cell com-
partment13,108. 
 
Figure 4  Immune responses to CMV 
CMV is capable of infecting a wide variety of cells ranging from fibroblasts to epithelial cells, endothelial cells 
and myeloid cells (e.g. monocytes and precursors thereof). Fibroblast infection is mediated by the glycoprotein 
complexes gB (GC I) and gH/gL/gO (GC III), while for the infection of the residual cell types, the pentameric 
complex (PC) is required in addition to GC I and GC III. Lytic replication is confined (among others) by T cell, B 
cell and NK cell mediated antibody responses. Antibodies that are directed against the pentameric complex 
are particularly potent in inhibiting endothelial/epithelial cell infection and might therefore be superior in pre-
venting intrauterine infection. During latency, which is established in certain cells from the myeloid lineage, 
only a small set of latency-associated genes is expressed. Viral reactivation from latently infected cells (for 
example as a result of monocyte differentiation) is controlled predominantly by T cell mediated immunity.  
 
III.4. Clinical implications 
In healthy individuals, primary infection is mostly asymptomatic or merely accompanied by 
mild symptoms resembling those of an infectious mononucleosis117. However, CMV causes 
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considerable morbidity and even life-threatening complications in immunocompromised in-
dividuals such as transplant recipients and AIDS patients118 120. Cytomegalovirus particles 
can infect a remarkably broad range of cells and spread to virtually every organ within its 
host121. As a result, CMV disease can result in a variety of clinical manifestations such as 
colitis, pneumonitis, encephalitis, hepatitis and retinitis122,123. 
Human cytomegalovirus also represents one of the most common congenital infections 
worldwide with an estimated prevalence of 0.64% at birth and is a leading cause of disa-
bility in children (Figure 5)124,125. The risk for intrauterine transmission is highest (30-35%) if 
a seronegative mother becomes infected with CMV during pregnancy125. By contrast, viral 
reactivation in a seropositive mother less frequently results in fetal infection (1.2-1.4%)7,126. 
Neonatal symptoms of congenital CMV infection include microcephaly, hepatosplenomeg-
aly, petechiae, jaundice, chorioretinitis, thrombocytopenia and anemia127. The mortality rate 
among infants with symptomatic CMV disease at birth is 10 30% and only about 10% fully 
recover, while the remaining children will have long-term sequelae ranging from sensori-
neural hearing loss and delayed neural development to mental retardation128,129. However, 
even children with congenital CMV infection that show no symptoms at birth may develop 
late sequelae, albeit with lower frequency (8-15%)130,131. Early infection of the fetus, partic-
ularly in the first trimester, is generally associated with an increased likelihood of severe 
complications132.  
 
 
Figure 5 - Global CMV seroprevalence levels and incidence of congenital CMV infection 
Cytomegalovirus seroprevalence rates among women of reproductive age (reproduced from Manicklal et 
al.124) are displayed in different shades of color, and congenital CMV birth prevalence rates are shown by the 
circles. Figure from Emery and Lazzarotto132. 
CMV is considered an opportunistic pathogen, mostly causing severe disease as a result of 
inadequate immune responses. Besides congenital infections, where the virus often encoun-
ters an immune system that is not fully developed yet, this is also the case during innate or 
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acquired immunodeficiency. Accordingly, an increased risk for CMV disease has been de-
scribed in numerous innate immunodeficiency syndromes like Fanconi anemia, severe com-
bined immunodeficiency (SCID) or common variable immunodeficiency (CVID)133 135. Ac-
quired immunodeficiency, mainly due to HIV infection, also predisposes for symptomatic 
CMV disease. The broad application of combined antiretroviral therapy (ART) has reduced 
the incidence of CMV disease from being the most significant opportunistic infection to a 
rarity during treatment122,136,137. However, given that a high proportion of HIV positive indi-
viduals is still without access to ART, CMV remains a significant co-morbidity in patients 
suffering from AIDS. 
Because the number of solid-organ and haematopoietic stem cell transplantations has been 
increasing in recent years, transplant recipients are another steadily growing group with a 
high incidence of CMV disease. New potent immunosuppressive agents contribute to de-
creasing the incidence of graft rejection, but at the same time, patients are left highly sus-
ceptible to opportunistic infections138. Although various pathogens frequently cause disease 
in transplant recipients (e.g. EBV, Adenoviruses, mycobacteria or fungi), CMV is still the 
most common infection139 142. The risk for severe complications is generally greatest if a 
CMV seronegative donor receives a graft from a seropositive donor (D+/R-)143. However, a 
multitude of additional factors such as the age of the transplant recipient, the state of im-
munosuppression, genetic predispositions or the type of organ graft influence the clinical 
outcome as well: For example, lung, small intestine and pancreas transplant recipients are 
at higher risk for severe complications than kidney or liver transplant recipients118,144. 
Antiviral agents such as Ganciclovir, Valganciclovir, Foscarnet and Cidofovir are available for 
the treatment of CMV disease and capable of reducing the incidence of CMV reactivation 
after transplantation145 147. However, renal toxicity and interactions with other drugs, as well 
as the emergence of resistant virus strains, limit their therapeutic potential148 150. Thus, to 
avoid unnecessary administration of antivirals, preemptive therapy is often applied instead 
of universal prophylaxis for the management of CMV reactivation after transplantation151,152. 
As part of this strategy, antiviral therapy is only initiated if a predefined threshold level of 
viral DNA copy number in blood is surpassed, because viremia usually precedes symptomatic 
CMV disease136,153. Although preemptive therapy is useful for reducing drug-related toxici-
ties, there is still controversy about whether it is preferable to universal prophylaxis, espe-
cially in high risk constellations (D+/R-)152,154. Next to small molecule drugs interfering with 
viral replication, CMV reactivation can also be controlled by adjusting the level of immuno-
suppression or through adoptive transfer of virus-specific T cells, but early identification of 
patients at risk for viral relapse is critical for the success of all these interventions155 157. 
 
III.5. Monitoring of CMV-specific immune responses 
Due to the key role of T cell mediated immune responses in controlling CMV replication, 
there is a strong correlation between loss of CMV-specific T cells and viral reactivation. As 
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early as 1991, Reusser et al. reported that in a cohort of bone marrow transplant recipients, 
none of the patients with detectable CMV-specific T cells developed CMV disease. At the 
same time, more than half of patients lacking CMV-specific T cell responses died of CMV 
pneumonia158. Since then, a plethora of studies was published highlighting the diagnostic 
value of virus-specific T cells for the prediction of CMV reactivation159 162. For example, more 
recent work from Espigado et al. showed that after hematopoietic stem cell transplantation, 
early reconstitution of CMV-specific T cell responses (  6 weeks), is associated with less 
incidence of CMV replication, reduced viral loads and better overall survival, compared to 
patients with delayed immune reconstitution163. Collectively, these results indicate that 
monitoring of virus-specific T cells is a promising approach for the early identification of 
patients that are at risk for CMV disease (Figure 6). 
 
Figure 6  Immune monitoring for the 
identification of patients at risk for CMV 
disease 
Following transplantation, the quantity or 
function of T cells may decline as a result of 
drug-induced immunosuppression. Loss of 
CMV-specific T cell responses can result in re-
activation of lytic CMV replication, concomi-
tant with viremia and symptomatic disease. 
Quantification of CMV-specific T cells could 
help to identify patients with an elevated risk 
for CMV disease prior to viremia (which is the 
current criterion for initiating the administra-
tion of antivirals during preemptive therapy).  
 
Various methods are currently available for assessing pathogen-specific T-cell immunity164. 
Such techniques are either based on direct detection of cells, for example after staining with 
MHC-multimers165, or the quantification of activation markers such as Interferon   
after stimulation with pathogen-derived antigens166. These markers can then be detected 
by intracellular cytokine staining (ICS), followed by flow cytometry analysis, or via Enzyme-
linked immunosorbent (ELISA) or Enzyme-linked immunospot (ELISpot) methods.  
Next to the detection method, various types of antigens are also available for stimulation, 
including viral lysates, peptide pools and recombinant proteins. IE-1 and pp65 are the pre-
ferred antigens for CMV in most assays, since they are the main targets of CD8+ T cells13,167. 
Currently, there is no consensus on the ideal method for monitoring of CMV-specific T cells 
and proposed threshold levels still lack extensive validation156. Nevertheless, there is accu-
mulating evidence that in the future, monitoring T cell immunity could become a corner-
stone in the management of Cytomegalovirus in transplant recipients. 
 
III.6. Current Status of CMV vaccine development 
In 2000, a committee from the US national institutes of health tasked with prioritizing ef-
forts for the development of novel vaccines assigned the highest level of priority to the 
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implementation of a CMV vaccine168. Taking the impact of CMV on morbidity and mortality 
into consideration, the committee estimated that if a vaccine with 100% efficacy was ad-
ministered to the entire population, a total of 70.000 quality-adjusted life years (QALY) 
could be gained per year in the United States. In addition, the annual health care costs 
saved would be an estimated 4 billion per year in the US alone (assuming that the vaccine 
would cost 50$ per course). However, although the first vaccine efforts date back to the 
1970s and a multitude of candidates has been developed since, a protective or therapeutic 
CMV vaccine has still not been licensed (Figure 7)169. An efficacious Cytomegalovirus vaccine 
is urgently needed, given that treatment options with antiviral agents are limited due to 
side effects and the emergence of resistant virus strains170 172. In addition, there is currently 
no therapy available for inhibiting intrauterine infection during pregnancy, although at least 
some concepts are undergoing clinical trials132,173. 
 
Figure 7  History of CMV vaccine development  
Summary of selected candidate vaccines that were evaluated in preclinical and clinical trials. Glycoprotein B 
(gB), pp65 and IE1 were mainly tested as potential targets, delivered by various platforms including the atten-
uated CMV Towne isolate174, recombinant viral vectors encoding full-length antigens and epitopes175,176, 
DNA177, dense body (DB)178 and subunit179  vaccines. BAC: Bacterial artificial chromosome; CTL: Cytotoxic T-
lymphocyte; MVA: Modified vaccinia Ankara. Figure from Dasari et al.180 
Of the numerous candidate vaccines that were developed over the last decades, only few 
made it past the early stages of clinical trials136. However, modest efficacies have previously 
been reported in phase II studies for both prophylactic as well as therapeutic approaches 
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(e.g. 50% efficacy for gB protein with adjuvant MF59)181,182. While these results are encour-
aging and imply that the development of a CMV vaccine is feasible, it also underlines the 
necessity to explore novel, alternative vaccine concepts. 
Since clear immunological correlates of protection from CMV infection have not been de-
fined yet, vaccine candidates should ideally induce both humoral and cell-mediated immune 
responses180,183. As described above (section III.2), several different glycoproteins are ex-
pressed on the virion surface, all of which are targets for humoral immunity. Until recently, 
subunit vaccines designed for the induction of protective antibody responses mostly fo-
cused on the fusion protein gB. The rediscovery of the pentameric complex in 2005 as a 
crucial component for the infection of epithelial and endothelial cells revealed a new target 
for such vaccine concepts184. Indeed, inclusion of the pentameric complex into subunit vac-
cines or attenuated virus led to promising results in animal models185,186. 
At the same time, cell-mediated immunity plays a crucial role in controlling viral latency and 
limiting virus spread. T cell responses are directed against a variety of viral antigens, with 
the tegument protein pp65 and the transcriptional regulator IE-1 representing major tar-
gets98,187. Interestingly, expression of CMV antigens is frequently detected in glioblastoma 
cells188,189, and as a result, therapeutic vaccination concepts that aim at expanding CMV-
specific T cells for enhancing antitumor immunity are currently being tested in clinical stud-
ies190.  
Viral vectors are a favored tool for the delivery of heterologous antigens, in part due to their 
capability to efficiently prime T cell responses during vaccination191. Several such vectors, 
like the poxvirus strain Modified Vaccinia Ankara (MVA) are currently being evaluated as 
therapeutic vaccine candidates in clinical trials, although their efficacy has yet to be demon-
strated192,193. However, repeated administration of an antigen by a given vector is impeded 
by the development of immunity to its backbone, which can be avoided by heterologous 
prime/boost immunizations. Hence, novel vectors should still be developed and assessed for 
their capacity to deliver CMV immunogens. Three different viral vector classes that were 
used in this work (MVA, AdV and SeV) are introduced in the following sections. 
 
III.6.1. Modified Vaccinia Ankara (MVA) 
Poxviruses containing foreign genes are a well-established platform for the development of 
novel vaccines and therapeutics in biomedical research. Advantages of poxvirus vectors in-
clude large packaging capacity for heterologous DNA, exclusive replication in the cytoplasm 
(minimizing the risk of genomic integration) and lack of persistence in the host, as well as 
high immunogenicity194,195. Most poxvirus vectors are based on the strain Vaccinia, which 
was originally used for the eradication of smallpox196. Vaccinia was long presumed to be 
derived from a strain of cowpox, but more recent analysis indicates that it likely originated 
from a strain of rodent or equine origin197. Although vaccinia exhibits strongly reduced vir-
ulence in humans, there are multiple well-documented cases of vaccination complications 
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as well as laboratory infections198,199. Hence, several highly attenuated, Vaccinia-derived vi-
rus strains were generated for usage as immunogen delivery vectors, including New York 
Vaccinia Virus (NYVAC)200 and Modified Vaccinia Ankara (MVA)201. MVA was generated 
from the vaccinia virus strain Ankara, which was used at the vaccine institute in Ankara for 
smallpox vaccine production194. Serial passaging of this strain on chicken embryo fibroblast 
(CEF) cells led to the loss of approximately 15% of the viral genome over more than 500 
passages202,203. The resulting MVA strain displays enhanced attenuation, as illustrated by its 
inability to replicate in human cell lines204. MVA is currently licensed as a vaccine against 
smallpox. Moreover, it is one of the most broadly used viral vectors for the delivery of anti-
gens from various pathogens.  
 
III.6.2. Adenovirus vectors 
Human adenoviruses (AdVs) comprise a large family (>70 serotype) of non-enveloped, dou-
ble-stranded DNA viruses that are subdivided into seven species termed A-G1,205,206. Depend-
ing on the serotype, AdV infection can affect the respiratory, gastrointestinal or urinary tract 
as well as the eye, occasionally causing severe disease. Nonetheless, natural infections with 
these ubiquitous viruses are mostly asymptomatic or merely accompanied by mild symp-
toms207. Recombinant, replication-defective adenoviruses are extensively utilized as vectors 
for vaccination, cancer treatment or the delivery of therapeutic genes. Reasons for the pop-
ularity of AdVs as vaccine vectors include high packing capacity and immunogenicity, com-
bined with an excellent safety profile and the capability to infect both dividing and non-
dividing cells208 211. Simple and inexpensive methods for vector construction and purification 
of high titer viral stocks from cell culture further contribute to making the AdV vector plat-
form versatile in use. 
Historically, most studies on basic aspects of Adenovirus biology were carried out using AdV 
type 5 (Ad5, a member of subgroup C), and as a consequence, recombinant vectors were 
almost exclusively based on Ad5 for many years212. However, broad usage of these vectors 
is limited by preexisting immunity to Ad5 in humans with the presence of neutralizing anti-
bodies (NAbs) reaching up to 90% in some regions213. Efficient transduction by Ad5 is also 
confined to cells expressing the Coxsackie virus and Adenovirus receptor (CAR)214. Direct 
binding to erythrocytes, liver sequestration of virions and hepatotoxicity after intravenous 
administration constitute additional disadvantages of Ad5-based vectors counteracting 
broad clinical application215 217. 
In order to exploit the natural diversity of Adenoviruses and to overcome the limitations of 
Ad5-based vectors, an increasing number of AdVs from different subgroups have been vec-
torized in recent years218. Vector alternatives like Ad6 (NAb frequency  68%213), Ad26 (NAb 
frequency  43-68%219) or Ad35 (NAb frequency  5-18%219) were demonstrated to be 
immunogenic and well tolerated in animal models and humans220 223. Beyond that, chim-
panzee Adenoviruses (chAdVs) like chAd3 and chAd63 are also emerging as a new vector 
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class, although preexisting immunity in humans (up to 33% NAb frequency for chAd63224) 
has been reported as well225 227. While the aforementioned AdV-based vaccine candidates 
mostly gave promising results in clinical trials, it has also become evident that repeated 
administration of the same vector is hampered by the induction of neutralizing antibod-
ies228. This underlines that novel AdV vectors should still be established to meet an increas-
ing demand for safe and efficacious delivery systems in gene therapy and vaccination229. 
Previously, an E1/E3-deleted gene therapy vector based on Adenovirus 19a (recently re-
named to Ad64230, NAb frequency 16-19%231,232), a member of subgroup D that causes 
epidemic keratoconjunctivitis in humans, has been described233,234. AdVs from this subgroup 
display a particularly broad host cell tropism since they bind to ubiquitously expressed sialic 
acids rather than CAR and might therefore be a promising alternative to Ad5-based vec-
tors235,236. 
 
III.6.3. Sendaivirus vectors 
Sendai virus (SeV) is a non-segmented, negative strand RNA virus that belongs to the family 
Paramyxoviridae and causes respiratory infections in mice237. A number of advantageous 
features have led to broad usage of SeV as a viral vector including exclusive replication in 
the host cell cytoplasm238, efficient transduction of both dividing and non-dividing cells239, 
broad target cell tropism240,241 and replication to high titers in cell culture242. Importantly, it 
is also considered non-pathogenic in humans243,244. Sendai virus is currently tested as a Jen-
nerian vaccine for human parainfluenza virus and as a viral vector for the delivery of human 
respiratory syncytial virus antigens245–247. In appreciation of its many favorable characteris-
tics, SeV is also emerging as a vector for the delivery of immunogens from unrelated path-
ogens such as HIV-1 Gag222,248. 
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III.7. Objective of this thesis 
The quantification of virus-specific T cell responses is a promising method for assessing cell-
mediated immunity to CMV in general and to predict viral reactivation from latency. Most 
methods for the identification of such T cells are based on the detection of activation mark-
ers like  upon antigen recognition via the T cell receptor complex (TCR). A prerequisite 
for TCR recognition of pathogen-derived peptides is their presentation by antigen-present-
ing cells (APCs) and accordingly, the efficiency with which antigens are delivered to these 
cells has a major impact on assay sensitivity (Figure 8). Thus, one main focus of this work 
was to increase the uptake of proteins into APCs to improve currently available methods 
for the measurement of cell-mediated immunity to CMV.  
 
Figure 8  Protein uptake and pro-
cessing by antigen-presenting cells 
Proteins are taken up from the extracellular 
space (1), degraded in endolysosomes (2), 
loaded onto MHC-II molecules and trans-
ported to the cell surface where they can 
interact with CD4+ T cells (3). Alternatively, 
in a process termed cross-presentation, pro-
teins escape endosomes and enter the cyto-
plasm, followed by proteasomal degrada-
tion (4). Peptides are then transferred to the 
endoplasmic reticulum, loaded onto MHC-I 
molecules and transported to the cell sur-
face where they are recognized by antigen-
specific CD8+ T cells (5). Enhanced protein 
uptake might increase the overall amount 
of MHC presentation and, as a conse-
quence, also T cell stimulation. 
Previously, it was reported by Barabas et al. that storage of the Epstein-Barr virus (EBV) 
protein BZLF1 in high molar urea solutions prior to stimulation of immune cells enhances 
the restimulation of antigen-specific T cells249. Since this is a simple and inexpensive method 
for increasing T cell reactivation rates, the molecular mechanism underlying this phenome-
non should be elucidated in order to evaluate whether this technique can be applied to a 
broader panel of antigens, comprising the CMV proteins IE-1 and pp65  BZLF1. 
As storage in urea induces protein carbamoylation, the main hypothesis to be tested here 
was that this posttranslational modification alters antigen uptake and T cell restimulation 
rates.  
Beyond ex vivo applications, CMV proteins that are modified for enhanced uptake into APCs 
might also be used for the priming of adaptive immune responses during vaccination. Fur-
ther, in order to influence magnitude and quality of the induced immune responses, a com-
bination of various delivery methods in heterologous prime/boost immunizations might be 
required. Of the many conceivable delivery systems, live attenuated viral vectors are partic-
ularly interesting tools due to their inherent immunogenicity. Hence, another main focus of 
this work was the generation and preclinical characterization of novel virus vectors deliver-
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ing CMV antigens. Two adenoviruses strains (Ad5 and Ad19a/64), the poxvirus strain Mod-
ified Vaccinia Ankara (MVA) as well as Sendai virus (SeV, a murine RNA virus) were chosen 
and recombinants expressing IE-1 or pp65 were generated. Since immunological infor-
mation on SeV and Ad19a/64 is still limited, basic aspects of vector biology should be ex-
plored prior to in vivo studies to exclude possible immune evasion mechanisms like inter-
ference with antigen processing. Here, the vectors should be compared in a series of ex 
vivo assays to the well-established vector platforms Ad5 and MVA regarding parameters 
such as target cell tropism, cytotoxicity as well as antigen expression and presentation (Fig-
ure 9). Most parameters should be measured after transduction of dendritic cells (DCs), 
partly because they are the most potent APCs in vivo. In addition, DCs that are pulsed ex 
vivo with CMV antigens might be readily applied as a therapeutic vaccine, a strategy which 
is currently being employed with some success in clinical studies for the treatment of glio-
blastomas expressing CMV antigens190,250. 
 
Figure 9  Transduction 
of dendritic cells by viral 
vectors 
The CMV antigens IE-1 or 
pp65 were inserted into the 
genomes of Modified Vac-
cinia Ankara (MVA), Adeno-
virus (AdV) and Sendai virus 
(SeV). After ex vivo trans-
duction of human dendritic 
cells, various parameters 
like transduction rates, anti-
gen expression and presen-
tation, cytotoxicity and mat-
uration of dendritic cells 
should be assessed.  
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IV. Results 
IV.1. Influence of posttranslational modifications on protein 
delivery to antigen-presenting cells 
Adaptive immune responses require priming of naïve lymphocytes, a function that is carried 
out mainly by professional antigen-presenting cells (APCs) like dendritic cells (DCs) and mac-
rophages. These cells specialize in taking up proteins from the extracellular space, which 
are subsequently processed and presented on major histocompatibility (MHC) complexes. 
A defining property of professional antigen-presenting cells is the co-expression of MHC 
class one (MHC-I) and class two (MHC-II) complexes, which allows presentation of peptides 
to both CD4 and CD8 positive cells, respectively (most cell types express MHC-I only). In 
addition, professional APCs express a number of costimulatory molecules that activate T 
cells, thereby engaging multiple independent pathways in parallel and lowering the thresh-
old signal required for T cell priming. Due to these properties, professional APCs hold a 
unique and central role in the initiation of immune responses and interaction with T cells. 
As a consequence, techniques that mediate efficient delivery of antigens to these cells have 
great potential both for the development of novel vaccine candidates (in vivo) as well as 
monitoring of antigen-specific effector cells (ex vivo).  
It was previously reported that storage of the EBV protein BZLF1 in high molar (4 M) urea-
solution results in increased stimulation of CD4+ and CD8+ T cells compared to urea-non-
treated protein (Figure 10). It was further demonstrated that the urea-treated protein is 
taken up via clathrin-mediated endocytosis into a number of APCs, including monocyte-
derived dendritic cells (moDCs), B cells and monocytes249.  
 
Figure 10 - Urea treatment in-
creases the restimulation of 
BZLF1-specific T cells  
Whole blood from an EBV-seroposi-
tive donor was stimulated with 
BZLF1 or urea-treated BZLF1 (10 
µg/ml each) for 7 hours with Bre-
feldin A (BFA, 10 µg/ml) present dur-
ing the last 4 hours. Cells were 
stained for CD3, CD4, CD8 and intra-
cellular IFN- by flow cy-
tometry analysis. Shown is the per-
centage of CD3+CD8+ or CD3+CD4+ 
cells expressing IFN-
sentative stimulation of eight inde-
pendent experiments using a total of 
4 different donors. Plots show log 
fluorescence intensity. Modified 
from Barabas et al. (2008)249. 
Although protein storage in urea might be a simple and cost-effective method for increasing 
uptake into APCs in general, it is unclear if this treatment will have a similar effect when 
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applied to other candidate proteins. Moreover, the molecular mechanism by which UREA-
treatment of the stimulating protein leads to increased T cell restimulation is not known. 
In aqueous solution, urea is present in an equilibrium with cyanic acid and ammonium fa-
voring urea (>99%)251,252. Tautomerization of cyanate leads to the formation of isocyanic 
acid, which in turn reacts with primary amino groups in a process termed carbamoylation. 
Protein carbamoylation is an irreversible, posttranslational modification that affects the α-
amino group at the N- -amino groups of lysine and arginine side chains 
(Figure 11). While in vitro, carbamoylation is often an undesired side effect of protein stor-
age in urea buffers253, it has become evident that this modification also occurs in vivo where 
it has impact on a number of pathophysiological processes. For instance, it is considered a 
hallmark of ageing as well as a biomarker for renal dysfunction and uremia254 257. Car-
bamoylation has also been associated (among others) with the development of atheroscle-
rosis, various immune system dysfunctions and the formation of anti-carbamoylated protein 
antibodies (reviewed in detail by Delanghe et al258). There are two main pathways by which 
cyanate formation and subsequent protein carbamoylation take place in vivo: i) Spontane-
ous dissociation of urea, a mechanism that leads to increased carbamoylation of serum 
proteins in uremic patients as a result of chronic kidney disease. ii) Formation of cyanate 
from the oxidation of thiocyanate, a reaction that is catalyzed by the enzyme myeloperoxi-
dase (MPO) in the presence of hydrogen peroxide. MPO is released from neutrophils and 
macrophages during inflammation, thus inducing a local increase in protein carbamoylation 
at inflammatory sites259. 
 
Figure 11  Mechanisms of protein car-
bamoylation  
The reaction of isocyanic acid (a tautomer of 
cyanate) with primary amino groups is 
termed carbamoylation. In vivo, car-
bamoylation occurs following the spontane-
ous dissociation of urea into cyanate and am-
monium (NH4+). Protein carbamoylation as a 
result of this pathway is increased during re-
nal dysfunction concomitant with uremia. Al-
ternatively, cyanate can be formed by the en-
zymatic oxidation of thiocyanate in the pres-
ence of hydrogen peroxide (H2O2). This is cat-
alyzed by myeloperoxidase (MPO), an en-
zyme stored mainly in the azurophilic gran-
ules of neutrophils that is released during in-
flammation. Smoking or certain dietary 
choices can lead to elevated levels of thiocy-
anate in blood, ultimately resulting in in-
creased protein carbamoylation during in-
flammation. Figure adapted with permission 
from Elsevier © Verbrugge et al.252, license 
number 4194070497430. 
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Since the immune system has evolved to distinguish self and altered-self components, and 
recognition of carbamoylated low-density lipoprotein (LDL) by monocytes had been re-
ported before260, it was intriguing to test if this modification might be responsible for the 
increased uptake of urea-treated proteins into antigen-presenting cells. 
 
IV.1.1. Impact of protein carbamoylation on T cell restimulation 
To assess a putative impact of carbamoylation on protein uptake into APCs and the subse-
quent restimulation of antigen-specific T cells, the CMV proteins IE-1 and pp65 as well as 
the EBV protein BZLF1 were chosen as model antigens. Besides carbamoylation, treatment 
with high molar urea also induces protein denaturation, which might influence the interac-
tion with antigen-presenting cells as well. Furthermore, if urea is not removed from the 
protein after the treatment, low amounts will be present during stimulation, possibly im-
pacting cellular homeostasis by changing the osmolarity of the culture medium. Thus, to 
separate a possible contribution of carbamoylation to T cell stimulation from any other in-
fluences urea might have, cyanic acid was used instead of urea to induce this posttransla-
tional modification. For sensitive and antigen-specific stimulation of primary T cells, stimu-
lator proteins have to meet certain quality criteria regarding purity and absence of bacterial 
contaminations such as lipopolysaccharide (LPS). Since there was no commercial source for 
full-length IE-1, pp65 and BZLF1 fulfilling those criteria, a suitable expression system first 
had to be determined, followed by establishment of a purification method under urea-free, 
native conditions. All proteins were fused C-terminally with a 6xHistidine tag, followed by 
a Strep tag (Figure 12A), thus allowing affinity purification using either nickel or Strep-Tactin 
beads261. For removal of the tandem affinity tag after purification, protein and tag were 
further separated by a short amino acid sequence recognized by the 3C protease of human 
rhinovirus262. To identify a suitable expression system, transient transfection of human 
HEK293F cells grown in suspension culture, inducible expression in E. coli cells as well as 
infection of insect cells with a recombinant baculovirus strain were evaluated. While yields 
were generally rather poor with HEK293F cells (below 50µg per l) and LPS contaminations 
proved challenging to avoid using E. coli, the best results regarding purity and yield were 
obtained with insect cells using the Bac-to-Bac expression system263,264 (data not shown). 
While there was some variation between the different proteins and individual purification 
batches, yields ranging from several hundred micrograms to milligrams per liter of cell cul-
ture could be readily obtained, all of which were sufficiently pure and contained undetect-
able or very low (<5 EU/mg) levels of LPS.  
Purification of pp65 from crude cell lysates was performed under native conditions using 
Ni-IDA beads (Figure 12B, section VI.3.2), followed by cleavage of the tag with Glutathione 
S-transferase (GST) tagged PreScissionTM protease (section VI.3.2). To remove cleaved tag 
and protease, the eluate was incubated with an excess amount of Strep-Tactin Sepharose 
(binding the removed tag as well as uncleaved protein) and Glutathione Sepharose (binding 
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the protease). Quantitative cleavage and removal of undesired components were verified 
by Western blot analysis (Figure 12C) while purity of the final product was further assessed 
by silver staining of proteins after SDS PAGE (Figure 12D). Silver staining revealed that pp65 
was sufficiently pure and only few contaminations were visible in the final product. How-
ever, even though the respective bands were not detected in Western blot analysis, they 
could also represent C-terminal degradation products in which the recognized epitopes 
were removed. 
 
Figure 12 - Purification of pp65 from insect cells 
(A) pp65 (65kDa) was fused C-terminally with a His/Strep tandem tag for affinity purification. Tag and protein 
are separated by the recognition sequence of the 3C protease of human rhinovirus, allowing removal of the 
tag by proteolytic cleavage using PreScissionTM protease after purification. (B) pp65 was purified from Bacu-
lovirus-infected High Five cells using Ni-IDA beads. During purification, Aliquots were collected from the in-
soluble fraction that was pelletized after cell lysis, the cell lysate (input), the washing steps as well as the 
elution fractions. Samples were subjected to SDS-PAGE and Coomassie-staining. (C) Proteolytic cleavage was 
performed for removing the His/Strep tandem affinity tag after purification of pp65 from crude cell lysates. 
GST-tagged PreScissionTM protease was added to the samples and after digestion, cleaved tag and protease 
were removed from samples by adding GSH- and Strep-Tactin-beads. Aliquots were collected at all steps and 
subjected to Western blot analysis. (D) After tag removal, the final product was analyzed via SDS PAGE and 
silver staining with the indicated protein quantities loaded per lane. 
Whereas IE-1 could be purified in the same manner as pp65 (Supplementary Figure S1), 
cleavage of the tag was unsuccessful in the case of BZLF1. This was unexpected since pres-
ence of the correct cleavage site could be confirmed on DNA level by Sanger sequencing. 
In addition, successful purification of the protein with Ni-IDA beads under native conditions 
indicated that the fusion protein was likely folded in a way that would allow the tag to be 
accessed (these findings are documented in detail in 265). 
Nevertheless, quantitative cleavage of the tag could not be achieved for this protein. Hence, 
it was decided not to subject BZLF1 to protease digestion at all and instead work with the 
full-length fusion protein (Supplementary Figure S2).  
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The amount of pp65, IE-1 or BZLF1 required to elicit T cell restimulation was then deter-
mined using PBMCs from 3 CMV or EBV seropositive donors each and titrating the three 
proteins separately. ELISpot analysis stimulated PBMCs revealed that robust reactiva-
tion was achieved using 0.5 µg/ml (pp65), 4.5 µg/ml (IE-1) and 3.3 µg/ml (BZLF1), respec-
tively (data not shown). Hence, these concentrations were used for PBMC stimulation in all 
following experiments (VI.5.3).   
Next, carbamoylation of these three proteins was induced using potassium cyanate (KOCN) 
instead of urea. The reaction kinetics for a given protein depend on a multitude of factors, 
with temperature, pH and the concentration of cyanic acid exerting the biggest influence. 
To avoid protein denaturation at higher temperatures, a previously published protocol 
where proteins are modified with 300 mM KOCN at 35 °C was adapted266. In order to 
quantify the amount of carbamoylation, an enzyme-linked immunosorbent assay (ELISA) 
was established using a polyclonal antibody mixture recognizing homocitrulline (car-
bamoylated lysine). The protocol was benchmarked to a commercial ELISA kit for the de-
tection of protein carbamoylation, where it showed comparable sensitivity and specificity 
(data not shown). Using this method, the amount of carbamoylation was quantified over 
time for pp65, BZLF1 and IE-1 (Figure 13, section VI.3.10). After 6 hours of incubation with 
300mM KOCN at pH 8.0 and 35 °C, ELISA signals appeared to reach a plateau for all pro-
teins. For IE-1, saturation was reached the fastest, possibly because this protein contains a 
higher proportion of lysine residues (7.3%), compared to pp65 (3.9) and BZLF1 (3.3). How-
ever, it cannot be concluded from this data that protein carbamoylation has in fact reached 
saturation at this point, since steric hindrances might at some point preclude additional 
binding of the detection antibody. Moreover, due to the usage of homocitrulline-specific 
antibodies, possible arginine carbamoylation cannot be detected with this method at all. 
Therefore, the incubation period with KOCN was extended to 24 hours for all following 
experiments. Proteins modified according to this protocol are hereafter referred to as carb-
pp65, carb-BZLF1 or carb-IE-1. 
 
Figure 13  Cyanate induces carbamoylation of lysine residues 
pp65, BZLF1 or IE-1 were incubated at 35 °C with 300 mM potassium cyanate (KOCN) for up to 6 hours. At 
various time points, samples were collected and carbamoylation was analyzed via ELISA using antibodies that 
recognize carbamoylated lysine residues. The data displayed in this figure were collected in part during the 
nd Tobias Brunner under my experimental supervision265,267. 
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S were completely suppressed if PBMCs were stimulated in the presence 
of millimolar amounts of KOCN (Supplementary Figure S3), it was always removed from 
protein samples via extensive dialysis after the carbamoylation reaction. To assess if car-
bamoylation has an influence on the restimulation of antigen-specific T cells, PBMCs from 
CMV or EBV seropositive donors were stimulated with equivalent amounts of unmodified 
or carbamoylated pp65, BZLF1 or IE-1 (Figure 14). For pp65 and BZLF1, stimulation with 
carbamoylated proteins  as compared to stim-
ulation with the non-carbamoylated proteins. At the same time, background signals that 
were determined by stimulating PBMCs from CMV or EBV seronegative donors were not 
elevated as a result of protein modification. This indicates that the detected increase in T 
cell responses to carbamoylated pp65 and BZLF1 was indeed antigen-specific. The extent 
to which T cell responses were increased varied greatly from donor to donor and between 
the two proteins with carb-pp65 inducing a mean increase in spot forming units (SFU) of 
39% (range 6 - 112%). Mean responses to carb-BZLF1 were increased by 80% (range 5 - 
161%), not including one donor who reproducibly reacted to carb-BZLF1 with decreased T 
cell responses. In contrast to pp65 and BZLF1, T cell responses to IE-1 were significantly 
reduced for all donors when stimulated with the carbamoylated protein compared to its 
unmodified counterpart. 
 
Figure 14  Carbamoylation increases the restimulation of pp65- and BZLF1-specific T cells 
PBMCS from the indicated number of donors were stimulated for 20 hours with unmodified or carbamoylated 
pp65 (0.5 µg/ml), IE-1 (4.5 µg/ml) or BZLF1 (3.3 µg/ml), respectively. 
ELISpot assay. Values obtained with cells from a given donor are connected by lines. P values were calculated 
using the Wilcoxon signed rank test (two-tailed; one asterisk: p<0.05; two asterisks: p<0.01). The data dis-
played in this figure were 
under my experimental supervision265,267. 
Carbamoylation irreversibly modifies proteins and, as a result, also the epitopes recognized 
by T cells if they contain modified amino acids. Thus, shorter incubation periods with cya-
nate, concomitant with a lower degree of modification, might have an influence on T cell 
restimulation rates. However, using pp65 and testing 3 separate CMV positive donors, it 
was found that the impact of carbamoylation was greatest when the degree of carbamyla-
tion was highest, i.e. when this protein was incubated for 24 hours with potassium cyanate 
(Supplementary Figure S4). 
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Further it should be tested, whether the presence of UREA during stimulation might directly 
irrespective of the carbamoylation effect. To test this, 
urea was added separately to PBMCs for a final concentration of 50 mM. This is equivalent 
to the amount of UREA that would be present if the proteins were stored in 4 M solution, 
as it was done by Barabas et al. in the original paper describing increased T cell restimulation 
rates for UREA-treated BZLF1249. In contrast to carbamoylation, the presence of UREA during 
stimulation had no significant influence on T cell restimulation for pp65 (Figure 15). Other 
UREA concentrations, ranging from 25 mM to 150 mM, were also tested in the same man-
ner for 2 individual CMV positive donors. Again, T cell responses were unaltered except for 
a trend towards reduced SFU numbers beyond a concentration of 100 mM, which is likely 
explained by UREA toxicity (data not shown). 
 
Figure 15  The presence of urea has no impact on pp65-specific 
T cell responses 
PBMCs from 7 CMV seropositive donors were stimulated for 20 hours 
with unmodified pp65 (0.5 µg/ml) in the presence (+) or absence (-) of 
urea (50 assay. 
Values obtained with cells from a given donor are connected by lines. P 
values were calculated using the Wilcoxon signed rank test (two-tailed). 
The data displayed in this graph were 
sis of Philipp Becker and Tobias Brunner under my experimental supervi-
sion265,267. 
 
In summary, carbamoylation has a positive impact on the restimulation of BZLF1- and pp65-
specific T cells whereas for IE-1, this modification clearly reduces restimulation rates. At the 
same time, the presence of urea during stimulation has no significant impact on T cell re-
sponses, although a possible impact of protein denaturation should still be explored sepa-
rately. It is therefore likely that the increased T cell responses reported by Barabas et al. for 
urea-treated BZLF1 are, at least in part, a result of protein carbamoylation. To further inves-
tigate the molecular details of this phenomenon, pp65 was mostly used as a model protein 
for the following experiments, since CMV positive blood donors with good pp65 responses 
dominated the cohort that was recruited for this work. 
 
IV.1.2. Impact of negative protein charges on T cell restimulation 
To further explore the mechanism by which carbamoylation alters T cell restimulation rates, 
it was next assessed if the observed effects are dependent on changes in the net charge of 
posttranslationally modified proteins. -amino group of lysine and the guanidino-group 
of arginine residues are protonated at physiological pH, but carbamoylation leads to the 
loss of this positive charge268. As a result, it lowers the net charge of a given protein along 
with its isoelectric point (Figure 16). 
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Figure 16 - Carbamoylation lowers the isoe-
lectric point of pp65 
pp65 was incubated for up to 24 hours with po-
tassium cyanate (KOCN) and samples collected at 
the indicated time points were separated accord-
ing to their net charge in isoelectric focusing (IEF) 
gel electrophoresis (section VI.3.9), followed by sil-
ver staining of the gel. This data was collected dur-
experimental supervision267.  
To estimate the extent to which charges are altered in the proteins used in this work, it was 
necessary to quantify the amount of lysine and arginine carbamoylation that takes place 
under the chosen conditions. The previously applied ELISA assay is an unsuitable method 
for addressing these questions, given that no quantitative evaluation of lysine car-
bamoylation is possible and arginine modifications are disregarded altogether (Figure 13). 
Hence, mass spectrometry was employed instead for analyzing the extent and pattern of 
carbamoylation. In order to quantify the amount of lysine carbamoylation, conversion of 
this amino acid to homocitrulline (HCit) was first measured (section VI.4.1). For this, car-
bamoylated pp65 was spiked with known quantities of isotopically labeled reference amino 
acids and hydrolyzed completely by boiling the sample in hydrochloric acid (HCl). The amino 
acid composition was then analyzed using a previously described method based on double 
isotope-dilution mass spectrometry269,270. For quantitative analysis of homocitrulline, it was 
critical to first determine hydrolysis conditions under which pp65 is completely disassembled 
into single amino acids while HCit remains (at least partially) intact. If partial homocitrulline 
degradation takes place during the incubation period with HCl, this can be corrected for by 
spiking the sample with a known amount of D7-citrulline (D7-Cit) before hydrolysis (there 
was no commercial source for isotopically labeled HCit). Compared do HCit, the side chain 
of citrulline is shortened by one CH2-group, but the reactivity of both carbamoyl groups 
should be alike. Complete pp65 degradation with partially intact HCit/d7-Cit levels was 
achieved by hydrolysis at 115 °C for 20 h: when the hydrolysis time was doubled or the 
temperature was increased to 150 °C, no intact HCit/d7-Cit were left, but virtually identical 
normalized concentrations of phenylalanine, proline and valine were measured, indicating 
complete protein hydrolysis with the milder conditions (data not shown). After suitable con-
ditions were established, the concentration of homocitrulline was measured and related to 
the total concentration of pp65, which was determined by quantifying phenylalanine, valine 
and proline (Figure 17). Using this technique, complete conversion of lysine to homocitrul-
line was found, demonstrating that this amino acid is quantitatively modified during a 24 
hour incubation period with 300 mM KOCN at 35 °C. 
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Figure 17  Double isotope dilution mass spec-
trometry analysis of pp65-derived amino acids re-
veals complete conversion of lysine to homocitrul-
line  
Carb-pp65 was spiked with known quantities of isotop-
ically labeled reference amino acids, hydrolyzed and an-
alyzed by LC-MS. The concentration of homocitrulline 
(HCit) was related to the total concentration of pp65 as 
determined by quantification of phenylalanine, valine 
and proline. Bars represent the mean concentration of 
the indicated amino acids derived from three independ-
ent hydrolysis experiments with error bars indicating 
the standard deviation (SD). The concentrations of pp65 
(mean of Phe, Val and Pro quantification) and HCit 
along with the coefficient of variation (CV) are summa-
rized next to the graph. The data was acquired in coop-
eration with Bernd Reisinger (PTB Braunschweig). 
Whereas double isotope-dilution mass spectrometry allowed quantitative analysis of HCit 
formation, modification of arginine residues could not be assessed in the same manner, 
since there was no commercial source for isotopically labeled carbamoyl-arginine. To gain 
further insights into the degree of arginine modification, carb-pp65 was characterized at 
the peptide level (section VI.4.2). Although trypsin is the most frequently used protease for 
generating peptides to be analyzed by mass spectrometry, it cleaves after lysine residues 
and may therefore be inhibited by carbamoylation. Thus, pp65 was instead digested with a 
combination of Asp-N (cleaves N-terminally of aspartate) and Glu-C (cleaves C-terminally of 
glutamic acid) proteases. Peptides were desalted, separated by reversed-phase HPLC and 
analyzed via tandem mass spectrometry. The peptides that could be unambiguously identi-
fied covered 10 out of 22 individual lysine positions (45%) and 20 out of 36 individual 
arginine positions (55%) of pp65 in total (Figure 18A). At each lysine position, car-
bamoylation was detectable, albeit to a varying extent (ranging from 38-100%) with a cu-
mulative modification degree of 90% (Figure 18B). By contrast, carbamoylation was only 
detected in one of the 20 arginine positions, where the degree of modification was 6% 
(0.3% in total). Higher susceptibility of lysine residues to carbamoylation has been reported 
before and can be explained by the roughly 100-fold higher nucleophilicity of this amino 
253. Even though the N-terminal amino 
group of pp65 was not covered by this analysis, it is very likely modified in a quantitative 
manner as well, considering that the pKa value is even lower (9.2) than that of lysine. Taken 
together, the chosen conditions for KOCN treatment likely induce near complete car-
bamoylation of the N-terminus as well as lysine residues, whereas arginine modifications 
seem negligible. 
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Figure 18 Arginine residues are hardly carbamoylated according to MS/MS analysis of pp65 pep-
tides  
(A) Peptide map of carbamoylated pp65 after Glu-C/Asp-N digestion. All detected peptides containing lysine 
or arginine residues are highlighted in blue. Amino acids that showed carbamoylation are marked in orange 
while those that were always detected without the posttranslational modification are highlighted in violet. 
Black lines |  indicate theoretical cleavage sites. 10 lysine (45%) and 20 arginine (55%) residues could be 
evaluated in total. (B) Degree of carbamoylation per position. All peptide sequences in which modification 
was detected are listed with the degree of carbamoylation referring to the position highlighted in blue. If the 
collision-induced dissociation (CID)-based MSMS spectrum was not sufficient to unambiguously determine the 
position of carbamoylation for peptides containing lysine and arginine, the precursor of interest was subjected 
to an additional LC-MSMS run using electron transfer dissociation (ETD). An example of CID- and ETD-spectra 
of the same peptide is shown in supplementary Figure S5. The data was acquired in cooperation with Bernd 
Reisinger (PTB Braunschweig).  
Assuming that these results are transferable to BZLF1 and IE-1, it becomes evident that 
quantitative deprotonation of lysine residues as a result of carbamoylation impacts the net 
charge of the chosen model proteins to a varying degree (Figure 19). While it shifts the sum 
of all charges from close to neutral to distinctly negative for pp65 (-3 to -25) and BZLF1 (-7 
to -15), IE-1 already has a net charge of -34 even without any modifications. Since IE-1 has 
the highest number of lysine residues out of the three model proteins, this value can be 
shifted to a maximum of -70. 
 
Figure 19 - Carbamoylation lowers the net 
charge of pp65, BZLF1 and IE-1 to a varying 
degree 
Net charge of the indicated model proteins in their 
unmodified state or assuming complete car-
bamoylation of lysine residues. 
 
By removing a sufficient number of positive charges from a given protein, it essentially be-
comes a polyanionic molecule. Many cell types, including antigen-presenting cells, express 
a variety of surface molecules belonging to the heterogeneous group of scavenger recep-
tors271. Given that these receptors have been described to bind polyanionic macromolecules 
before272, it was explored if the increased T cell restimulation rates of carb-pp65 and carb-
BZLF1 are a result of enhanced receptor-mediated uptake into APCs. Interaction of scaven-
ger receptors with their ligands can be inhibited by adding competing molecules such as 
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the negatively charged polysaccharide fucoidan273,274. To test if antigen-specific T cell re-
sponses are modified by this substance, PBMCs from 3 different CMV seropositive donors 
were stimulated in the presence of fucoidan with carb-pp65 or its unmodified counterpart 
(Figure 20). For donors 1 and 3, SFU numbers were not impacted by the addition of fucoidan 
when stimulating with unmodified pp65 while for donor 2, responses were increased. By 
contrast, T cell responses were noticeably reduced to a level that was comparable to the 
unmodified protein for all donors when stimulating fucoidan-pretreated cells with carb-
pp65. ve cells indicates that negative charges might 
indeed be critical for the effects mediated by protein carbamoylation. 
 
 
Figure 20  Fucoidan treatment inhibits increased T cell stimulation by carbamyolated pp65  
PBMCs from 3 CMV seropositive donors were pretreated with fucoidan (100 µg/ml) for 30 minutes or left 
untreated before stimulation with unmodified or carbamoylated pp65 (carb-pp65, 0.5 µg/ml). T cell responses 
w ssay. The data shown in this figure were 
of Tobias Brunner under my experimental supervision267.  
While negative charges seem to play an important role in the uptake of carbamoylated 
proteins into APCs, the added carbamoyl groups themselves might also contribute to this. 
To further explore the structural requirements for this phenomenon, another posttransla-
tional modification was compared to carbamoylation with regard to T cell restimulation. 
Maleylation, the reaction of maleic anhydride with primary amino groups at basic pH, was 
chosen for this purpose (section VI.3.7)275,276. This reaction also modifies -amino group 
of lysine residues with high specificity but in contrast to carbamoylation, one negative 
charge is added per reaction (Figure 21A). To compare the influence of carbamoylation and 
maleylation side-by-side, PBMCs from 3 CMV seropositive donors were stimulated in parallel 
with unmodified, carbamoylated or maleylated pp65 (Figure 21B). Compared to native 
 responses to a similar extent for all donors. Thus, 
in contrast to the removal of positive charges, the presence of carbamoyl groups is presum-
ably not critical for the increased T cell stimulation observed for carb-pp65. 
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Figure 21  Maleylation increases the restimulation of pp65-specific T cells similarly to car-
bamoylation 
(A) Reaction of maleic anhydride with amino groups at basic pH. (B) pp65 was incubated for 24 hours with 
30 mM maleic anhydride at pH 8.0 and 35 °C. PBMCs from 3 CMV seropositive donors were stimulated for 
20 hours with unmodified, carbamoylated or maleylated pp65 (0.5 µg/ml each) and T cell restimulation was 
 
Because the removal of positive charges appears to be crucial for the increased T cell res-
timulation of carbamoylated proteins, it was explored if a similar effect can be mediated by 
adding negative charges instead of removing positive ones through the modification of 
lysine residues. To explore this possibility, amino acids carrying a negative charge at physi-
ological pH were added to pp65. A sequence of 6 alternating aspartate and glutamate 
amino acids each was fused to the  end of the pp65 gene, thereby shifting the protein 
net charge from -3 to -15 (Figure 22A). As for wild-type pp65, a recombinant baculovirus 
strain containing the gene-of interest was generated for protein production. The protein, 
hereafter referred to as pp65-6xDE, was purified from baculovirus-infected insect cells in 
analogous manner to the wild-type protein (Figure 22B-D). PBMCs from 6 CMV seropositive 
donors were then stimulated with equivalent amounts of either wild-type pp65 or pp65-
6xDE, none of which were chemically modified (Figure 22E). However, the presence of 12 
additional negative charges had no detectable influence on T cell restimulation rates. 
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Figure 22  C-terminal addition of 6 Glu and Asp residues does not increase the restimulation of 
pp65-specific T cells 
(A) pp65 was fused C-terminally with 6 glutamic acid (Glu) and 6 aspartate (Asp) residues (designated pp65-
6xDE). (B) pp65-6xDE was purified from Baculovirus-infected High Five cells using Ni-IDA beads. During puri-
fication, aliquots were collected from the insoluble fraction that was pelletized after cell lysis, the cell lysate 
(input), the washing steps as well as the elution fractions. Samples were subjected to SDS-PAGE and Coo-
massie-staining. (C) Proteolytic cleavage was performed for removing the His/Strep tandem affinity tag after 
purification of pp65-6xDE from crude cell lysates. GST-tagged PreScissonTM protease was added to the samples 
and after digestion, cleaved tag and protease were removed from samples by adding GSH- and Strep-Tactin-
beads. Aliquots were collected at all steps and subjected to Western blot analysis. (D) After tag removal, the 
final product was analyzed via SDS PAGE and silver staining with the indicated protein quantities loaded per 
lane. (E) PBMCs from 6 CMV seropositive donors were stimulated for 20 hours with unmodified pp65 or 
pp65- Values obtained with 
cells from a given donor are connected by lines. The P value was calculated using the Wilcoxon signed rank 
test (two-tailed). The data shown in this figure 
my experimental supervision265.  
Summarizing these results, carbamoylation removes positive charges, thereby lowering the 
isoelectric point of a given protein. Under the chosen reaction conditions, lysine residues 
are quantitatively modified, while arginine carbamoylation hardly occurs at all. Due to the 
amino acid composition of the 3 model proteins IE-1, BZLF1 and pp65, carbamoylation has 
a strongly varying influence on the degree to which their isoelectric point is altered. The 
lowered net charge, rather than the presence of carbamoyl groups, seems to be a critical 
requirement for the increased restimulation of pp65-specific T cells. Yet, a comparable result 
cannot be achieved by adding 12 negatively charged amino acids to pp65, implying that 
the net charge was either not sufficiently lowered, or that there are additional structural 
requirements with regard to the topological localization of the negative charges contrib-
uting to the increased restimulation of antigen-specific T cells. 
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IV.1.3. Uptake of carbamoylated proteins into antigen-presenting cells 
Various steps that take place in antigen-presenting cells like protein uptake, processing and 
presentation precede T cell recognition and are therefore presumably rate-limiting. Thus, it 
is conceivable that carbamoylation impacts one or several of these steps. For instance, car-
bamoylation might i) increase protein uptake into APCs, ii) redirect modified proteins into a 
different APC subset, iii) enhance degradation and peptide loading on MHC complexes or 
iv) mediate increased cross presentation, concomitant with improved restimulation of CD8+ 
T cells. To explore these possibilities, the fate of carbamoylated proteins in professional 
antigen presenting cells was analyzed. 
Since professional APCs comprise a multitude of functionally distinct cell subsets, it was 
important to first identify cells capable of taking up unmodified or carbamoylated proteins. 
In peripheral blood, monocytes and B cells are the most abundant APC subsets, whereas 
dendritic cells and macrophages are present only in very small numbers277. To test which 
APC population contributes most to the restimulation of antigen-specific T cells during the 
stimulation of PBMCs, cells from a CMV seropositive donor were depleted of monocytes by 
removing CD14 positive cells via magnetic-activated cell sorting (MACS, section VI.5.4). Af-
ter negative MACS selection, monocytes were hardly detectable in flow cytometry analysis, 
but the frequency of B cells was largely unaltered (Figure 23A). By contrast, after subjecting 
cells to the control treatment, both populations were still present. 
readily detectable when stimulating control-treated PBMCs with unmodified or car-
bamoylated pp65 (Figure 23B). As expected, carb-pp65 elicited higher restimulation rates 
moval of monocytes and irrespective of pp65 modification. At the same time, neither CD14 
negative selection, nor control treatment had a significant influence on the frequencies of 
-producing effector cells (NK cells, CD4+ and CD8+ T cells, Supplementary Figure S6). 
This finding indicates that during the stimulation of PBMCs, monocytes are the main APC 
population responsible for the restimulation of antigen-specific T cells. 
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Figure 23  Monocytes are the 
main population of antigen-
presenting cells during PBMC 
stimulation 
(A) PBMCs from a CMV seroposi-
tive donor were depleted of CD14 
positive cells via magnetic-acti-
vated cell sorting (MACS, lower 
plot) or subjected to control treat-
ment (omission of the CD14 anti-
body/bead conjugate; upper plot). 
An aliquot from both samples was 
stained each for CD14 and CD19 
with fluorescently labeled anti-
bodies and subjected to flow cy-
tometry analysis. The pseudocolor 
plots show CD19- (X axis) and 
CD14-positive cells (Y axis) with 
the respective population fre-
quencies (%) displayed in each 
corner. (B) The PBMC samples de-
scribed in (A) were stimulated for 
20 hours with pp65 or carb-pp65 
(0.5 µg/ml each) and T cell re-
ELISpot. Bars represent the mean 
with SEM (standard error of the 
mean) of 3 individual stimulations. 
To confirm that monocytes are indeed capable of taking up and presenting pp65-derived 
peptides to T cells, they were separated from other PBMCs and stimulated in the presence 
of a pp65-specific T cell clone. CD14+ cells were isolated via positive MACS selection from 
PBMCs of a CMV seronegative donor. After 24 hours of cultivation, at which point expres-
sion of the monocyte marker CD14 was still very high (Figure 24A), cells were either pre-
treated with fucoidan or left untreated, followed by stimulation with unmodified or car-
bamoylated pp65 for two hours. Next, an HLA-matched, pp65-specific T cell clone was 
added along with Brefeldin A (BFA) to inhibit cytokine secretion. After 4 hours, cells were 
Figure 24B). 
-pp65 (approx. 
60%), compared to the unmodified protein (approx. 40%). In accordance with the results 
obtained using PBMC samples (Figure 20), fucoidan treatment had no influence on T cell 
responses when stimulating with pp65 whereas for carb-pp65, responses were markedly 
reduced and comparable to those obtained with the unmodified protein. In conclusion, 
monocytes seem to be the main APC population in PBMCs taking up pp65 and carb-pp65. 
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Figure 24 - pp65 carbamoylation enhances T cell restimulation with monocytes as antigen-present-
ing cells  
 (A) Monocytes were isolated from a CMV seronegative donor via MACS sorting using anti-CD14 beads and 
cultivated overnight. The next day, CD14 expression was assessed by flow cytometry after staining of samples 
with CD14- or isotype control antibody. (B) Samples described in (A) were pretreated with fucoidan (100 
µg/ml) for 30 minutes or left untreated before stimulation with pp65, carb-pp65 (0.5 µg/ml each) or PBS only 
(no protein) for 2 hours. An HLA-matched, pp65-specific T cell clone was added along with Brefeldin A (BFA, 
1 µg/ml) at an effector/target ratio of 1:1 and co-incubation lasted for 4 hours. Samples were then stained for 
Bars display the mean (with SEM) percentage of 
 double positive cells from 3 individual stimulations. The data shown in this figure was collected 
during the 267. 
Although during the stimulation of PBMCs, antigen-derived peptides seem to be presented 
mainly by monocytes, it was intriguing to assess whether protein carbamoylation has a 
similar effect when using other APC populations instead. To test this, monocytes were iso-
lated from PBMCs of a CMV seronegative donor via MACS selection and either differenti-
ated to monocyte-derived dendritic cells (moDCs) or monocyte-derived macrophages 
(moMφs) over a period of 5 days. After this time, expression of the dendritic cell marker 
CD1a was strongly upregulated in moDCs and virtually undetectable on macrophages (Fig-
ure 25A). At the same time, in accordance with previously published literature, expression 
of scavenger receptor A1 (SR-A1), was high on macrophages, but also detectable on the 
surface of dendritic cells, albeit to a lower degree278,279. These data demonstrate that two 
distinct APC subsets were generated from monocytes over a period of five days. To assess 
their capacity to restimulate antigen-specific T cells, dendritic cells or macrophages were 
incubated with equivalent amounts of pp65 or carb-pp65 for two hours. Next, the HLA-
matched, pp65-specific T cell clone was added along with BFA and cells were co-incubated 
for another 4 hours. T cell restimulation was again assessed by staining cells for CD8 and 
, followed by flow cytometry analysis. After stimulation with pp65, 24% 
-positive when using moDCs compared to 27% for macrophages. For 
both APC populations, T cell restimulation rates were considerably increased as a result of 
stimulation with carb-pp65 (58% and 62% for DCs and macrophages, respectively). This 
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shows that the previously observed effects are not confined to monocytes, but can be trans-
ferred to other subsets of professional APCs as well. 
 
Figure 25  pp65 carbamoylation enhances T cell restimulation also with dendritic cells and macro-
phages as antigen-presenting cells  
(A) Monocytes were isolated from a CMV seronegative donor via MACS sorting using anti-CD14 beads and 
cultivated for 5 days with GM-CSF and IL-4 (1000 U/ml each) for differentiation to monocyte-derived dendritic 
cells (moDCs, upper panel) or with 50 U/ml GM-CSF for differentiation to monocyte-derived macrophages 
s, lower panel). After differentiation, samples were stained for CD1a and scavenger receptor A1 (SR-
A1), followed by flow cytometry analysis. Displayed histograms are representative of results from 3 different 
donors. (B) s (lower graph) were stimulated with pp65, carb-pp65 (0.5 µg/ml 
each) or PBS only (no protein) for 2 hours. An HLA-matched, pp65-specific T cell clone was added along with 
Brefeldin A (BFA, 1 µg/ml) at an effector/target ratio of 1:1 and co-incubation lasted for 4 hours. Samples 
 display the mean (with 
figure were erimental supervision267.  
Increased uptake of carbamoylated proteins into APCs could be one possible explanation 
for the increased restimulation of pp65- and BZLF1-specific T cells. To test this hypothesis, 
a reporter system was established for the quantification of cellular pp65 uptake. Enhanced 
green fluorescent protein (eGFP) was fused in-frame to the  of the pp65 gene (Figure 
26A). As for wild-type pp65 and pp65-6xDE, a recombinant baculovirus strain containing 
the gene-of-interest was generated for protein production. The protein, referred to as GFP-
pp65, was purified similarly to wild-type pp65 from baculovirus-infected insect cells using 
Ni-IDA beads (Figure 26B). However, in contrast to pp65 and pp65-6xDE, the tandem af-
finity tag was not removed after purification (Figure 26C), because higher fluorescence in-
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tensity values were reproducibly obtained when cleavage and subsequent removal of pro-
tease and tag were omitted (data not shown). Uptake of the purified protein into human 
foreskin fibroblast (HFF) cells could be readily detected via confocal microscopy (Figure 26D). 
 
Figure 26  Purification of GFP-pp65 from insect cells 
(A) pp65 was fused N-terminally with enhanced green fluorescent protein (eGFP) and C-terminally with a 
His/Strep tandem tag. (B) GFP-pp65 was purified from Baculovirus-infected High Five cells using Ni-IDA beads. 
During purification, aliquots were collected from the insoluble fraction that was pelletized after cell lysis, the 
cleared cell lysate (input), the washing steps as well as the elution fractions. Samples were subjected to SDS-
PAGE and Coomassie-staining. (C) GFP-pp65 was analyzed by Western blot analysis using anti-pp65- or anti-
GFP-antibodies. (D) Human foreskin fibroblast (HFF) cells were incubated for 24 hours with GFP-pp65 (2.5 
µg/ml). Cells were fixed with paraformaldehyde (PFA), stained with DAPI and analyzed via fluorescence mi-
croscopy. 
mental supervision267 while confocal microscopy was performed in cooperation with Manfred Marschall (Frie-
drich-Alexander University Erlangen-Nürnberg). 
Next, GFP-pp65 was carbamoylated with potassium cyanate using the same conditions as 
for wild-type pp65. After 24 hours of incubation, carbamoylation was detectable via isoe-
lectric focusing gel electrophoresis. As compared to unmodified GFP-pp65, the isoelectric 
point was clearly shifted (Figure 27A). At the same time, carbamoylation had no significant 
influence on the fluorescence intensity of GFP-pp65, which is an important prerequisite for 
quantitative comparison of protein uptake (Figure 27B and C). To test if carbamoylation has 
an influence on the uptake of pp65 into APCs, THP-1 macrophages were chosen as a well-
established APC model280. THP-1 cells were differentiated to macrophages by incubation 
with phorbol myristate acetate (PMA) over a period of 6 days. To enhance the intracellular 
detection sensitivity of GFP-pp65, cells were pre-incubated with MG-132, an inhibitor of 
proteasomal degradation. Equivalent amounts of GFP-pp65 or carb-GFP-pp65 were added 
to the cells and after 4 hours, they were washed 5 times to remove proteins that were not 
taken up within this time frame. GFP fluorescence was then quantified by flow cytometry 
analysis (Figure 27D and E). Compared to unmodified GFP-pp65, protein uptake was clearly 
higher after carbamoylation, which might in turn also explain increased T cell restimulation 
when using carbamoylated proteins.  
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Figure 27  Carbamoylated GFP-pp65 is taken up more efficiently into THP-1 cells  
(A) GFP-pp65 was incubated for 24 hours with potassium cyanate or left untreated and samples were sepa-
rated according to their net charge in isoelectric focusing (IEF) gel electrophoresis. (B) GFP-pp65 was incu-
bated for 24 hours with 300 mM KOCN at 35 °C (carb-GFP-pp65) or in buffer lacking potassium cyanate (GFP-
pp65). Aliquots were collected before and after the incubation period and fluorescence intensities of all sam-
ples were measured on a VICTOR multiplate reader. Values obtained after 24 hours were normalized to those 
before the incubation period to account for chromophore maturation281. Bars represent the mean (with SD) 
of all samples (n=9). (C) Unmodified or carbamoylated GFP-pp65 were adjusted to 50 µg/ml and diluted in 
1:1 steps. Fluorescence intensities were measured on a VICTOR multiplate reader. Obtained values are pre-
sented as mean (with SEM) of 3 separate dilutions. (D) THP cells were incubated for 6 days with phorbol 
myristate acetate (PMA, 100 µg/ml) and pretreated for 30 minutes with MG-132 (10 µM) before addition of 
GFP-pp65 or carb-GFP-pp65 (2 µg/ml). After 4 hours, cells were analyzed via flow cytometry. Bars represent 
the mean (with SEM) of 3 individual samples. (E) Representative histogram of samples presented in (D). The 
mental supervision267. 
Although increased uptake of carbamoylated pp65, concomitant with enhanced MHC 
presentation of pp65-derived peptides, is a plausible explanation for improved T cell res-
timulation, other steps in the antigen presentation process could be affected as well. Pro-
teins that are taken up from the extracellular space, for example by clathrin-mediated en-
docytosis, are mostly degraded in phagolysosomes, followed by loading of peptides onto 
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MHC class II molecules and stimulation of CD4+ T cells. However, by a mechanism known 
as cross-presentation, stimulation of CD8+ T cells can also occur if peptides are instead 
loaded onto MHC class I complexes (for example as a result of protein leakage into the 
cytoplasm)282. It is therefore conceivable that carbamoylation selectively enhances cross 
presentation and that the increased T cell stimulation rates are mainly attributable to the 
additional reactivation of CD8+ cells. 
To investigate this, PBMCs from a CMV seropositive donor were depleted of CD8+ T cells by 
negative MACS selection (Figure 28A). Cells were then stimulated with unmodified or car-
Figure 28B). Irre-
spective of the presence of CD8+ cells during stimulation, carb-pp65 elicited higher T cell 
response rates than unmodified protein. As observed before, the presence of fucoidan re-
duced the number of spot forming units only for the carbamoylated protein. However, 
compared to the control treatment, the overall responses were lower as a result of MACS 
depletion, demonstrating that the contribution of CD8+ T cells was missing. These results 
show that carbamoylation does not exclusively enhance cross-presentation and that both 
class I and class II presentation benefit from the increased uptake of carb-pp65. 
 
Figure 28  Enhanced pp65 uptake 
benefits both MHC-I and MHC-II 
presentation 
(A) PBMCs from a CMV seropositive 
donor were depleted of CD8 positive 
cells via MACS sorting or subjected to 
control treatment (omission of the 
CD8 antibody/bead conjugate). An al-
iquot from both samples was stained 
each for CD3, CD4 and CD8 with fluo-
rescently labeled antibodies and sub-
jected to flow cytometry analysis. Cells 
were first gated for CD3 positive 
events (data not shown). The pseudo-
color plots show CD4- (X axis) and 
CD8-positive cells (Y axis) with the re-
spective population frequencies (%) 
displayed in each corner. (B) PBMC 
samples were pretreated with fu-
coidan (100 µg/ml) for 30 minutes or 
left untreated before stimulation with 
pp65 or carb-pp65 (0.5 µg/ml each) 
for 20 hours. T cell responses were 
resent the mean with SEM (standard 
error of the mean) of 3 individual stim-
ulations. The data shown in this figure 
sis of Tobias Brunner under my exper-
imental supervision267.  
In summary, monocytes are the main APC population presenting antigen-derived peptides 
during the stimulation of PBMC samples. However, enhanced T cell reactivation as a result 
of protein carbamoylation can also be achieved when dendritic cells or macrophages act as 
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APCs. The enhanced restimulation appears to be a direct result of elevated protein uptake 
into antigen-presenting cells and both MHC class I and class II presentation benefit from 
this.  
 
IV.1.4. Impact of protein carbamoylation on T cell priming in vivo  
So far, the impact of posttranslational lysine modifications was only assessed for the reac-
tivation of previously primed T cells, but enhanced protein uptake into APCs might also be 
beneficial for the priming of naïve T cells in vivo. Hence, it was interesting to investigate if 
protein carbamoylation could be used as a method for enhancing the immunogenicity of a 
given protein with potential implications for the design of novel vaccines or the improve-
ment of existing ones.  
To address this question, female Balb/c mice were immunized twice at week 0 and week 2 
in a homologous prime/boost regimen with either unmodified or carbamoylated pp65 (Fig-
ure 29A and B, section VI.7). Both proteins were injected intramuscularly (i.m.), together 
with the adjuvant poly-IC (a synthetic dsRNA that acts as a TLR3 agonist, thereby boosting 
APC functions and T cell responses283). As positive control, a separate group of mice was 
immunized twice with a mammalian expression plasmid containing the pp65 gene 
(pcDNA3.1-pp65) and as negative control, another group received PBS mixed with poly-IC 
only. Four weeks after the initial priming immunization, splenocytes were isolated and stim-
ulated over a period of 6 hours with a pp65 peptide pool in the presence of BFA. Cells were 
then -2), followed by 
flow cytometry analysis (Figure 29C).  
-2, cytokine positive cells were hardly detectable at all in the group 
immunized with PBS and poly-IC only. In mice immunized with plasmid DNA, the number 
positive cells was significantly above background levels with a median of 2.2% for 
CD8+ cells and 0.3% for CD4+ cells, respectively. In the same group, the percentage of IL-2 
producing cells seemed elevated as well (0.1% for CD8+ and 0.2% for CD4+ cells), but the 
difference to the control group was not statistically significant. However, neither pp65, nor 
carb-pp65 induced T cell responses that were significantly above the background, irrespec-
tive of the T cell subset or marker cytokine adressed. At the same time, antigen-independent 
stimulation of splenocytes from all groups with PMA and Ionomycin strongly induced cyto-
kine responses, demonstrating that the isolated splenocytes were viable and capable of 
-2 at the time of stimulation (Supplementary Figure S7A). Thus, no 
conclusions can be drawn from this experiment with respect to potential differences in im-
munogenicity between pp65 and carb-pp65. Further optimization of the immunization con-
ditions, for example regarding protein dosage, number of injections and formulation, will 
be required to elicit detectable T cell responses in vivo. 
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Figure 29  Neither unmodified nor carbamoylated pp65 induce detectable T cell responses in mice 
(A) Female Balb/c mice were immunized intramuscularly at weeks 0 and 2 in a homologous prime/boost 
regimen. Animals were subdivided into four groups that received the reagents specified in table (B). Group 1 
(n=4) received only PBS and poly(I:C) while groups 2 and 3 (n=8 mice each) were immunized with 4 µg pp65 
or carb-pp65 per animal and injection (both proteins were admixed with poly(I:C)). Group 4 (n=8) received 50 
µg plasmid-DNA encoding pp65 per immunization. (C) After 4 weeks, splenocytes were isolated and stimu-
lated for 6 hours with a pp65 peptide pool in the presence of BFA. Cells were stained for CD4, CD8, intracel-
-2, followed by flow cytometry analysis. The gating strategy for discriminating various sub-
populations is illustrated in Supplementary Figure S7B. -2 positive cells that are further 
subdivided into CD4+ or CD8+ T cells. Horizontal lines represent the mean and blue symbols the individual 
values of each animal. P values were calculated using the Mann Whitney test (two-tailed; two asterisks: 
p<0.01). 
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IV.2. Delivery of CMV antigens by viral vectors 
Although immunomonitoring of CMV-specific T cells is a promising approach for identifying 
patients in need for antiviral therapy, it is clear that the development of a prophylactic or 
therapeutic vaccine would represent the most powerful strategy for limiting CMV-associ-
ated morbidities229. As it is well established that T cell responses are critical in controlling 
latent CMV infection, inducing or expanding T cell responses is a major goal of most vaccine 
concepts99,284. CMV vaccine candidates delivering T cell immunogens like IE-1 and pp65 
might be applied as part of a prophylactic vaccine in combination with B cell immunogens 
to confine viral replication if sterile immunity cannot be achieved through the induction of 
antibody responses alone. At the same time, T cell vaccines could also be used in therapeutic 
concepts to boost immune responses in patients at risk for CMV reactivation.  
Viral vectors are a favored tool for the delivery of heterologous antigens, in part owing to 
their strong stimulation of innate immunity and their capability to efficiently prime T cell 
responses during vaccination191 (see also section III.6). Several vectors like the poxvirus strain 
Modified Vaccinia Ankara (MVA) are currently being evaluated as therapeutic vaccine can-
didates in clinical trials, but their efficacy has yet to be demonstrated192,193. Moreover, re-
peated administration of an antigen by a given vector is often impeded by the development 
of immunity to its backbone, which can be avoided by heterologous prime/boost immun-
izations. This underlines that novel vectors should still be developed and assessed for their 
capacity to deliver CMV immunogens. 
Therefore, the second part of this this thesis addresses the generation as well as the viro-
logical and immunological characterization of viral vectors delivering the T cell immunogens 
IE-1 and pp65. Two emerging vector platforms that have so far not been tested in the 
context of a CMV vaccine are based on human Adenovirus 19a/64 (Ad19a/64, see III.6.2) 
and Sendai virus (SeV, see III.6.3), a murine paramyxovirus. In this work, these novel vectors 
were first characterized in a series of ex vivo assays, in order to identify promising candi-
dates that are suitable for further in vivo testing. Hence, they were compared side-by-side 
to the well-established vectors Adenovirus 5 (Ad5) and Modified Vaccinia Ankara (MVA) 
carrying the same antigens. A major focus in the characterization of these vectors lay on 
the impact that transduction with these new vectors has on dendritic cells (DCs), because 
they are the main initiators of adaptive T cell immunity in vivo. Moreover, DCs that are 
manipulated ex vivo to present CMV antigens might be readily applied as a therapeutic 
vaccine. In this work, dendritic cells were generated by in vitro differentiation of monocytes 
to monocyte-derived dendritic cells (moDCs, section 0). This was achieved by MACS isola-
tion of CD14 positive cells from PBMC samples, followed by cultivation in the presence of 
GM-CSF and IL-4 over a period of 5 to 6 days. During differentiation to dendritic cells, 
expression of the monocyte marker CD14 is reduced while CD1a expression is upregu-
lated285. In order to confirm differentiation, expression of CD14 and CD1a was routinely 
measured by flow cytometry prior to usage of moDCs in any of the experiments (this quality 
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test is shown representatively for one donor in Supplementary Figure S8). Because mono-
cytes are a suspected site of CMV latency59,64, they were always isolated from blood samples 
of CMV seronegative donors to exclude possible expression of antigens like IE-1 or pp65.   
For the generation of vectors expressing IE-1 or pp65, the corresponding genes first had to 
be inserted into the respective viral genomes. In the case of MVA, this was achieved by 
cloning the genes encoding IE-1 or pp65 into a transfer vector called pLZAW1286. This plas-
mid contains DNA sequences (termed left and right arm) that are homologous to regions 
up- and downstream of the poxviral gene locus J2R. This region encodes the viral thymidine 
kinase (TK) in wild-type virus strains, but it is deleted in MVA. The gene-of-interest was 
placed between these homologous sequences and Baby Hamster Kidney (BHK) cells, which 
are permissive for MVA replication204, were transfected with the newly generated plasmids. 
Cells were then infected with the strain MVA-GFP that contains an eGFP gene in the J2R 
locus (Figure 30A). In cells that are simultaneously transfected and infected, homologous 
recombination can occur during the de novo synthesis of viral genomes196, thereby replacing 
GFP with the gene-of-interest (Figure 30B). Since recombination occurs with low fre-
quency196, recombinant viruses then have to be separated from the parental strain MVA-
GFP. This was achieved through a procedure termed plaque purification, where BHK cells 
are infected with different dilutions of newly harvested MVA suspensions. After infection, 
cells are overlaid with agarose to limit diffusion of viral particles within the cell culture dish 
and confine viral replication to a given area. After a period of three to four days, during 
which several rounds of viral replication can occur, holes in the BHK cell monolayer become 
visible. These plaques are a result of the cytopathic effect of MVA, thus indicating viral 
replication. Along with the gene-of-interest, the reporter gene LacZ (encoding the E. coli 
enzyme -Galactosidase) is also inserted from the pLZAW1 plasmid into the genome of 
recombinant MVA particles. Hence, single plaques can then be picked at a suitable dilution-
that form blue spots after staining with Bluo-Gal (5-bromo-3- -D-galactopyra-
noside). This process is then repeated over several rounds, until presence of the parental 
strain is no longer detectable via PCR. At this stage, the reporter gene LacZ is not required 
any more. In the integration cassette that is inserted into the MVA genome during homol-
ogous recombination, LacZ is flanked by the so-called »left arm« ( 500 bp of DNA that is 
found upstream of J2R) as well as a shorter version ( 300 bp) of this sequence. Thus, in a 
second recombination event, LacZ can be removed by homologous recombination during 
viral replication and white plaques are picked instead of blue ones during later stages of 
plaque purification (Figure 30B, see also section VI.6.1). 
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Figure 30  Generation of recombinant MVA-IE1 and MVA-pp65 via homologous recombination 
(A) In BHK cells that are transfected with pLZAW1 (containing IE-1 or pp65) and infected with MVA-GFP at 
the same time, homologous recombination can occur. During this process, GFP is replaced with the integration 
cassette containing IE-1 or pp65, as well as LacZ. (B) Site-specific integration of the desired genes is achieved 
by placing them between two sequences that are found upstream and downstream of the poxviral locus J2R 
(termed left or right arm, respectively). The entire integration cassette consists of the reporter gene LacZ, 
which is flanked by the left arm and a shortened repeat of that same sequence (termed left arm 2), the gene-
of-interest (in this case IE-1 or pp65) and the right arm. In an event referred to as second recombination, LacZ 
can be removed from the viral genome by intragenomic recombination.  
Plaque purification of MVA-IE-1 and MVA-pp65 was completed in a total of 5 rounds each 
(documented in detail in th 287). After this, high titer 
virus stocks were generated by large scale infection of BHK cells, followed by purification 
and concentration of MVA particles via two subsequent rounds of ultracentrifugation over 
a 30% sucrose cushion. The MVA strains were then subjected to a final quality control 
experiment: An aliquot from both of the newly produced master stocks was used to infect 
BHK cells and 10 single plaques were picked for each strain. The virus particles from each 
plaque were then used once more to infect BHK cells, followed by isolation of DNA and 
proteins from those cells. PCR screening reactions amplifying short fragments ( 400 bp) of 
IE-1 or pp65, as well as LacZ and GFP demonstrated that the transgenes were present in all 
plaques (Figure 31A). At the same time, LacZ and GFP were undetectable, showing that 
both the parental strain and the reporter gene were completely absent. Additionally, the 
complete open-reading frames of the IE-1 and pp65 were subjected to Sanger sequencing 
for each plaque with no detectable mutations. These results indicate that IE-1 and pp65 
were stably integrated into the MVA genome. This finding was further confirmed on protein 
level, since Western blot analysis demonstrated that IE-1 and pp65 were expressed in each 
case without detectable truncations (Figure 31B). In conclusion, all quality criteria were met 
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and the newly generated strains MVA-IE-1 and MVA-pp65 were deemed suitable for further 
experiments.   
 
Figure 31  Final quality control of MVA-IE-1  
(A) BHK cells were separately infected with virions isolated from ten single plaques that were picked after 
infection of cells with the master stocks of MVA-IE-1 (left) or MVA-pp65 (right). Genomic DNA was isolated 
and different PCR reactions were performed with primer pairs amplifying short fragments (~400bp, expected 
sizes shown next to the gels) of IE-1, pp65, LacZ or GFP. As positive control, DNA plasmids containing the 
respective target genes were used as template DNA in separate reactions. Genomic DNA isolated from unin-
fected BHK cells as well as PCR reactions without template DNA served as negative controls. (B) Protein 
extracts from the same cells were subjected to SDS-PAGE and Western blot analysis using IE-1- (left) or pp65-
specific (right) detection antibodies. Cells transiently transfected with pcDNA3.1-IE-1 or pcDNA3.1-pp65 were 
used as positive control, while cell lysates from uninfected BHK cells served as negative controls. The data 
nder my experimental 
supervision287. 
Recombinant Adenovirus or Sendai virus strains expressing IE-1, pp65 or GFP were gener-
ated by our cooperation partners Christian Thirion (Sirion Biotech GmbH) and Marian Wie-
gand (RSV Genius GmbH) with details on the respective procedures specified in sections 
VI.6.2 and VI.6.3. The immunological and virological characterization of all vectors is de-
scribed in the following sections.  
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IV.2.1. Delivery of IE-1 and pp65 by Adenovirus vectors 
One major limitation for application of subgroup C vectors like Ad5 is the requirement for 
CAR expression on the surface of a given cell subset for efficient transduction (see III.6.2). 
This is a particular obstacle for the direct delivery of genetic material to immune cells, where 
CAR expression is mostly low or entirely lacking288–290. By contrast, the tropism of adenovi-
ruses from subgroup D is much broader since they interact with sialic acids that are found 
on virtually every cell type. Hence, in order to be capable of delivering IE-1 and pp65 directly 
to antigen-presenting cells (APCs), the CMV vaccine candidates were based on the sub-
group D adenovirus Ad19a/64. The transgenes IE-1, pp65 or GFP were inserted into a E1/E3-
deleted vector234 at the position of the viral E1-region under the control of the CMV imme-
diate/early promoter291. For comparison, the same ORFs were likewise inserted into the E1 
region of a BAC-derived Ad5 vector under the identical promoter, or the Thymidin kinase 
locus of MVA under control of synthetic poxviral early/late promoter. AdV-mediated expres-
sion of all transgenes with the expected molecular weight was detectable by Western Blot 
after infection of permissive HEK293T cells (Figure 32A). 
In a first step, the capacity of Ad19a/64 and Ad5 to transduce different leukocyte popula-
tions was investigated. To identify susceptible cell types, freshly isolated human peripheral 
blood mononuclear cells (PBMCs) were first infected directly with Ad19a/64-GFP or Ad5-
GFP. Then, 24 hours post infection (hpi), the amount of GFP positive cells in various PBMC 
sub-populations that was defined via staining of the surface markers CD14, CD19, CD3, 
CD4, CD8 and CD56, followed by flow cytometry analysis (Figure 32B and C). After trans-
duction with Ad5, GFP expression was only detectable in monocytes, with approximately 
30% of cells being positive at a multiplicity of infection (MOI) of 1000. In contrast to this, 
all populations tested were GFP positive when transduced by Ad19a/64. The highest trans-
duction rates were observed in monocytes (80% positive at MOI 100), followed by NK cells, 
CD8+ T cells (30% each at MOI 1000) and CD4+ T cells (20% at MOI 1000). Even B cells 
were transduced with an efficiency of 10% at MOI 100, which however, did not increase 
upon further increasing the vector load, suggesting that only a fraction of the CD19 positive 
cell population is susceptible to Ad19a/64 transduction. While there was considerable vari-
ation between the efficacy of transduction within different cell populations, this data con-
firms that Ad19a/64 is indeed more efficient at delivering genes to leukocytes than Ad5. 
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Figure 32 - Ad19a/64 vectors are capable of transducing a broad panel of human blood cells 
(A) Western Blot analysis of transgene expression 48 hours post infection (hpi). HEK293T cells were infected 
at a multiplicity of infection (MOI) of 10 with Ad5 or Ad19a/64 vectors expressing the genes IE-1, pp65, or 
GFP as indicated. (B) Gating strategy to discriminate monocytes (CD14+), B cells (CD19+), NK cells (CD3-/CD56+) 
and T cells (CD4+ or CD8+). (C) Human peripheral blood mononuclear cells (PBMCs) from 3 different donors 
were transduced at the indicated MOIs with Ad5-GFP or Ad19a/64-GFP. The amount of GFP positive cells in 
the indicated populations was determined by flow cytometry at 24 hpi. Bars represent the mean and standard 
deviation (SD) of values from all donors. 
Since various leukocyte populations were generally found to be susceptible to Ad19a/64 
transduction, it was then tested whether this vector is capable of delivering CMV antigens 
to dendritic cells (DCs). Inducing antigen expression directly in this cell type by use of a 
suitable vector system might increase the magnitude of adaptive immune responses follow-
ing vaccination as DCs are the most potent initiators of adaptive immune responses in vivo. 
Moreover, ex vivo generated and virally transduced DCs expressing CMV antigens might be 
readily reapplied to patients for priming or expansion of T cell responses. Of the multiple 
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DC subsets with distinct properties that are found in humans, monocyte-derived dendritic 
cells (moDCs) are commonly used for such approaches, since they can be easily obtained in 
large quantities292–294. To assess transduction rates, moDCs were generated ex vivo as de-
scribed above, and were subsequently infected at different MOIs with viral vectors express-
ing IE-1, pp65 or GFP. Antigen expression was assessed via flow cytometry after 24 and 48 
hours, respectively (Figure 33). Both MVA and Ad19a/64 efficiently transduced moDCs and 
mediated GFP expression with the maximum (approximately 80% of cells GFP positive) 
reached at MOI 10. Whereas MVA was slightly superior to Ad19a/64 in mediating GFP 
expression at low MOIs (MFI at MOI of 0.1 and 1; Figure 33B and D), the median fluores-
cence intensity (MFI) values at MOI 10 were higher when Ad19a/64 was used, indicating 
greater protein levels per transduced cell. Using Ad5, similar transduction rates were ob-
served only at 100-1000-fold higher MOIs of 10,000, demonstrating that, compared to 
Ad19a/64, this vector is clearly limited in the transduction of moDCs. Due to the limited 
sensitivity of the monoclonal antibodies used in flow cytometry, the intracellular detection 
of IE-1 and pp65 was altogether less sensitive compared to GFP, but Ad19a/64 was again 
clearly superior to Ad5 in mediating antigen expression. At low MOIs, the percentage of 
antigen positive cells was higher for IE-1 and pp65 when MVA was used compared to 
Ad19a/64, although the corresponding values were very similar for GFP. Since the MFI val-
ues at low MOIs indicate higher protein quantities per cell for MVA, more events are prob-
ably capable of surpassing the signal threshold during the flow cytometric analysis under 
these conditions, which might explain these discrepancies. 
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Figure 33 - MVA and Ad19a/64 efficiently transduce dendritic cells 
MoDCs from 3 different CMV seronegative blood donors were infected at varying MOIs with the indicated 
vectors and intracellular presence of the transgenes GFP, IE-1, and pp65 was quantified via flow cytometry 
after 24 (A, B) and 48 hours (C, D). Results are given as the median percentage of cells positive for each 
antigen (A, C) with error bars representing the standard deviation. Median fluorescence intensity (MFI) values 
were normalized to the signals obtained from uninfected cells with bars representing the mean and standard 
deviation of values from all donors (B, D).  
Recognition of pathogen-derived peptides by T cells requires antigen processing and 
presentation on major histocompatibility complex (MHC) molecules. Thus, for in vivo prim-
ing of naïve T cells, MHC presentation of a given peptide is a critical prerequisite. During 
natural adenovirus infection, the viral protein E3/19K disrupts export of newly synthesized 
MHC-class I complexes to the cell surface in order to evade T cell-mediated immune re-
sponses295. Although the corresponding gene is deleted along with the entire E3 region 
from both AdV vectors used in this study, it should be ensured that there is no major 
Ad19a/64-mediated interference with MHC-class I presentation. To explore this, virally 
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transduced moDCs were co-cultivated with CD8 positive, HLA-matched T cell clones recog-
nizing IE-1- or pp65-derived peptides. As an indirect measure for antigen-presentation, T 
try analysis (Figure 34). MVA was most efficient at mediating T cell restimulation, inducing 
T cell responses began to recede. Following Ad19a/64 transduction, a comparable amount 
of T cell restimulation was observed at MOI 10 (Ad19a/64-pp65) or 100 (Ad19a/64-IE-1), 
respectively. Using Ad5 vectors, similar levels were reached only at MOI 10,000, thus turn-
ing out to be 10 to 100-fold less potent in restimulating pp65 or IE-1 specific T cell clones. 
Since the T cell restimulation rates were largely reflective of the transduction rates, we con-
clude that none of the AdV vectors tested here detectably inhibits MHC-class I presentation.  
 
Figure 34 - T cell stimulation by virally transduced DCs correlates with transduction rates 
MoDCs from 3 different CMV seronegative blood donors were infected at varying MOIs with the indicated 
vectors expressing IE-1 or pp65. 24 hpi, antigen-specific, HLA-matched T cell clones were added at an effec-
tor/target ratio of 1:1. After 6 hours of co-cultivation in the presence of Brefeldin A (BFA), cells were stained 
fraction of cells co-expressing 
 is displayed as the mean and standard deviation of values from all donors. 
It is well established that priming of naïve T cells by dendritic cells requires the latter to be 
in a fully mature state and that immature or only partially matured DCs are likely to induce 
tolerance or anergy in vivo296. Phenotypically, maturation coincides with increased expres-
sion of surface molecules such as CD80, CD83, CD86 and MHC-II. Hence, it was tested if 
any of these markers are upregulated in moDCs by measuring their expression levels 24 and 
48 hours after transduction (Figure 35). Transduction with both AdV vectors led to a dose-
dependent upregulation of HLA-DR and CD86, except for Ad19 at MOI 1000, where a slight 
downregulation of CD80 and CD86 was detected. When MVA was used, HLA-DR and CD86 
were also upregulated at MOI 0.1, whereas there was a pronounced downregulation of all 
four markers at higher MOIs with CD86 being affected the most. These data imply that 
additional inflammatory stimuli will be needed to induce full maturation of dendritic cells, 
but AdV vectors interfere to a lesser extent with this process than MVA. 
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Figure 35 - None of the tested vectors mediate full maturation of dendritic cells 
MoDCs from 3 different CMV seronegative donors were infected at various MOIs with IE-1 or pp65-expressing 
vectors. 24 and 48 hpi, samples were stained for HLA-DR, CD80, CD83 or CD86 and analyzed via flow cytom-
etry. Obtained median fluorescence intensity (MFI) values were normalized to those of uninfected cells. Log2 
values which represent the mean ( standard deviation) from all experiments are displayed in a heatmap 
indicating up-regulation (blue) or down-regulation (red) of a given marker. 
Many viruses induce apoptosis upon infection of dendritic cells, which can in turn impede 
T cell stimulation when using ex vivo transduced DCs as a therapeutic vaccine. Since prem-
ature death of virally transduced dendritic cells would limit their therapeutic potential or 
compromise their ability to elicit vaccine responses, the impact of MVA and AdV transduc-
tion on DC survival was investigated. moDCs were treated with IE-1- or pp65-expressing 
vectors and performed AnnexinV/7AAD staining after 24 and 48 hours (Figure 36). MVA 
infection induced the highest amount of cytotoxicity which was already evident at MOI 0.1. 
At higher virus concentrations, more than 90% of cells were positive for one or both cell 
death markers after 48 hours. Ad19a/64-mediated toxicity was detectable only starting 
from MOI 100 with almost all cells undergoing apoptosis at MOI 1000 over a period of 48 
hours. Thus, in contrast to MVA, DC transduction and antigen expression take place at MOI 
1 and 10 without apparent cytotoxicity when using Ad19a/64. By contrast, Ad5 transduc-
tion hardly induced cytotoxic effects at all over the observed time period although MOIs of 
up to 10,000 were tested. Although IE-1 was previously described to inhibit apoptosis by 
activating the phosphatidylinositide 3′-OH kinase (PI3K) pro-survival pathway297, the amount 
of toxicity mediated by IE-1 and pp65 expressing vectors was comparable.  
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Figure 36 - MVA causes the highest amount of cell death in dendritic cells 
MoDCs from 3 different CMV seronegative blood donors were transduced at varying MOIs with the indicated 
vectors. 24 or 48 hpi, cells were stained with AnnexinV-APC and 7AAD before flow cytometric analysis. Bars 
show the mean and standard deviation (SD) of values from all donors (nd: not determined). 
The majority of currently approved vaccines is administered via intramuscular injection, a 
scenario in which viral vectors are likely to induce antigen expression predominantly in mus-
cle cells and only to a lower extent directly in tissue-resident dendritic cells. In this scenario, 
antigen has to be acquired by DCs from the extracellular space and loaded onto MHC-class 
I molecules via cross-presentation for the priming of CD8+ T cells. To test if AdV-transduced 
cells or fragments thereof are taken up secondarily by DCs and if MHC-class I presentation 
takes place, an in vitro cross-presentation assay was employed. HeLa cells were transduced 
with AdV vectors expressing IE-1 or pp65 and 24 hpi, they were added to moDCs. After 24 
hours of co-culture, antigen-specific T cell clones were added and the intracellular presence 
cells can be excluded due to an HLA mismatch with the T cell clones used in this experiment. 
Prior to the addition of HeLa cells to DCs, they were washed multiple times to ensure that 
no residual extracellular virus particles were left that might infect DCs directly. To test if 
these washing steps sufficiently removed the inoculum, the supernatant of each washing 
step was added separately to moDCs. After 24 hours, antigen-specific T cell clones were 
added and restimulation was assessed as before. Four washing steps were sufficient to 
reduce T cell activation to background levels, indicating that no detectable amount of free 
virus remained in the culture (shown representatively for pp65 vectors in Figure 37A). Using 
GFP-expressing vectors, it was found that HeLa cells are susceptible to infection with both 
AdV vectors, although Ad19a/64 was again superior to Ad5 in mediating GFP expression 
(Figure 37B). Nonetheless, at MOI 1000, almost all HeLa cells were GFP positive irrespective 
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of the vector used with comparable MFI values. Accordingly, the degree of cross-presenta-
tion induced by Ad5 or Ad19a/64 transduced cells was generally very similar (Figure 37C). 
This finding also implies that many of the differences between Ad5 and Ad19a/64 that were 
observed in this study are a direct result of their distinct cell tropism. 
 
Figure 37  Cross-presentation of IE-1 and pp65 by Ad5 and Ad19a/64-infected cells 
(A) HeLa cells were transduced at MOI 1000 with Ad5- or Ad19a/64-pp65. 24 hpi, the supernatant from 
overnight culture (0) as well as from 4 subsequent washing steps with cell culture medium (1-4) was collected 
and added to moDCs. After 24 hours, a pp65-specific, HLA-matched T cell clone was added to moDCs at an 
effector/target ratio of 1:1. Co-
staining and flow cytometry analysis. Bars represent the mean and SD from 3 experiments with different blood 
donors. (B) HeLa cells were transduced at the indicated MOIs with Ad5-GFP or Ad19a/64-GFP and GFP ex-
pression was quantified 24 hpi via flow cytometry. (C) HeLa cells were transduced at the indicated MOIs with 
IE-1 or pp65 expressing AdV vectors. 24 hpi, cells were washed 4 times and added to moDCs at a 1:1 ratio. 
After 24 hours of co-cultivation, antigen-specific T cell clones were added for a HeLa/DC/T cell ratio of 1:1:1. 
T cell restimulation was measured after 6 hours as described in A. Connected lines indicate values that were 
obtained using moDCs from an individual donor (MFI: median fluorescence intensity; nd: not determined). 
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IV.2.2. Delivery of IE-1 and pp65 by Sendai virus vectors 
No case of symptomatic SeV infection in humans has been reported to date. Nevertheless, 
we wanted to achieve further vector attenuation, since next to CMV negative young 
women, possible target groups for a CMV vaccine also include immunocompromised pa-
tients such as transplant recipients. We chose a previously described SeV strain in which the 
amino acids 2-77 of the viral P gene were deleted. Partial deletion of this gene prevents 
switching of the viral RNA-dependent RNA polymerase (vRdRp) from mRNA synthesis to 
genome replication, ultimately inhibiting the generation of progeny virus298. This strain, 
hereafter referred to as replication-deficient SeV (rdSeV) served as the backbone for the 
insertion of the CMV antigens IE-1, pp65 or, as control, GFP (Figure 38A). For comparison, 
the same transgenes were inserted into the parental strain containing the full-length P-
gene, hence termed replication-competent SeV (rcSeV). MVA-IE-1 and MVA-pp65 again 
served as control/benchmark/reference. Expression of all transgenes could be readily de-
tected by western blot analysis after successful transduction of Vero cells (Figure 38B). To 
test if partial deletion of the viral P gene in rdSeV is sufficient to prevent replication in human 
moDCs, viral titers in the cell culture supernatant were determined over a period of 48 hours 
after infection. Whereas rcSeV was capable of replicating to high titers in moDCs, the num-
ber of infectious particles was considerably below the baseline level after 24 hours and 
undetectable after 48 hours for rdSeV, indicating that no virus was produced de novo (Fig-
ure 38C). When a functional P gene was provided in trans by a Vero cell-based helper cell 
line (V3-10), rdSeV replication was restored and similar to that of rcSeV in moDCs.  
 
Figure 38 - Sendai virus is capable of replicating in moDCs 
(A) Schematic representation of viral genomes highlighting transgene insertion sites (not to scale). SeV genes 
and MVA genome segments are indicated by their common labels299,300. The modified SeV P gene is high-
lighted as Pmut. (B) Western Blot analysis of transgene expression 48 hours post infection (hpi) of Vero cells 
at MOI 1 with replication-competent (rcSeV) or replication-deficient (rdSeV) Sendai virus strains expressing the 
indicated genes IE-1, pp65 or GFP. (C) Titration of cell culture supernatants at different time points after 
infection of human monocyte-derived dendritic cells (moDCs) with rcSeV-GFP or rdSeV-GFP at MOI 1. rdSeV 
was also used to infect the Vero cell line V3-10 (trans-complementing a full-length version of the viral P gene) 
at the same MOI. 3 hours post infection, cells were washed once with medium and an aliquot was collected 
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to determine baseline virus levels (residual virions that did not enter target cells and were not removed by 
washing). Viral titers are given as cell infectious units (CIU) per ml (bd: below detection limit). 
Next, it was tested if expression of the heterologous antigens IE-1, pp65 or GFP is induced 
in dendritic cells upon transduction with the different SeV strains. MoDCs were generated 
by ex vivo differentiation of monocytes and transduced at different MOIs with each vector. 
The percentage of antigen positive cells was determined 24 and 48 hours after transduction 
by flow cytometry (Figure 39). In contrast to GFP, IE-1 and pp65 were stained intracellularly 
using labelled antibodies prior to the measurement. In accordance with previously published 
data, rcSeV was found to be capable of efficiently transducing moDCs301. For the GFP-car-
rying vectors, antigen expression was generally MOI-dependent and at a similar level for 
rcSeV and MVA. Whereas MFI levels were slightly higher for MVA at low MOIs, peak ex-
pression levels were highest with rcSeV at MOI 10 and 100, respectively. The percentage of 
GFP-positive cells as well as the monitored MFI was, however, clearly lowest when using 
rdSeV, showing that partial deletion of the P gene has a negative influence on overall 
transgene production. Nevertheless, the capacity to transduce dendritic cells and mediate 
transgene expression are preserved. Compared to GFP, intracellular detection of IE-1 and 
pp65 was altogether less sensitive for want of suitable flow cytometry antibodies. Conse-
quently, expression of both IE-1 and pp65 was below the limit of detection for rdSeV and 
signals were significantly lower than those obtained after transduction with the correspond-
ing rcSeV or MVA vectors carrying GFP.  
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Figure 39 - SeV efficiently transduces moDCs with rcSeV eliciting higher transgene expression than 
rdSeV 
MoDCs from 3 different CMV seronegative blood donors were infected at the indicated MOIs and intracellular 
presence of the transgenes GFP, IE-1 and pp65 was quantified via flow cytometry after 24 (A, B) and 48 hours 
(C, D), respectively (nd: not determined). Results are presented as the percentage of cells positive for a given 
antigen (A, C), with connected lines indicating values that were obtained using cells from a given donor. 
Median fluorescence intensity (MFI) values were normalized to the signals obtained from uninfected cells with 
bars representing the mean and standard deviation of values from all donors (B, D). 
In addition to the vector-mediated expression of IE-1 and pp65 in dendritic cells, processing 
of the antigen and MHC-presentation are other critical prerequisites for the initiation or 
expansion of adaptive immune responses. As a surrogate marker for this process, the vec-
tors were tested for their capacity to restimulate antigen-specific T cell clones after trans-
duction of dendritic cells. 24 hours after infection at various MOIs, moDCs were co-culti-
vated with HLA-matched IE-1- or pp65-specific T cell clones and measured T cell reactivation 
r another 6 hours. To verify that the 
responses were antigen-specific, GFP-expressing vectors of each type were also tested in 
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-secretion even at high MOIs (data not 
shown). All vectors efficiently restimulated T cells with the maximum (approximately 80% 
Figure 
40). Whereas T cell responses were decreasing at higher MOIs when MVA was used, no 
such decrease in T cell restimulation was observed for the SeV vectors. Interestingly, rdSeV 
was equally capable of eliciting moDC-driven T cell restimulation as rcSeV despite hardly 
detectable antigen levels in moDCs in flow cytometry (Figure 39). Apart from minor differ-
ences, presumably reflecting differences in T cell receptor avidity of the clones used, the 
same trends were observable for IE-1 and pp65. 
 
Figure 40 - Infection with both Sendai vectors leads to efficient restimulation of T cells by trans-
duced moDCs 
MoDCs from 3 different CMV seronegative blood donors were infected at the indicated MOIs with IE-1- or 
pp65-expressing vectors. 24 hpi, antigen-specific T cell clones were added at an effector/target ratio of 1:1. 
After 6 hours of co-
analyzed via flow cytometry. Bars represent the mean and standard deviation of values from all donors (nd: 
not determined). 
For efficient priming or expansion of T cell responses, SeV-transduced DCs should exhibit a 
certain degree of longevity in vivo, which would otherwise hamper possible applications as 
a therapeutic vaccine. Sendai virus has long been known to cause strong cytopathic effects 
upon infection and was recently identified as a mediator of necroptotic cell death302,303. 
Thus, it was assessed if the attenuation of rdSeV might reduce undesired induction of cell 
death in dendritic cells. To test this, moDCs were transduced at various MOIs with IE-1- or 
pp65-expressing virus strains and performed AnnexinV/7AAD staining after 24 and 48 
hours, respectively. All tested vectors caused cell death in an MOI-dependent manner and 
irrespective of the transgene, with MVA evidently being the most toxic variant (Figure 41). 
24 hours after infection, the percentage of AnnexinV/7AAD positive cells for a given MOI 
was comparable between both Sendai vectors. However after 48 hours, the proportion of 
healthy cells was further decreased when rcSeV was used while it remained constant for 
rdSeV, confirming that this vector is clearly less toxic than the original strain or MVA. Gen-
erally, the inserted transgene had again no obvious influence on cell death induction in this 
assay (compare Figure 36). 
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Figure 41 - Attenuated rdSeV is less cytotoxic than rcSeV 
moDCs from 3 different CMV seronegative blood donors were infected at the indicated MOIs with IE-1 or 
pp65-expressing vectors. After 24 or 48 hours, samples were co-stained with AnnexinV/7AAD and cells posi-
tive for one or both markers were quantified by flow cytometry. Bars represent the mean and standard devi-
ation (SD) of values from all donors (nd: not determined).  
As mentioned above (section IV.2.1, Figure 35), in vivo T cell priming requires DCs to be in 
a fully mature state, which results in the upregulation of CD80, CD83, CD86 and HLA-DR. 
To assess whether any of these markers are upregulated in response to transduction with 
SeV or MVA vectors, the surface expression was measured via flow cytometry after 24 and 
48 hours (Figure 42). MVA-IE-1 and MVA-pp65 induced upregulation of CD80, CD86 and 
HLA-DR at MOI 0.1, while the expression of CD83 was largely unaltered. At higher MOIs, 
marker expression was generally lower than that of uninfected cells with CD86 and HLA-
DR being affected the most. In contrast, after transduction with the SeV vectors, markers 
were upregulated in a time- and MOI-dependent manner, except for some downregulation 
of CD80 and CD83 when rcSeV-IE-1 was used. Especially at higher MOIs, SeV vectors were 
clearly superior to MVA in mediating maturation with rdSeV inducing the highest overall 
upregulation. It is worth noting that SeV induced maturation seemed less pronounced for 
IE-1 carrying vectors which possibly reflects immunomodulatory properties of this protein. 
The observed tendencies were mostly more pronounced after 48 hours than after 24 hours.  
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Figure 42 - SeV induces maturation of dendritic cells 
moDCs from 3 different CMV seronegative blood donors were infected at the indicated MOIs with IE-1 or 
pp65-expressing vectors. After 24 or 48 hours, samples were stained for CD80, CD83, CD86 or HLA-DR and 
analyzed via flow cytometry. Obtained median fluorescence intensity (MFI) values were normalized to those 
of uninfected cells. Log2 values which represent the mean ( standard deviation) from all donors are displayed 
in a heatmap indicating up-regulation (blue) or down-regulation (red) of a given marker (nd: not determined). 
Along with the upregulation of costimulatory molecules on the surface of dendritic cells, 
secretion of distinct cytokines is also critical for T cell priming and definition of the induced 
effector phenotype. To explore the cytokine release profile of moDCs in response to trans-
duction with SeV or MVA, the secretion of various cytokines was measured in a cytometric 
bead multiplex assay. All vectors induced production of IL-6, while presence of the anti-
inflammatory cytokine IL-10 was hardly detectable and did not surpass the level produced 
by uninfected cells (Figure 43). IFNα responses were above background for all vectors at 
MOI 1 and, at MOI 10, only detectable when rdSeV was used. By contrast, TNF secretion 
was lowest for rdSeV, and IL-18 release was only detectable after MVA infection. The ob-
served trends were similar irrespective of the transgenes carried by the respective vectors, 
indicating that insertion of IE-1 or pp65 has no major influence on the cytokine profile of 
transduced moDCs. Combined with the pronounced upregulation of maturation markers, 
these data indicate that transduction with Sendai vectors alone might be sufficient to induce 
full maturation of dendritic cells. 
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Figure 43 - SeV transduction induces secretion of IL-6 and IFNα 
moDCs from 3 different, CMV seronegative blood donors were infected with either GFP, IE-1 or pp65 express-
ing vectors. 48 hours after infection, the presence of 13 different cytokines in the conditioned cell culture 
medium was assessed by a bead-based multiplex immunoassay. Uninfected cells that were untreated or stim-
ulated with LPS (1 µg/ml) served as controls. Selected cytokine concentrations are depicted with bars repre-
senting the mean and standard error of the mean (SEM) of 3 measurements from the same donor (performed 
in one experiment). Levels were not reproducibly above the limit of detection for IL- -12p70, IL-
17A, IL-23 and IL-33, and no significant differences in secretion were detected for MCP-1 and IL-8 (data not 
shown). 
Finally, it was tested if other immune cells besides DCs can be transduced by Sendai vectors 
for other potential gene delivery applications. Hence, rcSeV-GFP was used to infect human 
peripheral blood mononuclear cells (PBMCs) as a whole and the amount of GFP positive 
cells in different leukocyte populations was determined after 24 hours to identify permissive 
cell types (Figure 44). Except for B cells, all addressed subpopulations (NK cells, monocytes, 
CD4+ and CD8+ T cells) exhibited GFP expression, though to varying degrees. Since partial 
deletion of the P gene likely has no influence on target cell tropism, rdSeV is presumably 
capable of transducing these cells as well. Monocytes were transduced most efficiently, 
with approximately 80% of cells being GFP positive, followed by NK cells (50%) and T cells 
(20%) at MOI 10. Similar trends were observed at MOI 1 albeit with lower overall transduc-
tion rates. Since partial deletion of the P gene presumably has no influence on the cellular 
tropism of rdSeV, the obtained results are likely transferrable to this vector as well. These 
results suggest that Sendai virus could be a useful tool for transduction of a variety of im-
mune cells. 
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Figure 44 - SeV is capable of transducing T cells, NK cells and monocytes  
(A) Gating strategy for discriminating different leukocyte populations. PBMCs from 3 different CMV seroneg-
ative blood donors were infected at MOI 1 or 10 with rcSeV-GFP. (B) 24 hpi, the amount of GFP positive cells 
in the indicated populations was determined by flow cytometry. Bars represent the mean and standard devi-
ation (SD) of values from all donors. 
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V. Discussion 
V.1. Carbamoylation enhances protein uptake into antigen-
presenting cells  
Quantification of CMV-specific T cells is considered a promising approach for identifying 
immunosuppressed patients at risk for CMV disease that would ideally allow very early ini-
tiation of antiviral therapy before the onset of viremia while avoiding unnecessary drug 
administration. Various methods are currently available for quantifying pathogen-specific T 
cells, all of which have advantages and drawbacks. Visualization of pathogen-specific T cells 
via fluorescently labeled MHC multimers (e.g. MHC-I tetramers, pentamers or streptam-
ers304) allows fast detection of T cells, but their use in routine diagnostics is limited because 
i) the MHC complexes have to be matched with the HLA background of a given patient that 
is usually not known, ii) only pre-selected peptides can be assessed and iii) there is no infor-
mation on the functionality of the detected T cells. Other methods trying to circumvent such 
limitations rely mainly on the stimulation of autologous cells (e.g. from whole blood or 
PBMC samples) with pathogen-derived antigens, followed by indirect detection of antigen-
Reactivation can be measured for ex-
ample via intracellular cytokine staining (ICS) and flow cytometry analysis167, ELISpot305 or 
ELISA based methods306. ICS allows co-staining with various additional markers and ad-
vanced phenotyping on a single cell level, but may be more difficult to implement in routine 
diagnostics since it requires costly flow cytometry devices along with the expertise to oper-
ate them. By contrast, ELISpot and ELISA based methods often require overnight culture of 
cells, but they can be used more easily in a diagnostic setting since the devices used for 
evaluating the results are less expensive and hardly require any special training. In addition, 
both ELISA and ELISpot methods offer very high sensitivity, compared to ICS and multimer 
staining164,307,308. Although, + 
cells, CD8+ cells, NK cells) cannot be distinguished with these methods, ELISpot analysis 
permits quantification of -producing cells. Moreover, the amount of marker released 
per cell can be estimated from the spot diameters. When using ELISA-based interferon-
release assays (IGRAs) instead . Therefore, 
out of the currently available methods for T cell immune monitoring, ELISpot-based assays 
might offer the best balance between technical requirements, sensitivity and obtainable 
information. 
In addition to the read-out assay, a suitable reagent for T cell stimulation has to be selected 
as well. The majority of assays that measure antigen-specific reactivation of memory T cells 
use either overlapping peptide pools (e.g. 15-mers) or recombinant proteins for stimula-
tion305,309,310. Peptide pools allow sensitive restimulation of both CD4+ and CD8+ T cells, in 
part because they can simply replace peptides that are presented on the cell surface by 
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MHC complexes, thereby making cellular uptake, processing and MHC-loading unneces-
sary. However, the manufacturing process of peptide pools is costly and individual peptides 
differ with regard to solubility in aqueous solutions and long-term stability. As a result, it is 
difficult to predict if a given peptide within the pool is capable of being loaded onto MHC 
complexes. By contrast, recombinant proteins have to be taken up by APCs and subjected 
to the cellular antigen processing and presentation machinery, thus mimicking the natural 
antigen presentation process during CMV infection more closely. Moreover, in some cases, 
two distant parts of a protein can be excised and ligated together to form a novel peptide 
during processing of antigens by the proteasome311. This process is termed proteasomal 
peptide splicing and can generate unique MHC class I-restricted responses312. Although it 
was long presumed that proteasomal peptide splicing occurs only rarely, more recent work 
showed that it accounts for one-third of the entire HLA class I immunopeptidome in terms 
of diversity and one-fourth in terms of abundance313. Since spliced peptides are not ac-
counted for in the design of peptide pools, the corresponding T cells are not addressed. 
Thus, using full-length proteins instead of peptide pools and allowing proteasomal pro-
cessing might increase the sensitivity of T cell immune monitoring. In vivo, monocytes are 
a suspected site of CMV latency and therefore likely an important APC subset during viral 
reactivation64. Since monocytes are also the major APC population responsible for present-
ing pp65-derived peptides in PBMCs (Figure 23), antigen processing and presentation dur-
ing CMV reactivation might be closely mimicked by the stimulation of PBMCs with recom-
binant proteins. In turn, this could increase the prognostic value of the detected responses. 
However, efficient protein uptake into APCs is critical for the sensitivity with which antigen-
specific T cells are detected and the amount of cross presentation (i.e. MHC-I presentation 
of proteins taken up from the extracellular space) is likely rate limiting for the restimulation 
of CD8+ T cells. Therefore, methods for enhanced antigen delivery to APCs are needed. To 
this end, protein carbamoylation might be a simple and cost-effective method for improving 
protein uptake into APCs and increasing both MHC-I and MHC-II presentation.  
Out of the three proteins that were analyzed in this work, pp65 and BZLF1 showed in-
creased restimulation of antigen-specific T cells as a result of carbamoylation (Figure 14). In 
addition, enhanced protein uptake (Figure 27), concomitant with increased MHC-I and 
MHC-II presentation (Figure 28) could be demonstrated for carb-pp65. The extent to which 
T cell restimulation was increased varied strongly from donor to donor, possibly because 
the maximum amount of T cells was already restimulated in some donors. However, this 
might also be the result of a tradeoff between increased protein uptake into APCs and 
impaired recognition of T cell epitopes due to the modification of lysines. Given that this 
modification not only results in the addition of a carbamoyl group, but also in the removal 
-amino group of lysines, profound changes are introduced 
into affected epitopes that likely impair binding to MHC molecules or recognition by T cells 
specific for such peptides. According to this hypothesis, donors that hardly recognize any 
lysine-containing T cell epitopes would benefit most from carbamoylation, since antigen 
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uptake and presentation would be increased without T cell recognition being impaired. If, 
on the other hand, many lysine-containing epitopes elicit a dominant response within the 
T cell pool of a given donor, increased protein uptake into APCs would be less beneficial, 
since T cell recognition would be hampered at the same time. For instance, PBMCs from 
one donor reproducibly displayed reduced T cell reactivation rates when carbamoylated 
BZLF-1 was used for stimulation (Figure 14). It is possible that for this donor, BZLF1 recog-
nition was dominated by epitopes containing lysine residues and that T cell recognition was 
impaired as a result of carbamoylation. Recent work from Rist et al. showed that T cell 
responses to BZLF1 tend to cluster at specific regions of the protein and that the lysine-
containing peptide CRAKFKQLL (aa189-197) was recognized by numerous subjects despite 
expression of different HLA-alleles314. Although the HLA-background of the donor in ques-
tion was not determined, immunodominant T cell responses to epitopes that are modified 
as a result of carbamoylation might explain the reduced restimulation rates. This could be 
investigated by mapping the BZLF-1 T cell response of this donor with a pool of overlapping 
peptides spanning the entire protein. If strong responses to a lysine-containing epitope are 
found, a modified version of the peptide with homocitrulline instead of lysine could be 
compared to the wild-type peptide with regard to T cell restimulation. 
For IE-1, T cell responses were strongly reduced after carbamoylation. Again, this could be 
explained by carbamoylation-induced changes in the recognized epitopes, resulting in im-
paired T cell restimulation. Carbamoylation might have a more profound impact on IE-1 
than on the other model proteins, because it contains a higher proportion of lysines (7.3%) 
compared to pp65 (3.9%) or BZLF1 (3.3%). Hence, alterations might have a higher chance 
of affecting critical T cell epitopes. It should also be pointed out that IE-1 displays a remark-
ably negative net charge even without any modifications (-34), compared to pp65 (-3) and 
BZLF1 (-7). Because for pp65, the carbamoylation-mediated increase in T cell stimulation 
can be reversed by the addition of fucoidan (Figure 20) and maleylation has a similar impact 
as carbamoylation (Figure 21), negative charges might play a critical role for the increased 
uptake of this protein into APCs. Thus, given its already very low isoelectric point, it is pos-
sible that cellular uptake of IE-1 cannot be increased significantly by the carbamoylation-
mediated removal of positive charges. It is therefore possible that a negative impact of 
alterations in critical T cell epitopes outweighs increased protein uptake. In silico analysis of 
the electrostatic surface potential of IE-1 confirms that the surface of this protein is indeed 
dominated by negatively charged areas even without any modifications (Figure 45). To in-
vestigate if negative charges are also important for the uptake of unmodified IE-1 into APCs, 
fucoidan could be added to PBMCs prior to stimulation as previously performed for pp65 
(Figure 20). Carbamoylation could also have other detrimental influences on IE-1 that might 
explain reduced T cell stimulation. For example, protein stability might be affected by the 
shift in net charge from -34 to -70 (assuming complete modification of lysines). However, 
storage of carbamoylated IE-1 over a period of several weeks at 4 °C was not associated 
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with reduced protein concentrations (data not shown), indicating that precipitation of IE-1 
is an unlikely explanation for reduced T cell restimulation. 
 
Figure 45  The electrostatic sur-
face of IE-1 is dominated by neg-
ative charges 
The structure of the core domain of 
human IE-1 (amino acids 25-383 of 
491 in total) was predicted with 
HHPred315 using the recently pub-
lished structure of rhesus cytomeg-
alovirus IE-147 as a template. The 
electrostatic surface potential was 
calculated with the Poisson-Boltz-
mann Solvent Area method316 using 
the program Swiss Pdb Viewer and 
mapped to the surface of human 
IE-1. Red patches indicate regions 
with negative electrostatic poten-
tial, blue patches display regions 
with positive electrostatic potential. 
Whereas carbamoylation clearly altered the reactivation of antigen-specific T cells, the mere 
presence of urea during stimulation did not seem to have an impact on this (Figure 15). 
However, protein denaturation might also have an influence on protein uptake and presen-
tation and should still be assessed separately. To detach a possible influence of denaturation 
from carbamoylation effects, other chaotropic reagents such as guanidine hydrochloride 
could be used instead of urea for inducing protein denaturation without eliciting car-
bamoylation at the same time. 
Mass spectrometry measurements allowed quantitative analysis of the extent and localiza-
tion of carbamoylation. Two separate methods were employed to address this, namely iso-
tope dilution mass spectrometry (IDMS) and tandem mass spectrometry (MS/MS) analysis 
of pp65-derived peptides after GluC and AspN digestion. Results from both analysis tech-
niques indicate a high degree of lysine carbamoylation. According to IDMS, KOCN treat-
ment led to complete conversion of lysine residues to homocitrulline (Figure 17), whereas 
MS/MS analysis of peptides indicated that only 90% of lysines were carbamoylated (Figure 
18). During IDMS, hydrolysis conditions first had to be determined under which pp65 was 
completely disassembled into single amino acids while carbamoyl groups were still present, 
a least to some extent. Isotopically labeled D7-citrulline was spiked in for quantifying car-
bamoylated lysines and to measure the extent to which carbamoyl groups would be re-
moved under given hydrolysis conditions. After incubation with 6M HCl at 115 °C for 20 h, 
total hydrolysis was achieved while at the same time, 20% of the initially added amount of 
D7-citrulline was still detectable. From this, a factor was calculated to correct for homo-
citrulline (HCit) degradation during hydrolysis. Since compared to HCit, citrulline is short-
ened by one CH2-group, the reactivity of the two carbamoyl groups is presumably similar, 
but not identical. Thus, it is possible that the amount of HCit hydrolysis was overestimated 
and that the true extent of carbamoylation is in fact lower. Still, from the obtained data it 
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can be concluded that the extent to which lysines are modified is at least 90%, and that 
arginine modification hardly occurs at all (0.3%) under the chosen KOCN treatment condi-
tions. By extension, the N-terminus is very likely modified in a quantitative manner, since 
-amino group has an even higher nucleophilicity (pKa  9.2) than -amino group 
of lysines (pKa  10.5). Although these results were obtained with pp65, the observed 
trends most likely hold true for the other model proteins as well. 
The removal of positive charges lowers the net charge of a given protein, an effect that 
could be visualized by isoelectric focusing (Figure 16). Since for the majority of proteins, 
charged amino acids are mostly surface-exposed317,318, removal of positive charges presum-
ably enlarges areas which exhibit a negative electrostatic surface potential. Such clusters of 
negatively charged amino acids might be critical for the increased restimulation of antigen-
specific T cells by carb-pp65. This is supported by the observation that addition of fucoidan 
as a negatively charged competitor reduced T cell restimulation rates when carb-pp65 was 
used for stimulation (Figure 20). At the same time, fucoidan had no impact on T cell reacti-
vation when unmodified pp65 was used. This indicates that there might be two separate 
uptake mechanisms, one of which is largely independent of the electrostatic surface poten-
tial (e.g. macropinocytosis, phagocytosis, etc.) and another one which requires negative 
surface areas. Interestingly, one donor (#2) showed a trend for increased T cell restimulation 
for unmodified pp65 when fucoidan was added (Figure 20). Various immune-modulation 
effects have been described for fucoidan before, including promotion of antigen uptake 
into macrophages in vitro274 and adjuvant properties like enhancement of DC maturation in 
vivo319, possibly explaining increased T cell restimulation rates when using unmodified pp65. 
However, it is unclear why not all donors react to this reagent in the same manner. The 
finding that maleylation induces an increase in T cell restimulation that is similar to car-
bamoylation further shows that i) the added carbamoyl groups themselves are no structural 
requirement for increased uptake and that ii) removal of positive charges seems to be more 
important than the addition of negative ones. In line with this interpretation, the addition 
of 6 Asp and 6 Glu residues (6xDE) to the C-terminal end of pp65 did not result in increased 
T cell restimulation, compared to the wild-type protein (Figure 22). This indicates that the 
mere lowering of the isoelectric point is not sufficient for inducing increased protein uptake, 
but that further structural requirements, for example concerning the distribution of charges 
on the surface of a given protein have to be fulfilled as well. It is possible that the 6xDE-tag 
was folded in such a way that sterical hindrances precluded access by components mediat-
ing cellular uptake (e.g. receptors). Moreover, despite the exclusive presence of negative 
charges in this short sequence, the surface area of the tag could be too small for binding 
to a postulated interaction partner. It might be worthwhile to use model proteins where 3D 
structures are available for further attempts at inserting negatively charged amino acids in 
order to better predict the impact of such mutations on the electrostatic surface potential. 
Using defined APC subsets instead of an inhomogeneous mixture of antigen-presenting 
cells as it is found in PBMCs, it was observed that carbamoylated pp65 is superior to its 
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unmodified counterpart in mediating restimulation of a pp65-specific T cell clone, irrespec-
tive of whether monocytes, macrophages or dendritic cells (Figure 25) were pulsed with the 
protein. Increased uptake of carbamoylated proteins is therefore not just confined to mon-
ocytes, which are the main APC population when stimulating PBMCs (Figure 23), but can 
be extended to other cell types as well. This implies a common uptake mechanism for car-
bamoylated pp65 into various APC subsets. Antigen presenting cells express a variety of 
membrane-bound scavenger receptors (SRs) belonging to the group of pattern recognition 
receptors (PRRs)278. Scavenger receptors recognize numerous modified-self- and non-self-
ligands and carry out a remarkably wide range of functions including ligand uptake, 
transport of cargo within the cell, pathogen clearance and lipid transport271. This striking 
breadth in ligand interaction is not just attributable to the mere size of this family (more 
than 30 human SRs are currently known320), but also a result of promiscuous interactions 
with other co-receptors and recognition of structurally independent features such as nega-
tive charges. Although scavenger receptors are subdivided into various structurally unre-
lated subfamilies (termed A-L, not all of which are present in humans320), they often share 
very similar charge distributions within their binding domains. This is exemplified in Figure 
46 for the class A member »macrophage receptor with collagenous structure« (MARCO) 
and class E member »lectin-like oxidized LDL receptor 1« (Lox-1). Cationic patches that are 
present in both domains despite no similarity in their primary sequence could explain why 
some scavenger receptors preferentially bind negatively charged ligands271. 
 
Figure 46 - Structural features of the ligand-
binding sites of MARCO and Lox-1  
Shown are the cartoon representation (top) and 
the electrostatic potential (bottom) of the scaven-
ger receptor cysteine-rich (SRCR) domain (dimer-
ized) of macrophage receptor with collagenous 
structure (MARCO) and the C-type lectin domain 
of lectin-like oxidized LDL receptor 1 (Lox-11). Red 
patches indicate regions of negative electrostatic 
potential, blue patches show regions of positive 
electrostatic potential. Figure from Canton et al.271 
adapted with permission from Nature Publishing 
Group (license number 4211240999780). 
Indeed, the capacity of scavenger receptors to bind polyanionic ligands is well-established 
and has been described for various members, including SR-A1, CD36, MARCO and Lox-1321
325. In addition, the negatively charged polysaccharide fucoidan, which was used in this 
work as a competitor for the uptake of carb-pp65, binds scavenger receptors with high 
affinity as well326. It is therefore conceivable that the carbamoylation-mediated enlargement 
of negatively charged surface areas enables protein interaction with scavenger receptors, 
thus inducing increased cellular uptake and improved restimulation of antigen-specific T 
cells (Figure 47). 
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Figure 47  Possible uptake of carb-pp65 via scavenger receptors  
Unmodified pp65 can be taken up from the extracellular space via mechanisms such as phagocytosis or 
macropinocytosis. The removal of positive charges by carbamoylation presumably increases negatively 
charged areas on the surface of pp65. This might enable interaction with scavenger receptors, thereby en-
hancing protein uptake into APCs through additional receptor-mediated endocytosis.    
Finally, neither immunization of mice with unmodified, nor with carbamoylated pp65 re-
sulted in the induction of detectable T cell responses at all (Figure 29). As a result, no con-
clusions can be drawn from this experiment regarding the capability of carb-pp65 to induce 
T cell responses in vivo. To address this question in the future, a dose-escalation study 
should first be performed to identify the amount of pp65 required for induction of detect-
able T cell responses. Other model proteins that are commonly used and available in large 
quantities such as ovalbumin could also be tested instead of pp65. Further booster immun-
izations, different adjuvants or a heterologous prime/boost regimen (for example with DNA 
or the viral vectors described in IV.2) might be warranted as well to surpass the detection 
threshold. It is also possible that carb-pp65 induced T cell responses to homocitrulline-con-
taining peptides that could not be quantified with sufficient sensitivity, since carbamoylated 
lysines were not present in the peptide pool that was used for restimulation of splenocytes. 
Moreover, it should also be assessed in further experiments if carbamoylation alters the 
quality or quantity of the elicited antibody response.  
In summary, the data from this work lead to a model in which carbamoylation alters protein 
uptake into antigen-presenting cells due to the removal of positive charges. Although car-
bamoylation is therefore a simple method for increasing the sensitivity with which antigen-
specific T cells are detected, this has further implications in other areas beyond T cell im-
mune monitoring. For example, manipulation of the electrostatic surface potential of a 
given protein could also be used to enhance immunogenicity of protein-based vaccines in 
vivo. Instead of carbamoylation, other chemical modifications could be used to remove 
positive charges as well. Reversible modifications that are reverted at acidic pH could also 
be used to enhance protein uptake into APCs. Once endocytic vesicles containing modified 
proteins are acidified, the primary amino acid sequence would be restored and no immune 
responses would be induced to modified epitopes. Collectively, the data from this work 
indicates that it might be meaningful to take the electrostatic surface potential of a given 
protein into consideration when designing novel immunogens. 
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V.2. Ad19a/64 is an interesting alternative to Ad5 for Adeno-
virus-mediated gene delivery    
Although Ad5 was repeatedly demonstrated to induce strong T cell responses in various 
animal models, it has so far proven difficult to overcome preexisting vector immune re-
sponses in humans327. Furthermore, results from a prophylactic HIV vaccine phase IIb effi-
cacy trial (STEP trial), where the HIV antigens gag, pol and nef were delivered by Ad5 vec-
tors, even showed increased side effects and higher susceptibility to HIV infection in indi-
viduals with high preexisting Ad5 antibody titers328. Moreover, subgroup C strains are also 
inefficient at transducing cells that lack CAR expression. These limitations have spurred the 
search for alternative AdV vectors in recent years. The subgroup D strain Ad19a/64 that 
was used as the vector backbone in this study could be a useful alternative to Ad5 due to 
considerably lower preexisting immunity to this virus in humans (>90% vs. 16  19%)231,232 
and because of its known receptor usage suggesting a broader target cell tropism. 
Ad19a/64 entry was previously described to be dependent on the presence of common 
sialic acids as well as the viral knob protein, although the exact binding motif has not been 
elucidated yet236. 
The broad tropism of Ad19a/64 was demonstrated by transgene expression in various leu-
kocyte populations (Figure 32), with the highest transduction rates for monocytes and mon-
ocyte-derived dendritic cells234. By contrast, transduction of the tested leukocyte subpopu-
lations with Ad5 was either unsuccessful or only achievable at very high MOIs for monocytes 
and moDCs. This is in accordance with poor or lacking CAR expression on most leuko-
cytes290. CAR-independent infection of moDCs by Ad5 has also been reported previously 
and was suggested to rely on lactoferrin and DC-SIGN329. Nevertheless, compared to 
Ad19a/64, such alternative Ad5 entry pathways appear to be orders of magnitude less ef-
ficient in mediating the transduction of moDCs. 
Compared to Ad5, both Ad19a/64 and MVA were rather efficient at inducing antigen ex-
pression in moDCs (Figure 33). While at low MOIs, MFI values were highest for MVA, peak 
values were higher for the AdV vectors. This might be explained in part by different pro-
moters controlling transcription of GFP, IE-1 and pp65 since in both AdV vectors, the im-
mediate/early promoter of CMV is used whereas for the MVA vectors, a poxviral synthetic 
early/late promoter was chosen291. At the same time, when using Ad5, much higher MOIs 
(100-1000-fold) were required for reaching MFI values that were comparable to Ad19a/64.  
Consistent with the observed DC transduction rates determined for IE-1- and pp65-express-
ing vectors, MVA was best at mediating T cell restimulation (particularly at low MOIs), fol-
lowed by Ad19a/64 and, with some distance, by Ad5 (Figure 34). The same trends were 
observed for both antigens and minor variances between IE-1 and pp65 are likely explained 
by differences in peptide processing and presentation kinetics or T cell receptor avidities of 
the clones used. At MOI 100, the T cell restimulation rates were declining for MVA, a phe-
nomenon that was hardly observed even at higher MOIs for the AdV vectors.  
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This reduction in T cell restimulation is probably a direct result of cytotoxicity, since the 
poxvirus strain was found to induce the highest amount of cell death (evident already at 
MOI 0.1, Figure 36). Since Ad19a/64 induced detectable cytotoxic effects only starting from 
MOI 100, the window in which transduction and antigen presentation take place without 
the induction of cell death appears to be larger for this vector than for MVA. Interestingly, 
cell death was not above background levels for the tested MOIs using Ad5, though this is 
likely not a feature of Ad5 in general, but rather due to inefficient entry into moDCs.  
In accordance with previously published data, there was pronounced downregulation of 
maturation markers following MVA transduction starting from MOI 1 (Figure 35)330. At the 
same time, it was surprising that CD86 and HLA-DR were upregulated at MOI 0.1. Previous 
work by Pascutti et al. demonstrated that instead of MVA-infected DCs, uninfected by-
stander cells are increasing the expression of CD86 and HLA-DR, which could explain why 
upregulation was only observed at MOI 0.1331. The same markers were upregulated as a 
result of AdV transduction in a dose-dependent manner although the expression of CD80 
and CD83 was largely unaltered. Thus, during ex vivo transduction of dendritic cells, it might 
 or a TLR agonist to induce full 
maturation of moDCs and boost their stimulatory capacity.  
Finally, both Ad5 and Ad19a/64 were capable of transducing HeLa cells (which do express 
the CAR receptor332) at similar rates, with comparable protein levels being obtained at MOI 
1000 (Figure 37B). Accordingly, cross-presentation by DCs co-cultivated with transduced 
HeLa cells did not differ significantly between the two AdV vectors (Figure 37C). In this 
experimental setting, the amount of antigen produced in HeLa cells seems to be the major 
determinant of subsequent T cell restimulation rates.  
Taking these results together, Ad19a/64 could be a useful vector for the ex vivo delivery of 
immunogens to dendritic cells, since transduction, antigen expression and -presentation are 
superior to Ad5 while at the same time there is no interference with DC maturation, and 
cytotoxicity is clearly less pronounced than for MVA. The ability to transduce moDCs with-
out inhibiting maturation or inducing apoptosis is a particularly beneficial vector character-
istic, since dendritic cells presenting CMV antigens have great therapeutic potential for im-
munosuppressed patients such as transplant recipients. Currently, DCs pulsed with pp65 
mRNA are even tested in clinical studies for the treatment of glioblastoma190, where expres-
sion of CMV antigens is frequently detectable188,189.   
For more classical vaccination concepts, where intramuscular immunization is the most fre-
quently used delivery route, muscle cells are presumably the main producers of antigen. 
Since it was previously demonstrated that in contrast to Ad5, Ad19a/64 is also capable of 
transducing myocytes with high efficiency, it is likely that secondary antigen uptake by den-
dritic cells will be higher in vivo when this vector is used236. At the same time, direct in vivo 
transduction of dendritic cells is also a feasible route for antigen delivery when using 
Ad19a/64 or MVA. 
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These results provide evidence that vectors based on Ad19a/64 are promising tools for the 
delivery of CMV antigens and that further in vivo testing of the described immunogens as 
vaccine candidates in appropriate animal models is warranted. Beyond that, the favorable 
vector characteristics of Ad19a/64 could also be exploited for other applications such as 
prophylaxis or treatment of other chronic infections associated e.g. with various tumor dis-
eases as well as the delivery of tumor antigens for immunotherapy of cancer.  
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V.3. Attenuated SeV is a promising vector system for the de-
livery of antigens to dendritic cells 
In recent years, four different vaccine concepts utilizing viral vectors for the delivery of CMV 
antigens have made it into clinical trials (reviewed in192): Of those, a vector based on MVA  
containing pp65, as well as an exon of IE-1 and IE-2 each (HCMV-MVA Triplex), is the only 
one currently being tested in phase II. The results from phase I, investigating safety and 
immunogenicity in a small cohort of healthy adults in a homologous prime/boost regimen, 
were recently published193. While strong and durable T cell responses were induced upon 
priming, the booster immunization hardly showed an additional benefit. At the same time, 
anti-MVA immunity was detectable. In a different setting, however, it was previously re-
ported that immune responses elicited by the closely related vaccinia strain NYVAC could 
be increased in a heterologous prime/boost regimen employing a DNA prime, as compared 
to the NYVAC alone group333. Thus, it is likely that the immunogenicity of MVA could be 
improved upon by likewise combining it in a heterologous prime/boost regimen with sec-
ondary delivery modalities, such as the Sendai virus vectors described here. 
Live attenuated virus vectors often pose residual health risks when administered as a vac-
cine, but usually exhibit superior immunogenicity compared to inactivated virions. Although 
SeV has as yet not been reported to cause disease in humans, clinical trials have so far only 
been conducted with healthy individuals. Thus, for immunocompromised individuals, which 
are the main target group for therapeutic CMV vaccines, higher safety measures might have 
to be implemented. In order to increase the safety of Sendai virus-based CMV vaccine can-
didates, a replication-deficient SeV strain with a partial deletion of the P gene was chosen. 
This deletion interrupts the interaction between the viral P- and N proteins and, as a conse-
quence, renders the viral RNA-dependent RNA polymerase (vRdRp) incapable of switching 
from mRNA synthesis (using the negative-strand viral RNA genome as template) to the de 
novo production of (-)-strand viral genomes from viral (+)-mRNAs298. It was demonstrated 
in the present study that human dendritic cells are permissive for replication of SeV (Figure 
38), which underlines the requirement for further attenuation to limit proliferation during a 
state of immunosuppression in vivo. In this regard, the N-terminal truncation of the phos-
phoprotein already proved to be sufficient to inhibit the generation of viral progeny upon 
infection of DCs (Figure 38). Yet, after entry of rdSeV into a cell, mRNA synthesis (boosting 
RNA copy numbers in the cell) as well as protein translation still take place, thus preserving 
the advantages of live attenuated vectors to some extent. 
Although transgene expression is initiated in moDCs after SeV infection, the overall amount 
of protein was markedly reduced when using rdSeV compared to the parental strain (Figure 
39). Although reduced mRNA synthesis as a result of partial P deletion has been observed 
before, the underlying molecular mechanism has not been elucidated yet334. This might be 
explained by the inability of the vRdRp complex from rdSeV to switch to genome replication. 
During infection with wild-type SeV strains, newly generated genome copies could serve as 
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additional templates for subsequent rounds of mRNA synthesis, thereby amplifying overall 
gene expression. Importantly, despite decreased transgene levels, restimulation of antigen-
specific T cells was hardly affected, which is in accordance with previously published data 
suggesting that the intracellular quantity of a given immunogen is not connected to the 
amount of MHC-presentation on the cell surface335.  
All vectors that were compared in this study caused cell death in an MOI- and, with the 
exception of rdSeV, time-dependent manner (Figure 41). It is possible that cells which were 
negative for cell death markers after 24 hours initially remained uninfected and that sec-
ondary infections by newly released virions, concomitant with induction of apoptosis, ac-
count for the increase in dying cells between 24 and 48 hours. Because MVA was previously 
reported not to produce viral progeny in moDCs336, such an effect is only conceivable for 
replication-competent SeV, which might explain why the proportion of dead cells remained 
constant over the observed time period for rdSeV. Information on the duration of Paramyx-
ovirus replication in cell culture is scarce1, but viral titers were above the baseline level al-
ready at 24 hours after infection of moDCs with rcSeV (Figure 38C), showing that the rep-
lication cycle can be completed in this time frame. Thus, one or more rounds of infection 
would be possible within 48 hours. Nevertheless, an increase in dead cells over time was 
also evident for the replication-competent vectors at higher MOIs (10 and 100). Under these 
conditions, few cells should initially remain uninfected, which indicates that replication-de-
ficiency alone is an unlikely explanation for the reduced cytotoxicity of rdSeV. The discrep-
ancy might also be explained by the different patterns of cytokines released after infection 
with the different vectors. For instance, secretion of TNF, a potent inducer of cell death337, 
could be the cause of the toxicity observed here. In fact, the amounts of TNF produced 
upon infection mirror the degree of toxicity of the three vectors. 
Priming of T cells in vivo requires a finely tuned combination of signals from dendritic cells, 
the main constituents of which are (i) MHC-presentation of a given peptide, (ii) presence of 
co-stimulatory molecules on the DC surface and (iii) cytokine secretion338. Already at low 
MOIs, CD8+ T cell clones were efficiently restimulated by moDCs after transduction with all 
vectors tested, indicating no major viral interference with the antigen processing- and 
presentation-machinery. However, the restimulatory capacity of MVA-transduced DCs was 
diminished at higher MOIs, a phenomenon that was not observed for the SeV vectors and 
which may be linked to the higher cytotoxicity of the poxvirus strain. Reduced T cell stimu-
lation by MVA may also be the result of a noticeable downregulation of costimulatory re-
ceptors from MOIs 1 to 100 as part of a previously described immune evasion mecha-
nism330. By contrast, maturation markers tended to be upregulated in an MOI-dependent 
manner by both SeV vectors with only few exceptions, which is in accordance with findings 
by other groups describing Sendai virus as a potent inducer of DC maturation339,340. How-
ever, it was striking that upregulation of maturation markers after SeV infection was gen-
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erally less pronounced for IE-1-expressing vectors compared to their pp65-containing coun-
terparts, with CD83 even being downregulated to some extent. During CMV infection, IE-1 
plays a central role in suppressing various innate immune response pathways (reviewed in39) 
and may therefore also counteract DC maturation when expressed by heterologous vectors. 
The immediate-early protein IE-2 of CMV was recently found to induce proteasomal degra-
dation of CD83341, an immune evasion strategy that is similarly employed by other Herpes-
viruses such as HSV-1342. Since IE-1 and IE-2 are alternative splicing products from the same 
gene locus with the first 85 amino acids being identical due to the shared usage of two 
exons, it is conceivable that IE-1 could likewise be capable of inducing CD83 degradation. 
Such detrimental influences on DC maturation and function may be avoided by using a 
functionally inactivated IE-1 protein as previously proposed by Tang and colleagues343. Irre-
spective of a given transgene, SeV-transduced DCs might indeed be capable of priming T 
cell responses without the need for further components (like adjuvants) when taking into 
account that in addition to antigen presentation and DC maturation, the Sendai vectors are 
also capable of inducing secretion of proinflammatory cytokines such as IL-6 and IFNα. 
Finally, SeV was also found to exhibit a broad target cell tropism. In addition to human 
moDCs, T cells, NK cells and monocytes are efficiently transduced by Sendai virus as well. 
This opens up a variety of possible gene delivery applications in basic research and gene 
therapy. 
In conclusion, the favorable immunological characteristics of Sendai virus in combination 
with the enhanced safety profile of rdSeV, emphasize the potential of this vector system, 
thus warranting further testing of SeV as vaccine platform in general and as a CMV vaccine 
candidate in particular. 
  
  Materials and methods 
82 
 
VI. Materials and methods 
Unless noted otherwise, all chemicals were purchased from Sigma and Merck, cell culture 
flasks and general plastic material from BD Falcon, Sarstedt and Eppendorf. 
 
VI.1. Cell culture techniques 
Insect cell lines were cultivated at 26 °C, mammalian cells were cultured at 37 °C and 5 % 
CO2. Handling of cells was performed under sterile conditions in class II laminar flow hoods. 
Before reaching full confluence, adherent cells were split 1:10 by washing them with PBS, 
incubation with Trypsin-EDTA for 3 minutes and resuspension in culture medium. Suspen-
sion cells were kept within the desired density range by replacing a suitable volume of the 
culture with fresh medium. Once a week, suspension cells were centrifuged at 100 xg for 
10 minutes. The supernatant was discarded and the cell pellet was resuspended in a suitable 
amount of fresh culture medium. Cells concentrations were determined by mixing an ali-
quot of the cell suspension 1:1 with trypan blue (for visualizing dead cells) and counting 
living cells in a hemocytometer. 
 
Medium/Reagent Supplier Additives 
Phosphate buffered saline (PBS) Sigma-Aldrich none 
Penicillin/Streptomycin (Pen/Strep) Pan Biotech none 
Fetal calf serum (FCS) Sigma-Aldrich none 
TC-100 insect medium  Thermo Fisher 10% FCS, 1% Pen/Strep 
RPMI Pan Biotech 10% FCS, 1% Pen/Strep 
Ultraculture Lonza 1% Pen/Strep 
DMEM Thermo Fisher 10% FCS, 1% Pen/Strep 
Insect Xpress Lonza 1% Pen/Strep 
 
Cell line ATCC# Growth Culture medium 
BHK-21 C-13 adherent DMEM 
Hek293T CRL-3216 adherent DMEM 
HeLa CCl-2 adherent DMEM 
High Five n.a. suspension Insect Xpress 
Peripheral blood mononuclear 
cells (PBMCs) 
n.a. semiadherent UltraCulture 
Primary monocytes n.a. adherent RPMI 
SF9  PTA-3099 adherent TC-100  
THP-1 TIB-202 adherent RPMI 
T cell clones n.a. suspension RPMI 
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VI.2. Baculovirus expression system 
The proteins pp65, IE-1, BZLF1, pp65-6xDE, and GFP-pp65 were produced in insect cells 
after infection with recombinant baculovirus strains. Bacmids containing the respective 
genes were first generated by site-specific recombination in E. coli cells, followed by gen-
eration of recombinant baculovirus strains via transfection of SF9 cells with the purified viral 
genomes. For large-scale protein production, High-Five cells were infected with the newly 
generated baculovirus strains and proteins were purified via affinity chromatography.      
  
VI.2.1. Bacmid generation 
Recombinant baculovirus strains were generated using the bac-to-bac baculovirus expres-
sion system from Thermo Fisher344. First, the gene of interest (IE-1, pp65, BZLF1, pp65-6xDE 
or GFP-pp65) was inserted into the multiple cloning site (MCS) of the transfervector pFAST-
Bac-T1 by standard molecular cloning techniques345 via the EcoRI and KpnI restriction sites. 
Correct insertion of the gene-of-interest and absence of mutations was confirmed by Sanger 
sequencing. Plasmid DNA from sequence-verified clones was prepared via alkaline extrac-
tion, followed by isopropanol precipitation346. Chemically competent DH10Bac cells (200 µl) 
were thawed on ice and 15 ng of plasmid DNA were added, followed by 30 min of incuba-
tion on ice. Cells were heat-shocked by incubation in a 42 °C water bath for 45 seconds. 
Next, cells were cooled on ice for 2 min, followed by addition of 1 ml of lysogeny broth (LB) 
medium and incubation at 37 °C for 4 hours while constantly shaking the suspension at 
220 rpm. 100 µl of the suspension were then plated on LB agar plates containing kanamycin 
(50 µg/ml), gentamycin (10 µg/ml), tetracycline (10 µg/ml), IPTG (40 µg/ml) and Bluo-Gal 
(100 µg/ml). Plates were incubated for 48 h at 37 °C, after which time white colonies were 
picked and streaked onto new LB agar plates containing the same additives. After incubat-
ing these plates for 48 h at 37 °C, several white colonies were again picked and subjected 
to colony PCR analysis using the primers M13fwd and M13rev as well as the GoTaq Green 
that were positive for 
bacmids with a transgene insertion could be distinguished from parental bacmids via the 
amplified DNA sequence (2300 bp + the transgene size vs. 300 bp). Bacmid DNA was again 
isolated by alkaline extraction, followed by isopropanol precipitation. 
 
Reagent Supplier 
pFastBac-T1 (plasmid) Thermo Fisher 
E. coli DH10Bac cells (chemically compe-
tent) 
Thermo Fisher 
Ampicillin Sigma Aldrich 
Kanamycin Sigma Aldrich 
Gentamycin Sigma Aldrich 
Tetracycline Sigma Aldrich 
Isopropyl- -D-thiogalactopyranosid (IPTG) Sigma Aldrich 
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5-bromo-3- -D-galactopyranoside 
(Bluo-Gal)  
Biomol 
GoTaq Green Master Mix  Promega 
    
Primer  Sequence (5'-3') 
M13fwd GTTTTCCCAGTCACGAC 
M13rev CAGGAAACAGCTATGAC 
  
Medium  Composition 
Lysogeny broth (LB) 0.5% (w/v) yeast extract, 1% (w/v) tryptone, 1% (w/v) NaCl 
 
VI.2.2. Transfection of insect cells with recombinant bacmids 
9x105 SF-9 cells were seeded in a volume of 1.4 ml into each well of a 6-well plate, followed 
by+ incubation at 26 °C for 2 hours. For transfection of insect cells, the Effectene transfec-
tion kit (Qiagen) was used according to the manufact
DNA were diluted in 100 µl buffer EC. After addition of 6.4 µl enhancer, the suspension 
was briefly vortexed and incubated at room temperature (RT) for 5 min. Next, 20 µl of 
Effectene were added and after thorough vortexing (  10 sec), the mixture was incubated 
at RT for 10 min. 600 µl of TC-100 medium were mixed with the suspension and added to 
the cells by evenly distributing small droplets over the plate area. Cells were incubated at 
26 °C until they showed signs of viral infection as determined by visual inspection (3-6 days), 
including cell and nuclear enlargement or the formation of polyhedra. Baculoviruses were 
then harvested by transferring cells and culture medium into a new tube and centrifuging 
the suspension at 500 xg for 5 min. The supernatant, representing the P1 virus stock, was 
transferred into a new tube and stored at 4 °C until further use. 
For generation of high titer virus stocks, 1x107 SF9 cells in 30 ml TC-100 medium were 
seeded into a T175 cell culture flask and after 2 hours of incubation at 26°C, 500 µl of the 
P1 stock were added. When cells appeared thoroughly infected (3-4 days post infection), 
cells and medium were transferred into a 50 ml conical tube and centrifuged for 10 minutes 
at 500 xg and the supernatant (P2-stock) was stored at 4 °C until further use (up to 3 
months). 
 
VI.2.3. Infection of High Five cells 
High Five cells were held in suspension culture at a density between 3x105 and 2.5x106 cells 
per ml. For small scale cultures (40 ml), cells were cultivated in 125 ml Corning Erlenmeyer 
plastic flasks (Sigma-Aldrich) whereas for large scale cultures (300 ml), 1 l flasks were used. 
Cultures were constantly rotated on horizontal shakers at 140 rpm (40 ml cultures) or 100 
rpm (300 ml cultures). For infection with recombinant baculoviruses, an exponentially grow-
ing culture (viability  90% as determined by trypan blue staining) was set to a density of 
1x106 per ml and after 2 hours, the desired amount of virus suspension was added. The 
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added volume of virus suspension (P2 stock) was chosen in such a way that infected cells 
would stop dividing after 48 hours. The required amount of virus to reach the day of pro-
liferation arrest (dpa) after 48 hours was determined separately for the P2 stock of each 
baculovirus strain: in preceding experiments, various small scale cultures were infected with 
different dilutions of the P2 stocks and cell growth was assessed by daily counting of cells 
on a hemocytometer. After 3 days, cells were harvested by transferring cultures to 50 ml 
conical tubes that centrifuged for 5 min at 1000 xg and 4 °C. The supernatant was discarded 
and cell pellets were stored at -20 °C until protein purification (section VI.3.2). 
 
VI.3. Protein biochemistry techniques 
VI.3.1. Bradford assay 
Protein concentrations were determined via the Bradford assay347. Proteins solutions were 
stained using Bradford reagent (Biorad) according to the manufactur Sam-
ples were measured in triplicates and mean values were calculated. Dilutions of a bovine 
serum albumin (BSA) stock solution with known concentration were used for generating a 
calibration line, thus allowing protein quantification. Data acquisition was performed with 
a 680 microplate reader (Bio-Rad) and the endpoint of the colorimetric reaction was meas-
ured at 595 nm. 
 
VI.3.2. Protein purification from insect cells 
During purification of recombinant proteins via affinity chromatography, all solutions and 
buffers were precooled on ice. Likewise, samples were handled on ice and centrifuged at 4 
°C. At relevant steps during purification, aliquots were collected and stored at -20 °C until 
further analysis.  
The frozen pellets (each one corresponding to 50 ml of initial cell culture volume) of bacu-
lovirus-infected High Five cells (section VI.2.3) were thawed and resuspended in 40 ml PBS, 
followed by centrifugation at 1000 xg for 5 min. The supernatant was discarded and cells 
were resuspended in 20 ml lysis buffer supplemented with 1 tablet 
Protease inhibitor. The suspension was then incubated on an end-over-end shaker for 30 
min at 4 °C. Next, cells were subjected to ultrasound treatment by dipping the suspension 
into the macrotip of a Branson Sonifier 450 device (output control: 5.5, duty cycle: 80%, 
converter 102-C, 1/8) in 6 one-minute intervals with 1 minute of incubation on ice between 
pulses. The suspension was then incubated for another 15 min on an end-over-end shaker 
at 4 °C, followed by centrifugation at 4.000 xg for 30 min. The supernatant was transferred 
into a new 50 ml conical tube, 2 ml of resuspended Ni-IDA-beads (50% suspension) were 
added to each sample and the suspension was mixed on an end-over-end shaker for 2 h at 
4 °C. Cells were then centrifuged for 5 min at 1000 xg and the supernatant was replaced 
with 40 ml wash buffer. After one repetition of this washing step, the suspension was 
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transferred to a disposable 5 ml column. The beads were then washed on the column by 
adding a total of 40 ml wash buffer, with the flow-through being discarded. 
For BZLF1 and GFP-pp65 (where the His/Strep tandem tag was not cleaved), the protein 
was eluted after this step by adding 2 ml elution buffer, followed by 1 ml and then 3x 500 
µl of the same buffer (the flow through was collected at each step). Fractions with sufficient 
protein concentrations were pooled, sterile-filtered (filter pore size 0.45 µm), frozen in liquid 
nitrogen and stored at -80 °C until further use. 
For the remaining proteins (pp65, IE-1 and pp65-6xDE), the column was locked after the 
washing steps and 2 ml elution buffer were added along with 60 U Prescission Protease. 
The column was then incubated overnight on an end-over-end shaker at 4 °C. The next day, 
the columns were opened and the flow through was collected. Additionally, 1 ml and then 
3x 500 µl elution buffer were added to the beads with the flow through being collected at 
each step. Fractions with sufficient protein concentrations were pooled. 800 µl glutathione 
Sepharose and 1200µl Strep-Tactin Sepharose were added to a new disposable 5 ml column 
and washed with 10 ml wash buffer. The pooled elution fractions were then added to the 
column (which was locked) and the bead suspension was incubated on an end-over-end 
shaker for 4 h at 4 °C. The columns were opened and the flow through was collected. 
Additionally, 1 ml and then 3x 500 µl elution buffer were added to the beads with the flow 
through again being collected at each step. Suitable fractions were pooled, sterile-filtered 
(filter pore size 0.45 µm), frozen in liquid nitrogen and stored at -80 °C until further use. 
 
Reagent/Consumable Supplier 
 Roche 
dithiothreitol (DTT) Sigma-Aldrich  
Ni-IDA beads  Carl Roth  
Glutathione Sepharose  GE Healthcare 
Strep-Tactin Sepharose IBA Lifesciences 
 Thermo Fisher 
Prescission Protease  Thermo Fisher 
  
Buffer Composition 
Lysis buffer 
50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 0.5% 
(v/v) Tween-20, 1 mM DTT, pH to 8.0 with NaOH 
Wash buffer 
50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 
0.05% (v/v) Tween-20, pH to 8.0 with NaOH 
Elution buffer 
50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, 
0.05% (v/v) Tween-20, pH to 8.0 with NaOH 
 
VI.3.3. SDS-PAGE 
Proteins were separated according to their size in sodiumdodecylsulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE)348. Protein solutions were mixed with 5x Laemmli buffer and 
incubated at 95 °C for 5 minutes. Samples were then loaded onto a 10% or 12.5% SDS gel 
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standard for estimating the size of the proteins assessed. 
 
Reagent Supplier 
 Thermo Fisher 
    
Buffer Composition 
1x Laemmli buffer  
62.5 mM Tr -Mercaptoethanol; 0.5 
mM EDTA; 5% (v/v) glycerol; 0.005% (w/v) bromophenol blue; 
pH 6.8 
 
VI.3.4. Coomassie staining 
After electrophoresis, SDS gels were incubated for 15 minutes in Coomassie staining solu-
tion. Gels were then destained by incubation with 5% acetic acid until protein bands were 
clearly visible. 
 
Reagent Supplier 
Coomassie Brilliant Blue R-250 AppliChem 
    
Buffer Composition 
Coomassie staining solution 
1.25% (w/v) Coomassie Brilliant Blue R-250, 50% (v/v) 
ethanol, 7% (v/v) acetic acid 
 
VI.3.5. Western blot analysis 
Proteins separated by SDS-PAGE were transferred to a nitrocellulose membrane (pore size: 
0. via Western blot using a semi-dry blotting device (Serva Electrophoresis) according 
2 membrane for 1 hour). For saturating all 
protein binding spots on the membrane after blotting, it was incubated with 5% MTBS for 
at least one hour or overnight. Immunostaining was performed by washing the membrane 
3 times with TTBS before incubation with the primary antibody (which was diluted in TBS) 
for 1 hour. After another 3 washing steps with TTBS, the membrane was incubated for 1 
hour with the HRP-conjugated secondary antibody. Last, the membrane was subjected to 
3 more washing steps and substrate solution was added. After 5 minutes, the substrate 
solution was removed and signals were detected with a ChemiluxPro device (Intas). 
 
Buffer Composition 
TBS 50 mM Tris/HCl pH 7.5; 150 mM NaCl 
MTBS 50 mM Tris/HCl pH 7.5; 150 mM NaCl; 5% (w/v) non-fat dried milk powder 
TTBS 50 mM Tris/HCl pH 7.5; 150 mM NaCl; 0.05% (v/v) Tween-20 
Substrate solution  
100 mM Tris/HCl pH 8.5; 12.5 mM luminol; 1.98 mM coumaric acid; % 
H2O2 
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Primary antibody Supplier Cat-# Dilution 
goat anti GST Biomol 100-101-200 1:1000 
mouse anti His Thermo Fisher MA1-21315 1:1000 
mouse anti Strep Qiagen 34850 1:1000 
mouse anti pp65 Abcam ab53489 1:1000 
mouse anti IE-1 Abcam ab30924 1:1000 
mouse anti BZLF1 Santa Cruz  sc-53904 1:500 
rabbit anti GFP Santa Cruz sc-8334 1:2000 
 
Secondary antibody Supplier Cat-# Dilution 
anti mouse HRP Dianova 115-036-003 1:5000 
anti goat HRP Dako P0449 1:1000 
anti rabbit HRP  Dako P0448  1:5000 
 
VI.3.6. Silver staining 
After electrophoresis, the SDS gel was incubated for 1 h in fixation solution (the amount of 
each solution added was sufficient to cover the gel completely). The gel was then incubated 
for 10 min with 50% EtOH and afterwards for another 10 min with 30%. Next, the gel was 
incubated for 1 minute with sodium thiosulphate solution (0.2 g/l) and then washed three 
times with H2O. The gel was then incubated for 20 min with staining solution, followed by 
another three washing steps with H2O. After removal of H2O, developing solution was 
added and when bands were sufficiently distinct (5-10 min), the reaction was stopped by 
incubating the gel for 5 min with 5% acetic acid. Finally, the gel was washed twice with 
H2O.  
 
Buffer Composition 
fixation solution 50% methanol, 12% acetic acid, 50 µl formaldehyde (37% stock)/100 ml 
staining solution 0.1% (w/w) AgNO3, 75 µl formaldehyde (37% stock)/100 ml 
developing solution 
6% (w/w) Na2CO3, 50 µl formaldehyde (37% stock)/100 ml, 0.4 mg/l sodium 
thiosulfate 
 
VI.3.7. Posttranslational modification  
Protein samples (stored in elution buffer, see section VI.3.2) were diluted 1:10 with a 3 M 
stock solution of KOCN (for inducing carbamoylation) or a 300 mM stock solution of maleic 
anhydride (for inducing maleylation; both chemicals were dissolved in sodium phosphate 
buffer). Samples were then incubated at 35 °C for 24 hours. Afterwards, residual KOCN or 
maleic anhydride were removed via extensive dialysis to sodium phosphate buffer at 4 °C 
using the Pur-A-   
 
Reagent/Consumable Supplier 
KOCN Sigma-Aldrich 
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Maleic anhydride (99%) Sigma-Aldrich 
Pur-A- -8kDa Sigma-Aldrich 
  
Buffer Composition 
sodium phosphate buffer 50 mM NaH2PO4, 300 mM NaCl, 1 mM DTT, pH 8.0 
 
VI.3.8. Fluorescence analysis 
For measuring the fluorescence intensities of GFP-pp65 and carb-GFP-pp65, the protein 
solutions were diluted to the desired concentration in PBS and transferred into an uncoated 
96 well plate. Data was acquired at room temperature on a Victor3 multilabel plate reader 
(Perkin Elmer) with the following settings: excitation at 485 nm (CW lamp energy 12600), 
emission filter F535, measurement time 1 s. 
 
VI.3.9. Isoelectric focusing 
Isoelectric focusing was performed with the SERVAGel IEF 3-10 starter kit (Serva): 1-3 µg of 
protein were diluted with 2x loading buffer and loaded onto a precasted gel that was in-
cluded in the kit. Electrophoresis was performed for 60 min at 50 V, followed by 2 h at 200 
V. Afterwards, silver staining (section VI.3.6) was performed for visualizing bands. 
 
VI.3.10. Carbamoyl-ELISA 
Protein samples with varying concentrations (ranging from 100 ng/µl to 1 µg/µl) were di-
luted 1:100, 1:1.000 and 1:10.000. 100 µl per sample and dilution were added to a Nunc 
MaxiSorp flat-bottom 96 well plate. To determine the linear range of the assay, a BSA sam-
ple (1 µg/µl) that was carbamoylated according to the procedure described in section 
VI.3.10 was diluted in 1:10 steps from 100 ng/µl to 0.001 ng/µl and 100 µl of each dilution 
were added to the plate as well. The samples were then incubated overnight at 4 °C. Next, 
the plate was washed three times with 200 µl PBS-T and the supernatant was discarded. 
All washing steps were performed with a HydroFlex plate washer device (Tecan). 150 µl of 
blocking buffer were added to each well and the plate was incubated at RT on an orbital 
shaker (100 rpm) for 2 hours. Again, the plate was washed three times with 200 µl PBS-T 
and the supernatant was discarded. 100 µl of primary antibody solution were added to 
each well and the plate was incubated at RT on an orbital shaker (100 rpm) for 1 hour. The 
plate was then washed six times with 200 µl PBS-T, the supernatant was discarded and 100 
µl of secondary antibody solution were added, followed by incubation on an orbital shaker 
(100 rpm) for 1 hour at RT. Finally, the plate was washed 10 times with 200 µl PBS-T, the 
supernatant was discarded and 100 µl of TMB substrate (TMB A and TMB B were mixed 
shortly before), were added to each well. After 90 sec of incubation, the reaction was 
stopped by adding 50 µl of 1 M H2SO4 to each well and mixing thoroughly. Data acquisition 
was performed with a 680 microplate reader (Bio-Rad) and the colorimetric reaction was 
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measured at 450 nm. Only dilutions that were within the linear range of the assay were 
used for further analysis (Figure 13). 
 
Consumable Supplier 
Nunc MaxiSorp® flat-
bottom 96 well plate 
Thermo Fisher 
    
Buffer Composition 
Blocking buffer  5 % (w/w) BSA in PBS, 1mg/ml NaN3 
PBS-T 0.05% (v/v) Tween-20 in PBS 
TMB A 30 mM tri-potassium citrate-monohydrate, pH 4.1 with 10% (w/v) citric acid 
TMB B 0.24% (w/v) TMB, 10% (v/v) acetone, 90% (v/v) ethanol, 80 mM H2O2 
TMB substrate TMB A and TMB B mixed in a 20:1 ratio 
 
Antibody Supplier Cat# dilution 
Anti Carbamyl-lysine antibody  Abcam ab175135 1:1000 
Anti goat HRP secondary antibody  Abcam ab6741 1:1000 
 
 
VI.4. Mass spectrometry analysis 
VI.4.1. LC-MS analysis of amino acid composition 
The carbamylated pp65 protein was subjected to amino acid analysis and the extent of HCit 
formation was determined by comparing the HCit concentration with the concentrations of 
Phe, Val, and Pro (as surrogates for the total protein concentration). The method was based 
on double isotope dilution mass spectrometry as described previously349 351. In short, the 
same amounts of isotopically labeled Phe, Pro, Val as well as D7-Cit269 were added to the 
protein sample and to a reference solution containing the pure amino acids in their natural 
isotope forms as well as HCit. Sample and reference were treated equally and the peak area 
ratios of natural to labeled amino acids were determined in both solutions und used for 
amino acid quantification. After adjusting the peak area ratios to unity in a pre-experiment, 
three protein samples (12 µg in 5 mM ammonium acetate) and one reference were pro-
cessed as follows: Each solution was transferred to a 5 mL vacuum hydrolysis tube (Pierce) 
and dried in a stream of nitrogen. Subsequently, 400 µl 6 mol/l hydrochloric acid supple-
mented with 0.1 % (w/v) phenol were added, the liquid was frozen in liquid nitrogen and 
the tubes were evacuated. Hydrolysis was performed at 115 °C for 20 h. After drying in a 
stream of nitrogen, reconstitution was performed in 1 ml 80 % acetonitrile/5 mM ammo-
nium acetate pH 3.6 (v/v). LC-MS analyses were performed using a HP series 1100 HPLC 
interfaced with a HP Series 1100MSD G1946A mass spectrometer (G1314A binary pump, 
G1313A autosampler, both Agilent Technologies). Amino acids were separated on a 
Fisher) at 25 °C with a 
flow rate of 0.4 ml/min. 2 µl were injected to quantify natural and labeled Phe (m/z 
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166.1/176.1), Pro (m/z 116.1/122.1), and Val (m/z 118.1/124.1), whereas 10 µL were in-
jected to quantify HCit/D7-Cit (m/z 190.1/183.2) (ion traces given in parentheses). Isocratic 
elution was performed with 80 % acetonitrile/5 mM ammonium acetate pH 3.6 (v/v) over 
10 min. Detection was performed in positive-ion mode, and the electrospray ionization (ESI) 
source parameters were as follows: 4.0 kV spray voltage, 350 °C drying gas temperature, 
13 l/min drying gas flow, and 30 psig nebulizer pressure. 
 
Reagent Supplier 
L-phenylalanine-13C9/15  %) Fluka 
L-proline-13C5/15N (  %) Fluka  
L-valine-13C5/15N (  %) Fluka  
L-phenylalanine-13C9/15N  (  %) Cambridge Isotope Laboratories, Inc.  
L-proline-13C5/15N (  %) Cambridge Isotope Laboratories, Inc.  
L-valine-13C5/15N (  %) Cambridge Isotope Laboratories, Inc.  
homocitrulline (  %) Bachem  
2,3,3,4,4,5,5-D7-L-citrulline (D7-Cit) (  CDN Isotopes  
ammonium acetate (p.a.) Fluka  
 
VI.4.2. MS/MS analysis of pp65-derived peptides 
0.16 % Rapigest SF (w/v) was added to 16 µg carbamylated pp65 protein in 100 mM so-
dium phosphate pH 7.8 yielding a final Rapigest SF concentration of 0.1 % (w/v) for enzy-
matic digestion. The sample was reduced by 5 mM TCEP at 37 °C for 45 min and alkylated 
with 15 mM IAA at 25 °C for 30 min in the dark. After quenching the remaining IAA with 
20 mM DTT for 30 min in the dark, enzymatic digestion was performed as follows: Car-
bamoylated pp65 was incubated with 1/10 Glu-C (w/w) at 37 °C for 4 h, 1/20 Asp-N (w/w) 
was added, and incubation at 37 °C was continued overnight. After adding 5 % acetonitrile 
(v/v), the sample was acidified to pH 2 with TFA and incubated at 37 °C for 40 min to cleave 
Rapigest SF. The supernatant was removed and desalted using a CHROMABOND® C18ec 
cartridge (500 mg, Macherey-Nagel) according to the manufacturer´s protocol. After lyoph-
ilization, the sample was reconstituted in 50 µL 5 % acetonitrile/0.1 % formic acid (v/v) and 
6 µL were injected into an Agilent series 1200 LC system (G1312B binary pump, G1367C 
autosampler) (Agilent Technologies) coupled to a LTQ Orbitrap Elite hybrid mass spectrom-
eter (Thermo Fisher). Peptides were separated on a Phenomenex Aeris PEPTIDE XB-C18 col-
umn (250 x 2.1 mm, 3.6 µm) (Torrance) at 25 °C with a flow rate of 0.2 ml/min. Two-step 
gradient elution was performed from 2.5 % to 40 % acetonitrile/0.1 % formic acid (v/v) 
over 100 min as well as from 40 % to 80 % acetonitrile/0.1 % formic acid (v/v) over 50 min. 
The HESI-II probe was operated at the following conditions: 4.2 kV spray voltage, 
300 °C/320 °C heater/capillary temperature, and 36/17 sheath/auxiliary gas flow rate. Using 
a data-dependent top 5 method with a minimum signal threshold of 1000 counts, MS sur-
vey scans were acquired in the Orbitrap from m/z 200 to 2100 at a resolution of 120000. 
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The five most intense signals were subjected to collision induced dissociation (CID) in the 
ion trap with an isolation width of m/z 2, a normalized collision energy of 35 %, and an 
activation time of 10 ms. Dynamic exclusion of 14 s (1 repeat count, 12 s repeat duration) 
was applied. The AGC target was set to 1E6 for MS scans (200 ms maximum injection time) 
and to 1E4 for MSMS scans (50 ms maximum injection time). The settings predict ion injec-
tion time and enable monoisotopic precursor selection were enabled. Data were analyzed 
with the Proteome Discoverer 1.3 (Thermo Fisher) using the pp65 protein sequence as a 
database in combination with the SEQUEST search algorithm. MS and MS/MS tolerances 
were set to 10 ppm and 0.8 Da, respectively, and carbamidomethylation of cysteine was 
set as static modification, whereas carbamoylation of lysine and arginine was set as dynamic 
modification. As combined cutting of Asp-N and Glu-C cannot be specified in the program, 
no enzyme specificity was selected and only peptides with expected cleavages were se-
lected for further analysis352. To determine the degree of carbamoylation at a specific posi-
tion, all identified peptides containing the position of interest were processed with Thermo 
Xcalibur 2.2. For each peptide, the sum of intensities of all contributing charge states and 
isotopomers was extracted from the MS data and integrated over the respective chroma-
tographic peak. The degree of carbamoylation was calculated by dividing the sum of all 
peptides carbamoylated at a specific position by the sum of the areas of all peptides con-
taining the position of interest (the calculation is based on the assumption that unmodified 
and carbamoylated peptides as well as peptides of different length arising from missed 
cleavages exhibit the same mass spectrometric response factor). If the CID-based MSMS 
spectrum was not sufficient to unambiguously determine the position of carbamoylation 
for peptides containing lysine and arginine, the precursor of interest was subjected to an 
additional LC-MSMS run using electron transfer dissociation (ETD). The following fragmen-
tation parameters were applied: 3E5 AGC target (100 ms maximum injection time), 50 µA 
emission current, -70 V electron energy, 16 psi CI gas pressure, and 160 °C source temper-
ature.  
 
Reagent Supplier 
Rapigest SF  Waters  
-C protease (MS grade) Thermo Fisher 
Endoproteinase Asp-N (sequencing 
grade) 
Sigma-Aldrich  
-carboxyethyl)phosphine 
(TCEP)-HCl (premium grade) 
Thermo Fisher  
6 M hydrochloric acid (sequanal grade)  Thermo Fisher  
formic acid (98 100%, p. a.) Merck  
iodoacetamide (IAA) Sigma-Aldrich  
acetonitrile (Chromasolv grade Sigma-Aldrich  
trifluoroacetic acid (TFA) Sigma-Aldrich  
ammonium acetate (p.a.) Fluka  
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VI.5. Isolation, cultivation and differentiation of primary cells 
VI.5.1. Ethics 
Blood donations were collected from healthy, adult volunteers who gave written informed 
consent beforehand. Sample collections and experiments were approved by the ethics com-
mittee of the University of Regensburg (file reference 16-101-0347).  
 
VI.5.2. Isolation of PBMCs 
Heparinized blood samples (15  60 ml of blood were mixed with one droplet of Na-Hepa-
rin) were added to an equivalent volume of PBS and the suspension was carefully layered 
over 15 ml Ficoll in a 50 ml conical tube. Samples were centrifuged for 15 minutes at 1000 
xg with the centrifuge brake turned off. The upper plasma layer was carefully aspirated and 
discarded, leaving the mononuclear cell layer (lymphocytes, monocytes, and thrombocytes) 
undisturbed at the interphase. Next, the mononuclear cell layer was transferred to a new 
50 ml conical tube, which was subsequently filled to 50 ml with PBS and centrifuged for 10 
min at 350 xg with the brake turned back on. Afterwards, the supernatant was discarded 
and the pellet was resuspended in the desired medium or buffer (sections VI.5.3 and VI.5.4). 
 
Reagent Supplier 
Na-Heparin Ratiopharm 
Ficoll-Paque Plus  GE Healthcare  
 
VI.5.3. ELISpot assay 
For this assay, the T track basic ELISpot kit (Lophius Biosciences) was used: After PBMC 
isolation (section VI.5.2), the cell pellet was resuspended in 1 ml of Ultraculture (UC) me-
dium and living cells were counted with a hemocytometer. Next, UC medium was added 
for a concentration of 2x106 cells/ml and 100 µl aliquots were distributed to the desired 
number of wells in an ELISpot plate that was pre- -antibody by the man-
ufacturer. 50 µl of stimulation mixture were then added consisting of 35 µl UC medium and 
the stimulator protein that was diluted to 15 µl with sodium phosphate buffer (section 
VI.3.7). In some cases, fucoidan from Fucus vesiculosus (Sigma-Aldrich; final concentration 
100 µg/ml) was added to PBMCs 30 minutes before addition of the stimulation mixture. 
The plate was incubated for 20 h in a humidified incubator at 37 °C and 5% CO2. After-
wards, the supernatant was discarded and the plate was washed 6 times with 200 µl of 
buffer WB1. 100 µl of antibody solution (mAB-AP was diluted 1:180 in buffer DB) was 
added to each well and the plate was incubated for 2 h at RT in the dark. After this incuba-
tion period, the supernatant was again discarded and the plate was washed 3 times with 
200 µl of WB1, followed by 3 washing steps with 200 µl of WB 2 each. After removing the 
supernatant, 50 µl of stain solution were added per well and the plate was incubated at RT 
and protected from light until spots were clearly visible (10-15 min). The plate was then 
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washed 3 times with H2O and after drying, spots were counted on an AID robotic EliSpot 
Reader (Autoimmune Diagnostica GmbH). 
 
VI.5.4. MACS sorting 
After PBMC isolation (section VI.5.2), the cell pellet was resuspended in 50 ml P2 buffer and 
centrifuged for 10 min at 350 xg. The supernatant was discarded and the pellet was resus-
pended in 800 µl MACS buffer. Next, 100 µl of CD14 (Figure 23 and Figure 24) or CD8 
(Figure 28) microbeads were added and the suspension was incubated for 15 min at 4 °C. 
Afterwards, 10 ml of MACS buffer were added and the mixture was transferred to a 15 ml 
conical tube, followed by centrifugation at 600 xg for 10 min. During centrifugation, a 
MACS separation column was placed into a magnetic multistand and equilibrated with 1 
ml MACS buffer. After centrifugation, the supernatant was discarded and the bead/cell pel-
let was resuspended in 1 ml MACS buffer and added to the MACS column, allowing the 
liquid to pass through the column by gravity flow. For negative selection experiments (Fig-
ure 23 and Figure 28), the flow-through was collected and cells that were depleted of mon-
ocytes or CD8+ T cells were used for further experiments.  
For positive selection experiments (Figure 24) or for further differentiation of monocytes 
(Figure 25, sections IV.2.1 and IV.2.2), the flow-through was discarded and 1 ml of MACS 
buffer was added to the column. After all liquid had passed through the column, it was 
removed from the multistand and placed into a 15 ml conical tube. Again, 1 ml of MACS 
buffer was added to the column and the cells were flushed into the tube by pushing the 
plunger into the column. Cells were then counted and resuspended in the desired volume 
of medium (sections VI.5.5 and VI.5.6). 
 
Reagent/Consumable Supplier 
EDTA (cell culture grade) Invitrogen 
CD14 MicroBeads, human Miltenyi 
CD8 MicroBeads, human Miltenyi 
MACS Separation MS Columns  Miltenyi 
MACS Multistand  Miltenyi 
    
Buffer Composition 
P2 buffer  1% (v/v) FCS in PBS 
MACS buffer  1% (v/v) FCS, 20mM EDTA in PBS 
 
 
VI.5.5. Monocyte differentiation to moDCs or moMφs 
After monocyte isolation via MACS sorting (section VI.5.4), cells were diluted to 10 ml in 
MACS buffer and centrifuged for 10 min at 350 xg. Next, the pellet was resuspended for a 
cell density of 1x106/ml either in DC-medium containing 1000 U IL-4 and GM-CSF each (for 
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differentiation to moDCs) or in macrophage medium containing 50 U/ml GM-CSF only. The 
suspension was incubated in T25 cell culture flasks at 37 °C and 5% CO2 for 5-6 days. After 
two days, half the medium was transferred to a 15 ml conical tube, centrifuged 10 min at 
500 xg and cells were resuspended in 5 ml of the respective medium containing all afore-
mentioned supplements. The fresh medium was then transferred back to the cell culture 
flask along with the resuspended cells.  
At different time points, aliquots (100 - 500 µl) were collected from the flasks and the ex-
pression of surface markers was analyzed to assess differentiation: Cells were centrifuged 
for 5 min at 500 xg and 4 °C, the supernatant was removed and the cell pellet was resus-
pended in 500 µl of FACS buffer (which was precooled on ice). After repetition of this wash-
ing step, the supernatant was discarded and cells were resuspended in 30 µl of antibody- 
or isotype control antibody solutions (diluted in PBS) and incubated for 30 min in the dark 
at 4 °C. Afterwards, cells were again washed two times with 500 µl of FACS buffer. For 
CD14- or CD1a-stained cells (as well as their respective isotype control samples), cells were 
resuspended in 200 µl of FACS buffer and analyzed by flow cytometry. 
For SR-A1 (or the corresponding isotype control sample), cells were resuspended with 30 µl 
of secondary antibody solution (likewise diluted in PBS). After another 30 min incubation 
period at 4 °C in the dark, cells were again washed two times as described above and 
resuspended in 200 µl of FACS buffer, followed by flow cytometry analysis. 
 
Reagent/Consumable Supplier 
FCS, lot# 123M3398 Sigma-Aldrich 
Penicillin/Streptomycin (Pen/Strep) Pan Biotech  
RPMI 1640 with Glutamine and Pen/Strep Pan Biotech 
MEM non-essential amino acids (NE-AA), 100x stock solution  Gibco 
MEM Vitamins, 100x stock solution  Gibco 
L-Glutamine, 200 mM Stock solution  Pan Biotech 
Sodium Pyruvate, 100x stock solution  Gibco 
-Mercapto-EtOH, 50 mM stock solution  Gibco 
IL-4, premium grade Miltenyi 
GM-CSF, premium grade Miltenyi 
 
Buffer Composition 
DC-Medium 
425 ml RPMI 1640, 50 ml FCS, 5ml Pen/Strep, 5 ml NE-AA, 5 ml Vitamins, 5 ml 
Glutamine, 5 ml Sodium Pyruvate, 100 -Mercaptoethanol 
Macrophage Medium  RPMI 1640, 10% FCS, 1% Pen/Strep 
FACS buffer PBS with 1% FCS, 1mg/ml NaN3 
 
Primary antibody Isotype Conjugate Supplier Cat# dilution 
mouse anti human CD14  PE Biolegend 367104 1:50 
mouse anti human CD1a  APC Biolegend 300110 1:50 
mouse anti human SR-A1  none R&D Systems mab27081 1:50 
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Isotype control  Conjugate Supplier Cat# dilution 
MOPC-21-  PE Biolegend 400114 1:50 
MOPC-21-  APC Biolegend 400120 1:50 
 none Biolegend 401405 1:50 
 
Secondary antibody Conjugate Supplier Cat# dilution 
Goat anti mouse IgG PE Biolegend 405307 1:50 
 
 
VI.5.6. Expansion of T cell clones 
The CD8+ T cell clones 4G6 (recognizing the pp65-derived peptide TPRVTGGGAM on HLA-
B7) and 1C3 (recognizing the IE-1-derived peptide QIKVRVDMV on HLA-B8) were a kind gift 
from Dirk Busch (TU Munich). For usage in multiple experiments, they first had to be ex-
panded with suitable feeder cells (consisting of a mixture of PBMCs and LCL cells). 25x106 
HLA-matched PBMCs -irradiated at 35 Gy), 5x106 HLA- -irradiated at 
50 Gy) and 2x105 cells of the clone to be expanded were transferred in a total of 20 ml CTL 
medium into a T25 cell culture flask. The stimulatory anti-CD3 antibody OKT3 was added 
for a final concentration of 30 ng/ml. After 24 hours, human IL-2 was added (100 U/ml) 
and at day 4 of the co-culture, the suspension was centrifuged for 8 min at 200 xg. The 
supernatant was discarded and cells were resuspended in 20 fresh CTL medium containing 
IL-2 only (not the CD3 antibody). At day 8, half the medium was replenished by removing 
10 ml from the flask, centrifuging the suspension as described before and returning the cell 
pellet, resuspended in 10 ml fresh medium with IL-2 (100 /ml), to the flask. From day 9-12, 
cells were counted daily and split if necessary to keep the cell density between 1x106 and 
2x106/ml. At day 12, cells were counted, centrifuged and resuspended in freezing medium 
for a density of 2x106 cells/ml. Cells were then distributed to the desired number of cryo-
tubes and slowly frozen to -80 °C. Finally, cells were stored in liquid nitrogen until further 
use. 
 
Reagent/Consumable Supplier 
 Biochrom 
Ultra-LEAF anti-human CD3 Antibody OKT3 Biolegend 
human IL-2, premium grade Miltenyi 
Medium Composition 
CTL medium 
RPMI 1640, 10% human serum, 4 mM L-glutamine, 25 
-mercaptoethanol, 1% Pen/Strep 
 
T cell clone Cognate epitope HLA restriction 
4G6 TPRVTGGGAM  HLA-B7 
1C3 QIKVRVDMV HLA-B8 
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VI.5.7. Mixed leukocyte reaction (MLR) 
After five days of differentiation, the culture medium of moDCs or moMφs Figure 25, sec-
tion VI.5.5) was changed to RPMI with 10 % FCS and 1 % Pen/Strep. 5x104 cells in 100 µl 
were seeded each into the desired number of wells from a 96-well flat-bottom plate. For 
monocytes (Figure 24, section VI.5.4), the same number of cells per well (also diluted in 
RPMI) was seeded into 96 well plates directly after MACS isolation. Cells were then incu-
bated overnight at 37 °C and 5% CO2. 
The next day, pp65 or carb-pp65 (diluted to 15 µl with sodium phosphate buffer) were 
added along with 5x104 cells of an antigen-specific, HLA-matched T cell clone (in 35 µl RPMI 
medium) for a final volume of 150 µl. For monocytes, fucoidan (final concentration 100 
µg/ml) was added to some wells 30 minutes before addition of the stimulation mixture. 
After 2 h, BFA was added (1 µg/ml) and cells were co-cultivated for another 4 hours. 
The plates were then centrifuged for 5 min at 350 xg and 4 °C and the supernatant was 
discarded. Cells were washed two times with 200 µl of precooled FACS buffer with centrif-
ugation for 5 min at 350 xg and 4 °C after each step. After the second washing step, the 
supernatant was removed and the cell pellet was resuspended in 100 µl Cytofix/Cytoperm. 
Fixation lasted for 30 min at 4 °C, after which cells were washed twice with 200 µl 
Perm/Wash with centrifugation for 5 min at 500 xg and 4 °C after each step. Cells were 
then resuspended in 50 µl staining solution, consisting of anti-CD8-FITC and anti- -APC 
antibodies (diluted in Perm/Wash) and incubated for 30 min at 4 °C in the dark. Finally, cells 
were washed twice with 200 µl Perm/Wash with centrifugation for 5 min at 500 xg and 4 
°C after each step and cells were resuspended in 100 µl FACS buffer, followed by flow 
cytometry analysis. 
 
Reagent/Consumable Supplier 
paraformaldehyde (PFA) Merck Millipore 
Saponin from Quillaja bark (Lot 1310498) Sigma-Aldrich 
Fucoidan from Fucus vesiculosus Sigma-Aldrich 
Brefeldin A (BFA) Sigma-Aldrich 
 
Buffer Composition 
FACS buffer PBS with 1% FCS, 1mg/ml NaN3 
Cytofix/Cytoperm 
PBS with 4 % (w/v) paraformaldehyde (PFA) and 1 % 
(w/v) saponin 
Perm/Wash PBS with 0.1 % (w/v) saponin 
 
Antibody Isotype Conjugate Supplier Cat# dilution 
mouse anti human CD8a  FITC Biolegend 301006 1:60 
mouse anti human IFN-   APC Biolegend 502512 1:60 
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T cell clone Cognate epitope HLA restriction 
4G6 TPRVTGGGAM HLA-B7 
 
VI.6. Virological techniques 
VI.6.1. Generation of recombinant MVA vectors 
VI.6.1.1. In vitro recombination (IVR) 
The genes encoding IE-1 or pp65 were inserted into the MCS of the transfer plasmid 
pLZAW1 via the BamHI and EcoRI restriction sites by standard molecular cloning tech-
niques345. The newly generated plasmids pLZAW1-IE-1 and pLZAW1-pp65 were purified 
from E. coli 
tions. 
1x106 BHK-21 cells were seeded into each well of a 6 well plate in 2 ml medium and incu-
bated overnight at 37 °C and 5% CO2. The next day, the medium was removed and cells 
were infected with MVA-GFP at different MOIs (0.5, 0.167, 0.056, 0.019 and 0.006) in a 
total of 1 ml DMEM devoid of any supplements. Cells were then incubated for 2 h at 37 °C 
and 5% CO2. Afterwards, cells were transfected with pLZAW1 vectors using the Effectene 
Kit from Qiagen: the medium was removed and 1.4 ml DMEM with 10% FCS and 1% 
Pen/Strep were added. 0.88 µg of DNA per plasmid and well were diluted to 100 µl with 
buffer EC. After addition of 6.4 µl enhancer, the suspension was briefly vortexed and incu-
bated at room temperature (RT) for 5 min. Next, 20 µl of Effectene were added and after 
thorough vortexing (  10 sec), the mixture was incubated at RT for 10 min. 600 µl of DMEM 
medium were mixed with the suspension and added to the cells by evenly distributing small 
droplets over the plate area. The cells were then incubated for 72 hours at 37 °C and 5% 
CO2. Afterwards, cells were scraped off the bottom of the culture dish, transferred along 
with the medium to 2 ml reaction tubes and stored at -80 °C until further use. 
 
VI.6.1.2. Plaque purification 
2x106 BHK cells each were seeded into the desired number of 10 cm petri dishes in a total 
of 10 ml. Cell lysates from IVR were subjected to 3 freeze/thaw cycles by transferring the 
tubes to liquid nitrogen, followed by thawing at 37 °C. Then, the lysates were subjected to 
ultrasound treatment on the cup horn of a Branson Sonifier 450 device (output: 8.5; cycle: 
80%; 1 minute pause between pulses). The culture medium of BHK cells was discarded and 
replaced with different dilutions (a total of four 1:3 dilution steps for each MOI in the IVR 
reaction, beginning with 1:20 for MOI 0.0006 and 0.019, 1:100 for MOI 0.056, 1:200 for 
MOI 167 and 1:500 for MOI 0.5) in a total of 4 ml DMEM without any supplements. After 
two hours of incubation at 37 °C and 5% CO2, the viral inoculum was removed and cells 
were overlaid with 12 ml first overlay solution (which was freshly mixed shortly before). 
After 3 days of incubation at 37 °C and 5% CO2, the dishes were overlaid with 5 ml each 
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of second overlay solution (which was again freshly mixed shortly before), followed by an-
other incubation period for 6 hours at 37 °C and 5% CO2. Blue plaques were then picked 
with glass Pasteur pipettes and transferred into 1.5 ml reaction tubes along with 500 µl 
DMEM devoid of any supplements. The picked plaques were stored at -80 °C until the next 
plaque round, when they were subjected to 3 freeze/thaw cycles and ultrasound treatment 
as described above.   
The following plaque purification rounds were performed in an analogous manner to round 
one with slight modifications: 2 - 4 suitable plaque punches per construct were chosen from 
each preceding round for the next one. The plaque punches were always diluted 1:100, 
1:400, 1:1600 and 1:6400 and each dilution was used to infect BHK cells. Blue plaques 
were picked at the dilutions that were best suited for obtaining single ones, until no parental 
virus was detectable via PCR any more (section VI.6.1.3). At this point, white plaques were 
picked in all following rounds instead of blue ones until the presence of LacZ was not de-
tectable via PCR any longer.  
 
Reagent/Consumable Supplier 
Bluo-Gal  Biomol 
Neutral red Sigma Aldrich 
LMP-Agarose Affymetrix 
 
Buffer Composition 
2x DMEM (Roth) 
2xDMEM, 0.74 % (w/v) NaHCO3, 20% (v/v) FCS, 2% (v/v) Pen/Strep 
0.7% (w/v) L-glucose 
LMP solution 2.4% LMP agarose (w/v) in H2O dest., kept at 42 °C 
overlay solution A 2xDMEM with 20% FCS and 2% Pen/Strep, kept at 35 °C 
overlay solution B 
2xDMEM with 20% FCS, 2% Pen/Strep, 1.6 µg/µl Bluo-Gal, 210 µg/ml 
neutral red, kept at 35 °C 
first overlay solution 1:1 mixture of LMP solution and overlay solution A 
second overlay solution 1:1 mixture of LMP solution and overlay solution B 
 
VI.6.1.3. PCR screening 
DNA was isolated from MVA-infected BHK-21 cells using the QIAamp DNA mini Kit (Qiagen) 
-1, pp65, GFP or 
LacZ was performed with the GoTaq Green Master Mix kit (Promega) according to the man-
 
 
Primer  Sequence (5'-3') 
IE-1 fwd GCTTCTAGTCACCATAGGGTG 
IE-1 rev GCATTGAGGAGATCTGCATGAAG 
pp65 fwd GTAGATGTCGTTGGCGTCC 
pp65 rev CTTGAGTACCGACACACCTG 
GFP fwd GTGTTCTGCTGGTAGTGGTC 
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GFP rev CCTGAAGTTCATCTGCACCAC 
lacZ-Int-fwd CCGCTGGATAACGACATTGG 
lacZ-Int-rev CTGACAATGGCAGATCCCAG 
 
 
VI.6.2. Generation of recombinant AdV vectors 
Ad5 and Ad19a/64 vectors were generated as previously described by Ruzsics et al.353 and 
based on an Ad19a ME strain-derived BAC-cloned vector234,354.  Briefly, the genes-of-interest 
(GOI) IE-1, pp65 or eGFP were cloned into shuttle vectors pO6-A5-CMV-gfp and pO6-19a-
CMV-MCS, respectively, under the control of a CMV promoter. The CMV-GOI-SV40-pA was 
then transferred via Flp-recombination in E. coli into the respective BAC vectors containing 
the genome of E1/E3 deleted replication deficient Ad5 or Ad19a-based vectors. Recombi-
nant viral DNA was released from the purified BAC-DNA by restriction digest with Pac-I. The 
obtained linear DNA was transfected into Hek293 cells for virus propagation. Viral vectors 
were released from cells via NaDeoxycholate extraction. Residual free DNA was digested by 
DNase I. Afterwards, vectors were purified by CsCl gradient ultracentrifugation followed by 
a buffer exchange to 10 mM Hepes pH 8.0, 2 mM MgCl2, 4% Sucrose via PD10 columns 
(GE). Titration was performed based on the RapidTiter (Clontech) method by detection of 
infected HEK Hek293 cells via immunohistochemical staining with anti-hexon antibody 
(Ad5: Santa Cruz, Ad19a: Novus). Insert integrity was confirmed by PCR amplification of the 
GOI in DNA purified from the extracted vectors. Functionality of the insert was confirmed 
by qPCR and Western blot of infected NIH3T3 or Hek293 cells. 
 
VI.6.3. Generation of recombinant SeV vectors 
All recombinant Sendai virus variants were generated from a cDNA template encoded on 
plasmid DNA. cDNA templates of rcSeV-GFP and rdSeV-GFP were generated previously334. 
The new constructs rcSeV-IE-1, rcSeV-pp65, rdSeV-IE-1 and rdSeV-pp65 were cloned by 
exchanging the GFP transgene from the above named GFP expressing cDNA constructs 
against the respective transgenes (IE-1 and pp65) via NotI restriction digest. 
Recombinant viruses were recovered through virus rescue experiments from transfected 
BSR-T7 cells as described before298 with slight modifications. FuGENE6 (Roche) was used as 
transfection reagent at 2.0 µl/µg DNA. Virus was harvested from the supernatant and am-
plified in Vero cells (replication-competent SeV) or in the helper cell line V3-10245 (replica-
tion-deficient SeV vector). Virus preparations were titrated as previously described245 and 
titres are given as cell infectious units per millilitre (ciu/ml). The integrity of the various SeV 
vector genomes was confirmed by RT-PCR and sequencing. 
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VI.6.4. Viral infection 
For infection of various cell types, cells were diluted in the suitable culture medium (DMEM 
or RPMI, see section VI.1) devoid of any supplement. 3x104  5x104 cells in a volume of 30 
µl were added to each well and the plate was incubated for 2 h at 37 °C and 5% CO2. Virus 
suspensions were likewise diluted in RPMI or DMEM and added to the cells in a volume of 
20 µl. After 3 hours, the plate was centrifuged for 5 min at 350 xg, followed by removal of 
the supernatant and infected cells were cultivated in RPMI or DMEM with 10% FCS and 1% 
Pen/Strep for the desired amount of time. 
 
VI.6.5. Viral target cell tropism  
PBMCs were infected with GFP-expressing vectors (Figure 32 and Figure 44) according to 
section VI.6.4. and 24 hours post infection (hpi), the plate was centrifuged for 5 min at 350 
xg and 4 °C. The supernatant was removed and cells were washed with 200 µl precooled 
FACS buffer. After repetition of this washing step, cells were resuspended in 50 µl staining 
solution (all antibodies were diluted in PBS). After staining, cells were washed twice with 
200 µl FACS buffer as described above and analyzed on a FACS Canto II device (Becton 
Dickinson).   
 
Buffer Composition 
FACS buffer PBS with 1% FCS, 1 mg/ml NaN3 
 
Antibody Isotype Conjugate Supplier Cat# dilution 
mouse anti human CD3 IgG1  APC-Cy7 Biolegend 344818 1:60 
mouse anti human CD4 IgG1  BV421 Biolegend 300532 1:60 
mouse anti human CD8 IgG1  AmCyan Becton Dickinson 339199 1:60 
mouse anti human CD14 IgG1  PE Biolegend 367104 1:60 
mouse anti human CD19 IgG1  APC Biolegend 302211 1:60 
mouse anti human CD56  PerCP Biolegend 318341 1:60 
 
VI.6.6. Intracellular IE-1/pp65 staining  
moDCs were infected with IE-1- or pp65-expressing vectors (Figure 33 and Figure 39) ac-
cording to section VI.6.4. 24 or 48 hours after infection, the plate was centrifuged for 5 
min at 350 xg and 4 °C. moDCs were then washed twice with 200 µl precooled FACS buffer 
with centrifugation at 350 xg and 4 °C for 5 min after each step. Next, cells were fixed by 
resuspending the pellet in 100 µl Cytofix/Cytoperm and incubating the plate for 30 min at 
4 °C. The plate was centrifuged for 5 min at 350 xg and 4 °C and the supernatant was 
discarded. Cells were washed twice with 200 µl Perm/Wash with centrifugation at 350 xg 
and 4 °C for 5 min after each step. After removal of the supernatant, cells were resuspended 
in 50 µl primary antibody solution (IE-1- or pp65-antibody diluted in Perm/Wash) and incu-
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bated for 30 min at 4 °C. Cells were washed twice with 200 µl Perm/Wash with centrifuga-
tion at 350 xg and 4 °C for 5 min after each step. Next, 50 µl of secondary antibody solution 
(diluted in Perm/Wash as well) were added to the cells, followed by incubation for 30 min 
at 4 °C in the dark. Cells were again washed twice with 200 µl Perm/Wash with centrifuga-
tion at 350 xg and 4 °C for 5 min after each step. Finally, cells were resuspended in 200 µl 
FACS buffer and flow cytometry analysis was performed using a FACS Canto II device (BD 
Biosciences). 
 
Buffer Composition 
FACS buffer PBS with 1% FCS, 1 mg/ml NaN3 
Cytofix/Cytoperm PBS with 4 % (w/v) paraformaldehyde (PFA) and 1 % (w/v) saponin 
Perm/Wash PBS with 0.1 % (w/v) saponin 
 
Primary antibody Supplier Cat# Dilution 
mouse anti IE-1 Abcam ab30924 1:50 
mouse anti pp65 Abcam ab53489 1:50 
 
Secondary antibody Conjugate Supplier Cat# dilution 
Goat anti-mouse IgG PE Biolegend 405307 1:50 
 
VI.6.7. T cell restimulation by virally transduced moDCs 
moDCs were infected with IE-1- or pp65-expressing vectors (Figure 34 and Figure 40) ac-
cording to section VI.6.4. 24 hpi, T cells were added at an effector/target cell ratio of 1:1 
along with BFA (1 µg/ml). After 6 hours of co-incubation, cells were stained according to 
section VI.5.6.  
 
Antibody Isotype Conjugate Supplier Cat# dilution 
mouse anti human CD8a  FITC Biolegend 301006 1:60 
mouse anti human IFN-   APC Biolegend 502512 1:60 
 
T cell clone Cognate epitope HLA restriction 
4G6 TPRVTGGGAM HLA-B7 
1C3 QIKVRVDMV HLA-B8 
 
VI.6.8. Analysis of DC maturation 
moDCs were infected with IE-1- or pp65-expressing vectors (Figure 35 and Figure 42) ac-
cording to section VI.6.4. 24 hpi or 48 hpi, the plates were centrifuged for 5 min at 350 xg 
and 4 °C and the supernatant was discarded. moDCs were then washed twice with 200 µl 
precooled FACS buffer with centrifugation at 350 xg and 4 °C for 5 min after each step. 
Cells were fixed by resuspending the pellet in 100 µl PBS with 4% (w/v) PFA and incubating 
  Materials and methods 
103 
 
the plate for 30 min at 4 °C. Afterwards, the plate was centrifuged for 5 min at 350 xg and 
4 °C and the supernatant was discarded. moDCs were again washed twice with 200 µl 
precooled FACS buffer with centrifugation at 350 xg and 4 °C for 5 min after each step. 
Samples were then stained by adding 50 µl of antibody solution (diluted in PBS) and incu-
bating the plate for 30 min at 4 °C in the dark. After two final washing steps with FACS 
buffer as described above, cells were diluted in 200 µl FACS buffer and analyzed on a FACS 
Canto II device (BD Biosciences). 
 
Buffer Composition 
FACS buffer PBS with 1% FCS, 1 mg/ml NaN3 
 
Antibody Isotype Conjugate Supplier Cat# dilution 
mouse anti human CD80  FITC Biolegend 557226 1:60 
mouse anti human CD83  PE/Cy7 Biolegend 305326 1:60 
mouse anti human CD86  V450 Becton Dickinson 560359 1:60 
mouse anti human HLA-DR  APC Biolegend 307610 1:60 
 
 
VI.6.9. AnnexinV/7AAD assay 
To determine the amount of viable cells 24 or 48 hours after infection, the APC Annexin V 
Apoptosis Detection Kit with 7-
instructions (Figure 36 and Figure 41). Flow cytometry analysis was performed using an 
Attune NxT flow cytometer (Life Technologies). 
 
VI.6.10. Cytokine secretion analysis 
48 hours after infection, cell culture supernatants were collected and stored at -20 °C until 
analysis. For cytokine quantification, the Legendplex Human Inflammation Panel (13-plex 
Kit, Bio-legend) was used according 
was performed using an Attune NxT device (Life Technologies) and cytokine concentrations 
were determined using the software provided with the kit (Figure 43).  
 
VI.6.11. Cross presentation assay 
HeLa cells were infected with IE-1- or pp65-expressing AdV vectors (Figure 37) according 
to section VI.6.4. 24 hpi, cells were washed 4 times with RPMI1640 medium, followed by 
detachment from cell culture plates with Trypsin/EDTA solution (Pan Biotech). HeLa cells 
were added to moDCs at a 1:1 ratio. After 24 hours of co-incubation, T cells were added 
along with Brefeldin A (BFA, 1 µg/ml) at a moDC/T cell ratio of 1:1. Co-incubation lasted for 
6 hours after which cells were fixed and stained for CD8 and as described in section 
VI.5.6. 
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VI.7. Animal experiments 
All animal experiments were approved by the responsible veterinary department of the gov-
ernment of Lower Franconia (file number DMS-2532-2-69). 4 weeks old, female 
BALB/cAnNCrl mice were ordered from Charles River Laboratories and housed for two 
weeks at the animal facility D4 (University of Regensburg) in a pathogen-free environment. 
After this period, (week 0) and after two weeks (Figure 29), the animals were immunized 
after sedation with the inhalation anesthetic isoflurane (Baxter). pp65, carb-pp65 (4 µg each 
with 100 µg/ml poly(I:C)) or pcDNA3.1-pp65 (50 µg), dissolved in a total of 50 µl PBS, were 
injected into the tibialis anterior muscle of the left hind leg.   
Two weeks after the booster immunization, each spleen was removed with surgical instru-
ments in a sterile manner and transferred to 10 ml PBS in a 50 µl conical tube. The spleen 
was placed in a cell strainer, which was transferred to a petri dish along with 10 ml of PBS. 
The spleen was then mashed through the strainer with the plunger of a 5 ml syringe into 
the petri dish. The cell strainer was rinsed with 5 ml PBS and discarded. The splenocyte 
solution was transferred from the petri dish into a 50 ml conical tube and centrifuged for 5 
min at 300 xg. The supernatant was removed and the pellet was resuspended in 5 ml lysis 
buffer, followed by centrifugation for 5 min at 300 xg. The supernatant was discarded and 
the pellet was resuspended in 10 ml wash medium, followed by another centrifugation step 
for 5 min at 300 xg. After repeating this washing step two more times, cells were resus-
pended in 1 ml splenocyte medium, counted and set to a density of 2x107 cells/ml. 
100 µl aliquots were then distributed to the desired number of wells in a 96 well round 
bottom plate. Next, 100 µl of stimulation mixture were added, consisting of a pp65 peptide 
pool (600 ng/peptide) and BFA (200 ng), diluted in splenocyte medium. For positive control, 
some wells were stimulated with 100 µl PMA (0.1 µg/ml), ionomycin (1 µg/ml) and BFA (200 
ng), diluted in splenocyte medium. For negative control, BFA only (200 ng), likewise diluted 
in splenocyte medium, was added to some cells. The splenocyte cultures were then incu-
bated at 37 °C and 5% CO2 for six hours. 
Afterwards, the plates were centrifuged at 4 °C for 5 min (350 xg) and the supernatant was 
discarded. Cells were then washed twice with 150 µl precooled FACS buffer with centrifu-
gation at 350 xg and 4 °C after each step. After removal of the supernatant, CD4 and CD8 
antibodies were added (diluted to 30 µl in PBS) and cells were incubated for 30 min at 4 °C 
in the dark. Cells were then washed twice with 150 µl precooled FACS buffer with centrif-
ugation at 350 xg and 4 °C after each step. Next, 150 µl Cytofix/Cytoperm were added, 
followed by incubation for 30 min at 4 °C in the dark. After the incubation, cells were 
washed twice with 150 µl precooled Perm/Wash with centrifugation at 350 xg and 4 °C 
after each step. After the second washing steps, the supernatant was removed and cell 
-2 antibody solution (diluted to 30 µl with 
Perm/Wash). Cells were then incubated for 30 min at 4 °C in the dark. Finally, cells were 
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again washed twice with 150 µl precooled Perm/Wash with centrifugation at 350 xg and 4 
°C after each step. The cell pellets were resuspended in 200 µl FACS buffer and analyzed 
on an Attune NxT acoustic focusing cytometer (Thermo Fisher). 
 
Reagent/Consumable Supplier 
Plastipack 1 ml syringe Becton Dickinson 
27G needle 0.4x19 mm Becton Dickinson 
Poly(I:C) Sigma-Aldrich 
Brefeldin A (BFA) Sigma-Aldrich 
pp65 Pepmix  Lophius Biosciences (138 15mers, spanning pp65 with 11 aa overlap) 
PMA Sigma-Aldrich 
Ionomycin Sigma-Aldrich 
HEPES (1 M) Gibco 
-Mercapto-EtOH Gibco 
cell strainer 100 µm Thermo Fisher 
 
Buffer Composition 
Lysis buffer 150 mM  NH4Cl, 1 mM KHCO3, 0,1 mM Na2EDTA, pH 7.2 with HCl                          
Splenocyte medium 
Ultraculture medium with 1% L-Glutamine, 1% Pen/Strep, 20 mM HEPES, 
-Mercapto-EtOH 
Wash buffer PBS with 1% Splenocyte medium 
FACS buffer PBS with 1% FCS, 1 mg/ml NaN3 
Cytofix/Cytoperm PBS with 4 % (w/v) paraformaldehyde (PFA) and 1 % (w/v) saponin 
Perm/Wash PBS with 0.1 % (w/v) saponin 
 
Antibody Isotype Conjugate Supplier Cat# dilution 
rat anti-mouse IFN-   PE Biolegend 505808 1:60 
rat anti-mouse IL-2  APC Biolegend 503809 1:60 
rat anti-mouse CD4  APC/Fire Biolegend 100459 1:60 
rat anti-mouse CD8a  PerCP/Cy5.5 Biolegend 100733 1:60 
 
VI.8. Analysis of flow cytometry data 
Flow cytometry analysis was performed using either a FACS Canto II device (Becton Dickin-
son) or an Attune Nxt Acoustic focusing cytometer (Thermo Fisher). If spectral overlap had 
to be compensated, singly stained samples for each color as well as an unstained sample 
were prepared and the automatic compensation function of the given cytometer
(FACS DIVA or ) was used. Raw data was analyzed using the soft-
ware Flowjo (version 10). For gating cells, doublets were always excluded first in an FSC-
A/FSC-H plot and cells debris was excluded according to FSC/SSC properties. Further gates 
were defined as required (e.g. Figure 23, Figure 28, Figure 32, Figure 44 and Figure S7). 
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VI.9. Statistics 
Statistical analysis was performed with the software GraphPad Prism (Version 5.01). 
 
VI.10. Homology modeling and electrostatic surface potential 
calculation 
The structure of human IE-1 was modeled for the amino acids 25 - 383 with HHPred315, 
using the structure of the Macacine herpesvirus 3 IE-1 core domain (PDB: 4WID)47 as a 
template (Figure 45). The electrostatic surface potential was calculated with the Poisson-
Boltzmann solver of the software DeepView (Swiss-PdbViewer, Swiss Institute of Bioinfo-
matics) with the following settings: Dielectric constant (solvent): 80; dielectric constant (pro-
tein): 4; solvent ionic strength (mol/ml): 0; use charged residues only. 
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I. Appendix 
I.1. Abbreviations 
Ad5 Adenovirus type 5 
Ad19a/ Adenovirus type 19a/64 
AdV Adenovirus 
AIDS Acquired immunodefi-
ciency syndrome 
APC Antigen-presenting cell 
ART Antiretroviral therapy  
BFA Brefeldin A 
BHK Baby hamster kidney cells 
Bluo-Gal 5-bromo-3- -D-
galactopyranoside 
CID Collision-induced dissoci-
ation  
CIT Citrulline 
CMV Cytomegalovirus 
CV Coefficient of variation  
CVID Common variable immu-
nodeficiency 
DC Dendritic cell 
dpa Day of proliferation arrest  
DTT Dithiothreitol 
EBV Epstein-Barr virus 
eGFP Enhanced green fluores-
cent protein 
ELISA Enzyme-linked immuno-
sorbent assay 
ELISpot Enzyme-linked immuno-
spot assay 
ETD Electron transfer dissocia-
tion  
FSC Forward scatter 
GC Glycoprotein complex 
GFP Green fluorescent protein 
GM-CSF Granulocyte-macrophage 
colony-stimulating factor 
GP Glycoprotein 
HBV Hepatitis B virus 
HCit  Homocitrulline 
HCl Hydrochloric acid 
HCMV Human Cytomegalovirus 
HCV Hepatitis C virus 
HIV Human immunodeficiency 
virus 
HFF Human foreskin fibroblast 
HLA Human leukocyte antigen 
HPLC High pressure liquid chro-
matography 
IAA Iodoacetamide 
IE-1 Immediate-early 1 
IEF Isoelectric focussing 
IFN Interferon 
IL Interleukin  
IVR In vitro recombination 
IPTG Isopropyl- -D-thiogalac-
topyranosid 
IRL Internal repeat long 
kb Kilobase 
kDa Kilodalton 
KOCN Potassium Cyanate 
LB Lysogeny broth 
LC-MS Liquid chromatography-
mass spectrometry 
LPS Lipopolysaccharide 
MACS Magnetic-activated cell 
sorting  
MARCO macrophage receptor 
with collagenous struc-
ture 
MCS Multiple cloning site 
MCMV Murine cytomegalovirus 
MHC Major histocompability 
complex 
MLR Mixed leukocyte reaction 
MOI Multiplicity of infection 
 Monocyte-derived macro-
phages  
moDCs Monocyte-derived den-
dritic cells  
MS mass spectrometry 
MVA Modified Vaccinia Ankara 
NK cell Natural killer cell 
ORF Open-reading frame 
PBMC Peripheral blood mono-
nuclear cells 
PBS Phosphate buffered saline 
PC Pentameric complex 
  Appendix 
108 
 
PFA Paraformaldehyde 
PMA Phorbol-12-myristate-13-
acetat 
poly(I:C) Polyinosinic:polycytidylic 
acid 
pp65 Phosphoprotein 65 kDa 
PRR Pattern recognitinon re-
ceptor 
QALY Quality-adjusted life year 
qPCR Quantitative polymerase 
chain reaction  
rpm Revolutions per minute 
RT Room temperature 
SCID Severe combined immu-
nodeficiency 
SD Standard deviation 
SDS-PAGE Sodium dodecyl sulfate 
polyacrylamide gel elec-
trophoresis 
SEM Standard error of the 
mean 
SeV Sendai Virus 
SFU Spot forming units 
SR Scavenger receptor 
SR-A1 Scavenger receptor A1 
SRCR Scavenger receptorcyste-
ine-rich domain 
TCEP tris(2-carboxyethyl)phos-
phine 
TFA Trifluoroacetic acid  
TK Thymidin kinase 
TLR Toll-like receptor 
TRL Terminal repeat long 
TRS Terminal repeat short 
UL Unique long 
US  Unique short 
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I.2. Supplementary data 
 
 
Figure S1 - Purification of IE-1 from insect cells 
(A) IE-1 (55kDa, apparent molecular weight 72kDa48) was fused C-terminally with a His/Strep tandem tag for 
affinity purification. Tag and protein are separated by the recognition sequence of the 3C protease of human 
rhinovirus, allowing removal of the tag by proteolytic cleavage using PreScissionTM protease after purification. 
(B) IE-1 was purified from Baculovirus-infected High Five cells using Ni-IDA beads. During purification, aliquots 
were collected from the insoluble fraction that was pelletized after cell lysis, the cell lysate (input), the washing 
steps as well as the elution fractions. Samples were subjected to SDS-PAGE and Coomassie-staining. (C) Pro-
teolytic cleavage was performed for removing the His/Strep tandem affinity tag after purification of IE-1 from 
crude cell lysates. GST-tagged PreScissionTM protease was added to the samples and after digestion, cleaved 
tag and protease were removed from samples by adding GSH- and Strep-Tactin-beads. Aliquots were collected 
at all steps and subjected to Western blot analysis. (D) After tag removal, the final product was analyzed via 
SDS PAGE and silver staining with the indicated protein quantities loaded per lane. 
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Figure S2 - Purification of BZLF1 from insect cells 
(A) BZLF1 (29 kDa) was fused C-terminally with a His/Strep tandem tag for affinity purification. Tag and protein 
are separated by the recognition sequence of the 3C protease of human rhinovirus, allowing removal of the 
tag by proteolytic cleavage using PreScissionTM protease after purification. (B) BZLF1 was purified from Bacu-
lovirus-infected High Five cells using Ni-IDA beads. During purification, Aliquots were collected from the in-
soluble fraction that was pelletized after cell lysis, the cell lysate (input), the washing steps as well as the 
elution fractions. Samples were subjected to SDS-PAGE and Coomassie-staining. (C) Western blot of pooled 
elution fractions after affinity chromatography. Tag cleavage was not performed for BZLF1. (D) The final 
product was analyzed via SDS PAGE and silver staining. The data was collected during the master thesis of 
Philipp Becker under my experimental supervision265.  
 
 
Figure S3  
ELISpot 
2x105 PBMCs each from a CMV seropositive donor were culti-
vated for 20 hours in the presence (+) or absence (-) of pp65 or 
20 mM potassium cyanate (KOCN). T cell responses were quan-
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Figure S4  24 hours of KOCN treatment 
leads to the greatest increase in T cell res-
timulation rates  
pp65 was incubated for up to 24 hours with 300 
mM potassium cyanate. Aliquots were collected 
at the indicated time points and subjected to di-
alysis for removal of KOCN. PBMCs from 3 CMV 
seropositive donors were stimulated for 20 
hours with the different pp65-isoforms and T cell 
-ELISpot. Ob-
tained spot-forming unit (SFU) values were nor-
malized to those of unmodified pp65.  
 
 
 
Figure S5  ETD spec-
trum allows unambigu-
ous identification of car-
bamoylation site 
MSMS spectra of the single-
carbamylated peptide 
NTRATKMQVIG generated 
by (A) collision-induced dis-
sociation (CID; charge state 
2) and (B) electron transfer 
dissociation (ETD; charge 
state 3). While in the case 
of CID fragmentation, car-
bamylation cannot unam-
biguously be assigned to ly-
sine or arginine (both 
marked in red), ETD frag-
mentation clearly proofs 
the carbamylation of lysine 
(marked in red). The data 
was acquired in coopera-
tion with Bernd Reisinger 
(PTB Braunschweig). 
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Figure S6  CD14 depletion has no detectable impact on NK and T cell frequency  
PBMCs from a CMV seropositive donor were depleted of CD14 positive cells via magnetic-activated cell sorting 
(MACS, lower panel) or subjected to control treatment (omission of the CD14 antibody/bead conjugate; upper 
panel). An aliquot from both samples was stained each for CD3, CD4, CD8 and CD56 with fluorescently 
labeled antibodies and subjected to flow cytometry analysis. The pseudocolor plots show NK cells (CD3-
/CD56+) CD4 T cells (CD3+/CD4+) and CD8 T cells (CD3+/CD8+) with the respective population frequencies (%) 
displayed in each corner. The data shown in t
Brunner under my experimental supervision267. 
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Figure S7 - Splenocyte 
stimulation with 
PMA/Ionomycin induces 
-2 synthesis 
(A) Mice were immunized 
according to the regimen 
in Figure 29 and at week 4, 
splenocytes were isolated 
and stimulated for 6 hours 
with BFA only (as negative 
control) or BFA with 
PMA/Ionomycin (positive 
control). Cells were stained 
for CD4, CD8, intracellular 
-2, followed by 
flow cytometry analysis. 
Gr -2 
positive cells that are fur-
ther subdivided into CD4+ 
or CD8+ T cells. Horizontal 
lines represent the mean 
and blue symbols the indi-
vidual values of each ani-
mal. (B) Gating strategy for 
-2 
positive T cells. Cell dou-
blets and aggregates were 
first excluded in a forward 
scatter area (FSC-A) vs. for-
ward scatter height (FSC-H) 
plot. Next, a gate was set 
around splenocytes ac-
cording to FSC/SSC proper-
ties and T cells were identi-
fied by plotting CD4 signals 
against CD8. From CD4 
and CD8 positive cells 
plotted against IL-2 signals 
and gates identifying cyto-
kine-positive cells were de-
fined according to the re-
spective background val-
ues (determined using an 
unstimulated sample).  
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Figure S8  CD14/CD1a 
expression during mon-
ocyte differentiation to 
moDCs  
Monocytes from a CMV 
seronegative donor were 
isolated via MACS sorting 
using CD14 anti-
body/bead conjugates 
and cultivated for 5 days 
in the presence of IL-4 and 
GM-CSF (1000 U/ml each). 
Directly after isolation and 
at day 5, samples were 
collected and stained for 
CD14 or CD1a, followed 
by flow cytometry analy-
sis.  
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